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Chapter 1a
Asymmetric dimethylarginine (ADMA) and cardiovascular disease
Mariska Davids and Tom Teerlink
Ned Tijdschr Klin Chem Labgeneesk 37 (2012) 10 - 14
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Abstract
Asymmetric dimethylarginine (ADMA) is an endogenously produced inhibitor of nitric oxide synthase that may impair endothelial function and accelerate atherosclerosis. ADMA is generated during proteolysis of posttranslationally methylated proteins. Especially the liver and kidneys serve as sinks for ADMA, by clearing large amounts of ADMA from the circulation. Failure of one these organs leads to elevated plasma levels of ADMA, which, by impairing the function of other organs, ultimately may lead to multiple organ failure. Prospective studies have shown that ADMA, independent of traditional risk factors, predicts cardiovascular events in high risk patients groups as well as in the general population.
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Endothelium-derived nitric oxide (NO), which is synthesized from arginine by NO synthase (NOS), is an important regulator of vascular homeostasis. In addition to being a powerful vasodilator, NO inhibits the adhesion of 
inflammatory cells to the vascular wall, the aggregation of platelets and the proliferation of smooth muscle cells (1). Inactivation and/or reduced synthesis of NO is seen in conjunction with risk factors for cardiovascular disease (CVD) and may promote endothelial dysfunction, hypertension, thrombus formation and atherogenesis (2). Asymmetric dimethylarginine (ADMA), a byproduct of cellular protein turnover, is an endogenous competitive inhibitor of NOS (3). Consequently, elevated ADMA levels may initiate and accelerate atherosclerosis and precipitate cardiovascular events. In the following sections we describe the metabolism of ADMA, discuss some analytical aspects and review the epidemiological evidence for ADMA as a cardiovascular risk factor.
Metabolism and clearance of ADMA
The structure of ADMA and its metabolic origin and fate are shown in figures 1 and 2, respectively. The plasma concentration of ADMA is the resultant of many processes at the cellular and whole body level (4). Posttranslational methylation of the terminal guanidino-group of arginine residues in proteins is catalyzed by a family of protein arginine methyltransferases (PRMTs), comprising two classes (5). Both classes catalyze the monomethylation of arginine, but upon attachment of a second methyl group to monomethylarginine, the reaction product is PRMT-dependent. Type 1 PRMTs catalyze the formation of ADMA, whereas type 2 PRMTs produce symmetric dimethylarginine (SDMA). Arginine methylation plays a 
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Figure 1Structures of arginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA). Arginine is the substrate of nitric oxide synthase (NOS). ADMA, but not its structural isomer SDMA, inhibits NOS activity.
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crucial role in expanding the functional repertoire of the cellular proteome 
(6). Most methylated proteins interact with nucleic acids and are involved in processes like transcription, RNA splicing, DNA repair, and epigenetic regulation of gene expression (7). With a few exceptions, protein methylation is irreversible and methylated arginine residues remain an integral part of the protein until it is degraded by proteolysis (6). Free ADMA, formed during proteolysis, is hydrolyzed by the intracellular enzyme dimethylarginine dimethylaminohydrolase (DDAH), of which two isoforms exist (8). Some ADMA escapes degradation and leaves the cell via cationic amino acid transporters (CAT) that also mediate uptake of ADMA by neighboring cells or distant organs, thereby facilitating an active interorgan transport (9, 
10). Clearance of ADMA from the plasma occurs for a small part by urinary 
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Figure 2Schematic overview of the metabolism and clearance of asymmetric dimethylarginine (ADMA) at the cellular and whole body levels. Arginine residues of proteins are methylated by protein arginine methyltransferases (PRMT) and free ADMA is formed upon proteolysis of these proteins. ADMA is hydrolyzed by intracellular dimethylarginine dimethylaminohydrolase (DDAH) or exported from the cell by cationic amino acid transporters (CAT). Leukocytes and erythrocytes may also release ADMA into the circulation. Clearance of ADMA from the circulation occurs again by CAT-mediated uptake followed by degradation, especially by organs with a high DDAH activity, such as kidney and liver.      = Amino acid;     = Arginine;     = ADMA.
19
1aPart I: General introduction, objectives and outline of the thesis
Ned Tijdsch Klin Chem Labgeneesk 37 (2012) 10 - 14
excretion, but the bulk of ADMA is degraded by DDAH, after uptake from the circulation (11). Using a rat model, we were able to show that organs with high DDAH activity, notably the kidneys and the liver, are mainly responsible for clearance of ADMA (12-14). Blood flow through the organs was measured by injection of radiolabeled microspheres and ADMA concentrations were determined in the aorta and in the renal, hepatic and portal veins. From these measurements fractional extraction (i.e. the percentage that is cleared from 
the plasma) and organ fluxes were calculated. Fractional extraction of ADMA was slightly higher in the kidney than in the liver. However, because blood 
flow through the liver is higher than through the kidneys, the liver clears more ADMA from the circulation than the kidney. In humans, measurement 
of arteriovenous concentration differences also revealed net renal and hepatic extraction of ADMA (15, 16). The essential role of the liver in the 
elimination of ADMA in humans was confirmed in several clinical studies by our group and other investigators [reviewed in (17)]. Liver cirrhosis and alcoholic hepatitis were found to be associated with elevated plasma levels of ADMA (18, 19). In patients undergoing major liver resection, ADMA levels 
were significantly elevated in a subgroup with prolonged postoperative hepatic injury (20), and in patients undergoing liver transplantation, the preoperative ADMA concentrations were elevated and dropped very rapidly after transplantation (21).Taken together, these results show that deterioration of organ function, by diminished clearance, may lead to increased plasma levels of ADMA. Conversely, high plasma levels of ADMA may exacerbate organ dysfunction. In a study among critically ill patients, plasma ADMA concentration was independently related to the presence of hepatic and renal failure. In a logistic 
regression model, plasma ADMA ranked as the first and strongest predictor for outcome, with a 17-fold increased risk for ICU death in patients who were in the highest quartile of ADMA (22). Possibly, extensive interorgan transport of ADMA is causally involved in the cascade of failing organs in patients with multiple organ failure (23).
Analytical aspects
Reliable quantification of low plasma concentrations of ADMA and SDMA, 
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in the presence of many other amino acids that are present in far higher concentrations, is an analytical challenge. A large number of analytical approaches has been described, most of which are based on high performance 
liquid chromatography (HPLC) with fluorescence detection (24). Considering the very narrow distribution of ADMA concentrations in healthy subjects 
(24-26), the importance of low imprecision of the analytical procedure cannot be overemphasized. We have developed an HPLC method for the 
simultaneous quantification of arginine, ADMA, and SDMA, with an inter-
assay coefficient of variation <3% for ADMA (27). To increase throughput, we later adapted the method by performing separation on a monolithic 
column, that allows operation at high flow rates without loss of separation 
efficiency (28). Liquid chromatography with mass spectrometric detection, usually in tandem mode, is increasingly used for determination of ADMA and related analytes (29, 30), but accurate and precise quantification requires the use of stable isotope labeled internal standards. Furthermore, an ELISA for the determination of ADMA in plasma is commercially available (31). This technique allows relatively rapid analysis of large numbers of samples, but seems less selective, accurate, and precise than chromatographic techniques 
(32).
Regarding measurement of ADMA in plasma, we have observed no significant 
differences in concentrations of arginine, ADMA, and SDMA between EDTA- and heparin-plasma samples (24), but citrate-plasma should not be used because the rather large volume of citrate solution in the blood collection tubes leads to a considerable and variable dilution. Serum is also suitable 
for the analysis of ADMA and SDMA, but arginine concentrations are 60% higher in serum compared to plasma. Storage conditions are not very critical. 
Plasma can be stored indefinitely at -70°C or below, and at least several years 
at -20°C, without alteration in analyte concentrations, and repeated freeze/
thaw cycles have no effect.
ADMA and cardiovascular diseaseBecause ADMA reduces NO production by competitive inhibition of NOS, elevation of ADMA is considered a risk factor for endothelial dysfunction and CVD. Many other risk factors for CVD, such as hypertension, diabetes mellitus, 
21
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hypercholesterolemia and hyperhomocysteinemia, are also associated with reduced availability of NO and endothelial dysfunction, and it has been 
suggested that ADMA is the ultimate mediator of the adverse effect of these risk factors on the vascular endothelium (33).Intima-media thickness (IMT) of the carotid arteries is a surrogate marker of generalized atherosclerosis and future CVD, both in the general population and in high-risk patient groups. Both in univariate and multivariate regression analysis, the plasma concentration of ADMA was directly related to carotid IMT in healthy volunteers and in patients with renal failure (34, 
35). The results of prospective clinical studies provide the most compelling 
evidence for a role of ADMA in the development of CVD. In one of the first prospective studies, conducted in a cohort of 225 patients with end-stage renal disease, ADMA and age were the strongest predictors of cardiovascular events and total mortality, even after adjustment for other traditional and novel risk factors (36). Since then, many other prospective studies in high-
risk populations have confirmed that ADMA is an independent CVD risk factor [reviewed in (37, 38)]. In contrast, adequate information on the relevance of ADMA as a marker of morbidity and mortality in the general population is sparse (38). We have investigated this issue in the Hoorn Study, a community-based prospective cohort study among 2484 men and women, aged between 50 and 75 years (39). The main outcome measure was the combined incidence of fatal and non-fatal CVD events during 10 year follow-up. After adjusting for age, gender and established risk factors, a high plasma concentration of ADMA (i.e. highest quintile versus the four lower quintiles) 
was associated with a hazard ratio for CVD of 1.49 (95% confidence interval 
1.16 to 1.90) in subjects without diabetes and 0.48 (95% confidence interval 0.24 to 0.98) in subjects with diabetes. In another large community-based 
cohort, the Framingham Offspring Study, ADMA was significantly associated with all-cause mortality, but not with CVD incidence (40). Interestingly, in that 
study, effect modification by diabetes status was also observed. In patients with diabetes, there was a trend towards lower risk of total mortality with increasing quartiles of ADMA (41). The independent observation of this 
apparent protective effect of high ADMA levels in patients with diabetes in 
two large prospective studies makes it unlikely that this is a chance finding, 
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and merits further investigation. It may reflect a true protective effect of ADMA, for instance by inhibition of uncoupled NOS that produces superoxide instead of NO, or may simply indicate that measurement of ADMA in plasma 
does not adequately gauge its effect on the cardiovascular system. Both generation and DDAH-mediated metabolism of ADMA as well as inhibition of NOS activity by ADMA are intracellular processes, but most studies report on plasma ADMA levels, based on the underlying assumption that 
the concentration of ADMA in plasma accurately reflects intracellular ADMA levels. It is tempting to speculate that there may be (patho)physiological conditions in which intracellular and circulatory ADMA are inversely associated. A situation like this may occur if CAT expression or activity is diminished, resulting in a slow cellular egress of ADMA, thereby increasing intracellular, but decreasing extracellular ADMA levels (10).
Conclusions and outstanding questionsOver the past decade it has become clear that ADMA is a risk factor for CVD in individuals at high risk, such as patients with chronic kidney disease or coronary artery disease. More recent studies have extended this observation to the general population, in which ADMA was shown to be an independent risk predictor of moderate strength. Two patient categories stand out in terms of aberrant ADMA-associated risk. In critically ill patients with failure of multiple organ systems, high plasma levels of ADMA are associated with an extremely high mortality risk. In contrast, in patients with type 2 diabetes, high ADMA is associated with a reduced cardiovascular risk. Most clinical studies report on plasma ADMA levels, based on the underlying 
assumption that the concentration of ADMA in plasma reflects intracellular ADMA levels. Reports on the relation between plasma and intracellular ADMA levels in vascular and other tissues and organs are scarce, and further 
study in this field is urgently needed.On a parallel note, the relation between the concentration of ADMA in plasma 
and in erythrocytes is an interesting field of inquiry. Increased plasma levels of ADMA have been found in diseases that are associated with elevated hemolysis, such as sickle cell disease (42, 43) and HELLP syndrome (44), 
and in vitro experiments have confirmed release of ADMA upon erythrocyte 
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lysis (45). Further experiments are required to delineate the exact role of erythrocytes in the metabolism and transport of ADMA. Likewise, peripheral blood mononuclear cells (PBMC) produce and excrete ADMA (46), but whether measurement of the intracellular concentration of ADMA in PBMC or other types of leukocytes provides clinically useful information remains to be established.Finally, homoarginine, a naturally occurring homologue of arginine that 
affects NO production, seems to be an interesting new player in the 
cardiovascular field. A recent study found low homoarginine levels to be independently associated with cardiovascular and all-cause mortality in patients referred for coronary angiography and in patients undergoing hemodialysis (47). Studies are needed to elucidate the underlying (patho)physiological mechanisms, the biochemical pathways involved in synthesis and degradation of homoarginine, and potential interactions with the metabolism of ADMA.
In conclusion, ADMA is coming of age in the field of CVD risk, but our understanding of its metabolism and role in the vascular system is still far from complete.
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Objectives and outline of the thesis
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Study objectivesMost clinical studies report on plasma asymmetric dimethylarginine (ADMA) levels, based on the underlying assumption that the concentration of ADMA 
in plasma reflects intracellular ADMA levels. Reports on the relation between plasma and intracellular ADMA levels in vascular and other tissues and organs are scarce. Therefore, the main focus of this thesis was to study the metabolism of intracellular ADMA, and its relation to plasma levels. From this the following objectives were derived:
•	 Develop and validate a sensitive mass spectrometric method for the simultaneous determination of ADMA, symmetric dimethylarginine (SDMA), monomethylarginine (MMA), arginine and homoarginine in biological samples.
•	 Study the relation between ADMA levels in plasma and in blood cells, such as erythrocytes and peripheral blood mononuclear cells (PBMC).
•	 Delineate the role of erythrocytes in the metabolism, storage and transport of ADMA.
•	 Establish the role of dimetharginine dimethylaminohydrolase (DDAH) activity in the regulation of ADMA concentrations in tissue and plasma.
•	 Determine if ADMA levels in cardiovascular tissue are better reflected by intracellular ADMA concentrations in PBMC than by plasma levels.
Homoarginine may also affect nitric oxide (NO) production and there is some evidence that this naturally occurring homolog of arginine is associated with cardiovascular disease. This resulted in the following objectives:
•	 Review current literature on homoarginine in relation to cardiovascular disease.
•	 Elucidate the biochemical pathways involved in synthesis of homoarginine.
•	 Determine the effect of homoarginine levels on blood pressure in a cross-sectional cohort study among the general population.
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1bPart I: General introduction, objectives and outline of the thesisOutline of the thesis
Part II: Intracellular ADMA: metabolism and relation to plasma levelsFor the accurate and precise determination of arginine, ADMA, SDMA, MMA, and homoarginine in plasma and intracellularly in tissues and cultured cells, a new method was developed. This method, based on liquid chromatography with detection by tandem mass spectrometry (LC-MS/MS), and its validation are described in Chapter 2.The separate contribution of proteolysis to the generation of free cellular ADMA was studied in the humane erythrocyte after cytolysis and is described in Chapter 3. Also the relation between plasma ADMA and intracellular ADMA in erythrocytes from healthy and critically ill patients was studied. Furthermore, ADMA storage by and release from intact erythrocytes was explored.
Chapter 4 focuses on the relation between plasma ADMA and intracellular 
levels in different tissues, describing the role of DDAH activity in the regulation of plasma and tissue concentrations of ADMA in an animal model of prolonged critical illness.The relations between plasma and intracellular concentrations in PBMC of ADMA and homoarginine were studied in healthy volunteers and are described in Chapter 5.
To further explore if ADMA in PBMC, better than ADMA in plasma, reflects the ADMA levels in cardiovascular tissue, ADMA was measured in plasma, PBMC and tissue specimens from heart and aorta obtained from patients undergoing coronary artery bypass grafting. The rationale and design of this study is described in Chapter 6a, and the relations observed between plasma ADMA and intracellular ADMA in PBMC, heart and aorta are described in 
Chapter 6b.
Part III: Homoarginine and cardiovascular diseaseResearch on the physiological role of homoarginine in cardiovascular disease is limited. Therefore, we focused on the metabolic routes involved in homoarginine synthesis and degradation. In Chapter 7 literature on metabolic pathways that may be involved in the synthesis of homoarginine, and its potential role in cardiovascular physiology is reviewed.
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Analysis of amino acids, including homoarginine and ADMA, is performed in 
diverse fields of research, but often without justification or specification of specimen type. Therefore, the impact of coagulation and anticoagulants on amino acid concentrations was explored (Chapter 8).
Chapter 9 describes the relation between levels of the nitric oxide synthase (NOS) substrates arginine and homoarginine, and the NOS inhibitor ADMA with blood pressure, which was investigated in the Hoorn Study, a population-based cohort study among elderly subjects.The possibility of homoarginine formation from lysine catalyzed by arginine:glycine amidinotransferase (AGAT), one of the enzymes of the creatine synthesis pathway, was studied in cultured lymphoblasts of an AGAT-deficient patient and a control cell line (Chapter 10).
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Part II
Intracellular asymmetric dimethylarginine (ADMA): metabolism and relation to plasma levels
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Chapter 2
Simultaneous determination of asymmetric and symmetric dimethylarginine, L-monomethylarginine, L-arginine, and L-homoarginine in biological samples using stable isotope dilution chromato-graphy tandem mass spectrometryMariska Davids, Eliane Swieringa, Fredrik Palm, Desirée E.C. Smith, Yvo M. Smulders, 
Peter G. Scheffer, Henk J. Blom, and Tom Teerlink
 J Chromatrogr B 900 (2012) 38 - 47
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Abstract
Production of the endogenous vasodilator nitric oxide (NO) from L-arginine by NO synthase is modulated by L-homoarginine, L-monomethylargine (MMA), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Here we report on a stable isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of these metabolites in plasma, cells and tissues. After addition of the internal standards (D7-ADMA, D4-L-homoarginine and 13C6-L-arginine), analytes were extracted from the samples using Waters Oasis MCX solid phase extraction cartridges. Butylated analytes were separated isocratically on a Waters XTerra MS C18 column (3.5 µm, 3.9 x 100 mm) using 600 mg/L ammonium formate in water - acetonitrile (95.5:4.5, v/v) 
containing 0.1 vol% formic acid, and subsequently measured on an AB Sciex API 3000 triple quadrupole mass spectrometer. Multiple reaction monitoring 
in positive mode was used for analyte quantification. Validation was performed in plasma. Calibration lines were linear (r2 ≥0.9979) and lower 
limits of quantification in plasma were 0.4 nmol/L for ADMA and SDMA and 
0.8 nmol/L for the other analytes. Accuracy (% bias) was <3% except for 
MMA (<7%), intra-assay precision (expressed as CV) was <3.5%, inter-assay 
precision <9.6%, and recovery 92.9 - 103.2% for all analytes. The method showed good correlation (r2 ≥0.9125) with our previously validated HPLC-
fluorescence method for measurement in plasma, and was implemented with good performance for measurement of tissue samples. Application of the method revealed the remarkably fast (i.e. within 60 min) appearance in plasma of stable isotope-labeled ADMA, SDMA, and MMA during infusion of D3-methyl-1-13C-methionine in healthy volunteers.
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IntroductionAsymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are formed through the methylation of L-arginine residues in proteins by two separate classes of enzymes called protein arginine methyltranferases (PRMT) (1), thereby expanding the functional repertoire of these proteins (2). In the formation of both ADMA and SDMA, L-monomethylarginine (MMA) is formed as an intermediate product (1). After degradation of the methylated proteins, ADMA, SDMA and MMA are released into their free form. ADMA and MMA are endogenous inhibitors of nitric oxide synthase (NOS) (3-5), the enzyme responsible for the conversion of L-arginine into nitric oxide (NO), the most potent vasodilator in the human body (6). SDMA is generally considered not to inhibit NOS. However, Tsikas et al. (7) showed that SDMA possesses a weak inhibitory potency towards neuronal NOS. Additionally, SDMA may limit NO production by competing with L-arginine for cellular uptake. For the clearance of ADMA and MMA, cells contain the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which hydrolyzes ADMA to dimethylamine and L-citrulline, and MMA to methylamine and L-citrulline 
(4, 8). Cationic amino acid transporters in the plasma membrane facilitate the transport of cytosolic ADMA, SDMA, and MMA to the circulation (9, 10), from where they are either taken up by other cells or tissues, or excreted by the kidneys (11).L-Homoarginine is a structural analog of L-arginine that may also act as a substrate for NOS. However, compared to arginine, the Km value of 
homoarginine is much higher, reflecting a lower catalytic efficiency of NOS using homoarginine as substrate (12). Therefore, production of NO may be reduced at a high L-homoarginine/L-arginine ratio. In its relation to cardiovascular disease it remains unclear whether high or low 
L-homoarginine levels are beneficial. Recently, low levels of L-homoarginine in plasma have been associated with cardiovascular mortality and stroke in a large cohort study (13, 14). In contrast, numerous studies have revealed an association between high, rather than low, plasma levels of ADMA and cardiovascular disease (15, 16). Likewise, high plasma levels of SDMA have been associated with increased cardiovascular and all-cause mortality 
(17, 18), and may also reflect renal dysfunction (19). Notably, formation of 
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ADMA, SDMA and MMA, as well as inhibition of NOS, occur inside cells, and therefore, for the prediction of cardiovascular disease, intracellular levels of ADMA, SDMA, MMA, L-arginine, and L-homoarginine may be more relevant than their plasma levels (20).Investigation of the intracellular metabolism of these compounds and the relation between their intracellular and circulatory concentration, requires a precise and sensitive method that can handle a variety of sample matrices. Liquid chromatography tandem mass spectrometry (LC-MS/MS) is used increasingly for the simultaneous determination of L-arginine, ADMA, and SDMA in biological samples (21, 22). For L-homoarginine a LC-MS/MS method has recently been described as well (23). Di Gangi first published an ultra-HPLC-MS/MS-method for the combined determination in plasma and urine of all L-arginine analogs that may have an impact on NOS metabolism (24). 
With our current HPLC-fluorescence method (25, 26) we are able to measure L-homoarginine in combination with L-arginine, ADMA and SDMA, but MMA 
cannot be quantified since it is used as the internal standard. Furthermore, 
the HPLC-fluorescence method is very precise and accurate for the analysis 
of plasma, urine and culture media, but lacks the sensitivity and specificity 
required for reliable quantification in small tissue samples. Additionally, the 
fluorescence method is not suitable for the determination of stable isotope-labeled forms of ADMA, SDMA and MMA in tracer studies, which can be very useful in determining the key processes in formation and degradation of these compounds. Therefore, the aim of the present study was to develop and validate a highly precise and sensitive stable isotope dilution LC-MS/MS method for the combined determination of ADMA, SDMA, MMA, L-arginine, and L-homoarginine, in biological samples.
Experimental
ChemicalsL-Arginine, ADMA dihydrochloride, SDMA di(p-hydroxyazobenzene-p’-
sulfonate) salt, MMA acetate, L-homoarginine hydrochloride, Nε,Nε,Nε-
trimethyllysine hydrochloride, Nα-acetyllysine, and Nε-acetyllysine were obtained from Sigma (St. Louis, MO, USA). 13C6-L-Arginine ([U-13C6; 
99.2%]-L-arginine, 99.2%) and D7-ADMA ([2,3,3,4,4,5,5-D7; 98%]-ADMA, 
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98%) were purchased from Eurisotop (Saint Aubin Cedex, France) and D4-L-homoarginine ([4,4,5,5-D4; 98.7%]-L-homoarginine, 98%) from Toronto Research Chemicals (Toronto, Canada). D3-Methyl-1-13C-methionine 
(95%) was obtained from Isotec (Miamisburg, OH, USA).Hank’s Balanced Salt Solution (HBSS) was obtained from Invitrogen, (Carlsbad, CA, USA). Acetonitrile and formic acid were purchased from VWR 
prolabo (Amsterdam, The Netherlands), and 1-butanol and 70% perchloric acid from Merck (Darmstadt, Germany). All solvents were of analytical 
grade. Water was purified with a Milli-Q system from Millipore (Billerica, MA, USA).
Calibration standards, internal standards, and quality controlsCalibration standardsBecause no analyte-free matrix is available, calibration samples were prepared in water.For each analyte (L-arginine, MMA, ADMA, SDMA and L-homoarginine), a stock solution of 1 mmol/L in water was prepared. From these stock solutions a combined solution of MMA, ADMA, SDMA and L-homoarginine was prepared containing 10 µmol/L of each analyte. This combined solution together with the 1 mmol/L stock solution of L-arginine was used for the preparation of seven calibration standards with concentrations of 0.1, 0.2, 0.4, 0.8, 1.2, 2.0, and 5.0 µM for ADMA, SDMA, MMA, and L-homoarginine and with concentrations of 10, 20, 40, 80, 120, 200, and 500 µmol/L for L-arginine. All stock solutions and 1 mL aliquots of the calibration standards 
were stored at -20°C.
Internal standardsFor each of the three internal standards, D7-ADMA, D4-L-homoarginine, and 13C6-L-arginine, stock solutions of 1 mmol/L were prepared in water. The internal standard solutions were diluted with water to 0.2 µmol/L for both D7-ADMA and D4-L-homoarginine and to 20 µmol/L for 13C6-L-arginine. D7-ADMA was used for the quantification of ADMA, SDMA and MMA, D4-L-
homoarginine for the quantification of L-homoarginine, and 13C6-L-arginine 
for the quantification of L-arginine (Table 1). The internal standard solutions 
were stored in aliquots of 1 mL at -20°C.
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Quality controls
For method validation purposes quality control (QC) samples were prepared by spiking a plasma pool. To this end, a separate set of stock solutions of 1 mmol/L for each analyte was made in water. From theses stocks a combined solution was made containing 10 µmol/L MMA, ADMA, SDMA and L-homoarginine, which was used with the L-arginine stock standard of 
1 mmol/L to prepare three QC-levels of low middle and high concentration containing 0.55, 0.95 or 2.5 µmol/L ADMA, SDMA, MMA, and L-homoarginine, 
and 55, 95 or 250 µmol/L L-arginine. The QC solutions were stored in 
aliquots of 1 mL at -20°C. Plasma was spiked by drying 200 µL aliquots of the 
QC solutions under N2 at 60°C and reconstituting in 200 µL of a plasma pool (see Section Plasma samples).
Table 1 – Analyte-specific mass spectrometric parameters
D7-ADMA4626070248D3-MMA
D7-ADMA24250214262D3-ADMA
-4626088249D4-L-Homoarginine
-342707423713C6-L-Arginine
-4626077266D7-ADMA
D7-ADMA24250214265D6-ADMA
D4-L-Homoarginine4626084245L-Homoarginine
13C6-L-Arginine3427070231L-Arginine
D7-ADMA22280231262
D7-ADMA22280228262D3-SDMA
D7-ADMA22280231265D6-SDMA
46
46
22
46
24
(V)
Collision
Energy
260
260
280
260
250
(V)
Focusing
Potential
D7-ADMA70245MMA
D7-ADMA70259
D7-ADMA228259SDMA
D7-ADMA70259
D7-ADMA214259ADMA
Q3 
(m/z)
Q1
(m/z) 
Internal 
standard
Mass 
transition
Analyte
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SamplesPlasma samplesFor validation of the method a pool of heparin plasma from approximately 100 subjects was prepared. Additionally, plasma was obtained from 27 apparently healthy volunteers after they gave their informed consent, for 
the comparison between the LC-MS/MS method and our HPLC-fluorescence method (25, 26). To test if the method is sensitive enough for the determination of newly formed D3-ADMA, D3-SDMA, D3-MMA, D6-ADMA, and D6-SDMA in plasma during infusion of D3-methyl-1-13C-methionine, samples of a tracer study were analyzed. The rationale and main results of this study have been previously reported (27, 28). In short, D3-methyl-1-13C-methionine was given intravenously to both patients with end-stage renal disease and 
to healthy controls for the determination of methyl-fluxes through the three major pathways of the one-carbon metabolism (transmethylation, remethylation, and transsulfuration). For the current investigation we used 
samples from the healthy controls that had been stored at -20 °C.
Rat tissue samplesFrozen rat tissue samples from aorta, kidney medulla, kidney cortex and liver from an ongoing study were weighed before analysis, and per gram tissue 2 mL 0.6 mol/L perchloric acid was added. The samples were homogenized on ice using an Omni-2000 homogenizer (Omni international, Waterbury, CT, USA), and subsequently centrifuged at 1,915 x g and 4°C. The supernatant was transferred to a clean tube and centrifuged for 5 min at 20,160 x g and 4°C. The resulting supernatant was used for further analysis of the methylated 
arginines, using both the HPLC-fluorescence method (25, 26) and the current LC-MS/MS method.
Human umbilical vein endothelial cells (HUVEC)
For determination of matrix effects, HUVEC were isolated, cultured, and harvested as described previously (29). HUVEC-pellets were lysed on ice in 500 µL 100 mmol/L NaH2PO4 pH 7.3, using an ultrasonic probe (Bandalin Sonopuls mini 20 with MS 1.5 titanium microtip) for 3 x 10 s at ~0.250 kJ 
(= 90% of maximum power). Proteins were precipitated by adding 200 µL 
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lysate to 200 µL 1.2 mol/L perchloric acid, and after centrifugation (10 min; 
4°C; 20,160 x g) the supernatant was used.
Sample pretreatmentSample cleanupTo 200 µL plasma or perchloric acid supernatant, 50 µL of each internal standard solution (D7-ADMA, D4-L-homoarginine, and 13C6-L-arginine) and 800 µL 0.25 mol/L Na2HPO4 were added. The cationic amino acids were extracted with 1-mL (30 mg) Oasis MCX solid phase extraction (SPE) cartridges (Waters, Milford, MA, USA) as described previously (25, 26). After SPE, the samples were collected in glass vials and the solvent was evaporated 
at 60°C under N2.For the construction of standard curves, calibration samples were prepared by mixing 200 µL of the calibration standards prepared in water with 50 µL of each internal standard solution, and drying under N2 at 60°C. The calibration samples were not subjected to SPE, but directly derivatized, since the ratio between analyte and internal standard did not change upon SPE (data not shown).Additionally, it was determined whether SPE was necessary or if protein 
precipitation alone would be sufficient. To this end, one aliquot of the plasma pool was subjected to SPE, whereas from a second aliquot proteins were precipitated by adding 200 µL acetonitrile to 200 µL plasma. The samples 
were thoroughly mixed and after centrifugation (10 min; 4°C; 20,160 x g), 200µL of the supernatant was dried under N2 at 60°C.Sample derivatizationThe analytes were measured as their butyl-ester derivatives to increase their retention under reversed-phase conditions and allow chromatographic separation of ADMA and SDMA. The derivatization reaction was based on the method described by Schwedhelm et al. (30) and was performed by adding 100 µL of 1.25 mol/L HCl in 1-butanol to the dried samples. The capped vials 
were mixed thoroughly and heated to 70°C for 30 min, after which the caps were removed and the samples were dried under N2 at room temperature. Before analysis the samples were reconstituted in 150 µL mobile phase (Described in Section Instrumentation and settings).
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Instrumentation and settingsAnalysis was performed by injection of a 10 µL sample onto a 3.9 x 100 mm XTerra MS C18 column with 3.5 µm particles (Waters, Milford, MA, USA) using a Perkin Elmer Series 200 HPLC system (Perkin Elmer Inc. Shelton, 
CT, USA), comprising pump, degasser, cooled autosampler (4°C), and column 
oven (20°C). Chromatographic separation of the analytes was achieved with 
isocratic elution at a flow rate of 0.8 mL/min, using 600 mg/L ammonium 
formate in water-acetonitrile (95.5:4.5, v/v) containing 0.1 vol% formic acid as mobile phase. Using a switching valve (VICI International AG, Schenkon, 
Switzerland) the first two minutes of the flow after injection were directed 
to the waste. Before entering the mass spectrometer the flow was split 1:4. Analytes were detected using electrospray ionization (ESI) in positive mode on an API3000 triple quadrupole mass spectrometer (AB Sciex Technologies, Toronto, Canada), with the nebuliser gas at 9 L/min, the collision activated dissociation gas at 4 L/min, and the curtain gas at 10 L/min. For all gasses nitrogen was used. The ion spray voltage was set at 2 kV and the source 
temperature at 500 °C. The declustering potential (DP) was 40 V, the entrance potential (EP) 10 V, and the collision cell exit potential (CXP) 12.5 V. For all 
the analytes the dwell time was 150 ms and Q1 and Q3 were operating at unit mass resolution. Multiple reaction monitoring in positive mode was used for 
analyte quantification, and the analyte-specific mass transitions and analyte dependent parameters are listed in Table 1. In Figure 1 the structures of all analytes and internal standards are depicted together with the fragments formed after collision. Data was collected and analyzed using Analyst 1.4.2 software (AB Sciex Technologies, Toronto, Canada).
Evaluation of matrix effects
Because no analyte-free matrix is available, the matrix effects were evaluated by post-column infusion of the internal standards (20µmol/L 13C6-L-arginine, 0.2µmol/L D7-ADMA, and 0.2µmol/L D4-L-homoarginine). During infusion of the internal standards at 1µL/min, internal standard-free matrices were injected onto the column to reveal potential ion-suppression. For this purpose, we used undiluted, 10-fold diluted, and 100-fold diluted plasma (Section Sample pretreatment), a tissue sample from rat liver 
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(Section Rat tissue samples), and a HUVEC sample (Section Human umbilical 
vein endothelial cells (HUVEC)), that were subjected to sample cleanup and derivatization before injection.
Analytical method validationValidation was done according to the FDA-guidelines for bio-analytical method validation (31). The tested validation parameters were linearity, 
intra-assay and inter-assay accuracy and precision, matrix effects, recovery, and re-injection stability. Additionally, as suggested by Araujo (32), accuracy was tested by the comparison with a reference method, for which purpose 
our previously described HPLC-fluorescence method was used (25, 26).For the determination of the linear range, three series of seven calibration samples were independently measured. Samples contained 10, 20, 40, 80, 120, 200, and 500 µmol/L L-arginine and 0.1, 0.2, 0.4, 0.8, 1.2, 2.0, and 5.0 µmol/L ADMA, SDMA, MMA, and L-homoarginine. Calibration curves 
were fitted by least-squares linear regression with weighing factor 1/concentration2.Intra-assay accuracy and precision were tested using a plasma pool spiked 
with the QC-solutions (Section Quality controls). At each concentration level, 15 spiked plasma aliquots, as well as 15 spike-free aliquots, were measured 
within one analytical run. The accuracy (expressed as % bias) was determined by comparing the mean concentration of the spiked plasma to the expected value (mean plasma concentration + concentration of the spike), whereas 
the variation of the measured aliquots (CV%) indicated analytical precision. For inter-assay precision aliquots spiked at each concentration level were prepared and measured on 15 separate days.The recovery, after SPE and derivatization, was determined using a plasma 
pool spiked with the QC-solutions (Section Quality controls). At each concentration level, 15 spiked plasma aliquots, as well as 15 spike-free 
aliquots, were measured within one analytical run. The recovery (%) was 
calculated from the difference between the mean concentration of spiked plasma and the mean concentration of the spike-free plasma, divided by the concentration of the added spike. We have previously reported data on recovery of analytes after the SPE-procedure, determined using our HPLC-
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fluorescence method (25). To test linearity, precision, recovery and accuracy at low concentrations (e.g. for the measurements in cells and tissues), the calibration samples and the spiked and non-spiked plasma samples were reanalyzed after 10-fold and 100-fold dilution. Finally, re-injection stability was determined by re-injecting the samples from the intra-assay accuracy 
and precision determination after storage for 2 weeks at 4°C.
Results and discussion
Chromatography
In figure 2A the chromatograms of a calibration sample (0.2 µmol/L L-arginine, and 2 nmol/L ADMA, SDMA, MMA, and L-homoarginine) are 
shown and in figure 2B typical chromatograms of a 10-fold diluted plasma sample. The analytes were measured as their butyl-ester derivatives, which enabled complete chromatographic separation of ADMA and SDMA. This allows the measurement of the most intense common mass transition of ADMA and SDMA (259 → 70), in addition to the measurement of their unique mass transitions (259 → 214 and 259 → 228, respectively) that have a lower intensity. The additional sensitivity may be useful when the concentrations are near the detection limit or when only small quantities of sample are available. To test if the common transition yields equal precision and accuracy, it was validated together with the unique transitions of ADMA and SDMA (Section Method validation).In biological samples, the channel for L-homoarginine (mass transition = 245 → 84) showed an additional peak at 3.2 min (Figure 2B). After injecting 
solutions of Nε,Nε,Nε-trimethyllysine, Nα-acetyllysine, or Nε-acetyllysine, which may also result in the mass transition 245 → 84, it was found that 
Nε,Nε,Nε-trimethyllysine was responsible for the peak at 3.2 min.
Evaluation of matrix effectsPost-column infusion of the internal standards D7-ADMA and D4-
homoarginine did not reveal notable interference (<1%) from ion-
suppression upon injection of the different matrices (plasma, tissue, or cell lysate, subjected to sample cleanup and derivatization). Only when during infusion of 13C6-L-arginine undiluted plasma was injected, ion-suppression 
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Figure 2 Typical chromatograms of a standard solution and a plasma sample. The calibration sample (A), taken from the 100-fold diluted calibration range, contained 0.2 µmol/L L-arginine and 2 nmol/L ADMA, SDMA, MMA, and L-homoarginine. The plasma sample (B) is diluted 10-fold.
A
B
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was observed at the retention time of L-arginine (48.6%). Upon injection 
of 10-fold diluted plasma the ion-suppression was reduced (11.1%), and injection of 100-fold diluted plasma virtually eliminated ion-suppression 
(< 1%). Injection of cell or tissue samples did not lead to interference at the retention time of L-arginine. The ion-suppression was most likely caused by competition for ionization between L-arginine and its internal standard in the ESI-source. When L-arginine standards in water (7.2 µmol/L, 26.4 µmol/L and 45.6 µmol/L) were injected, ion-suppression increased in parallel 
(23.4%, 43.8%, and 51.6%, respectively), in support of this notion. Although 
the stable isotope-labeled internal standard of L-arginine is affected to the same extent, and should compensate for the reduced ionization at high L-arginine concentrations, for plasma samples it is preferable to use at least a 10-fold dilution.When sample cleanup of a plasma pool was performed by protein precipitation instead of SPE (see Section Sample cleanup), no matrix 
effects were observed within the runtime of 10 min. However, after 10 min, interferences were observed in the subsequent injections. These 
interferences should not affect analytes that have their own stable isotope-
labeled internal standard. Quantification of MMA and SDMA, however, is done using D7-ADMA and might suffer from these interferences. To overcome this, interferences from the late-eluting compounds could be removed with a steep gradient after elution of the last analyte of interest, i.e. SDMA. However, this would require re-equilibration of the column before each new injection, thereby increasing analysis time. Therefore, SPE is preferred over protein precipitation for sample cleanup.
Method validationLinearityThe linearity of the method was tested over a calibration range of 10 - 500 µmol/L for L-arginine and 0.1 - 5.0 µmol/L for ADMA, SDMA, MMA, and L-homoarginine. For each analyte three independently measured calibration lines were used to determine the linearity. To obtain the calibration lines the peak-area of the analyte divided by the peak-area of the internal standard was plotted on the y-axis and the concentration of the standard divided 
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by the concentration of the internal standard on the x-axis. Linearity was expressed as mean slope ± SD, mean intercept ± SD, and r2 (Table 2). ADMA 
and SDMA have different regression equations for the unique mass transition 
compared to their common mass transition. This difference is in agreement with the higher intensity of the peaks measured for the common transition. For the 10-fold and 100-fold diluted calibration range, slopes and intercepts 
were not significantly different from the values reported in Table 2, and for all analytes the calibration curves were also linear (r2 >0.9984 for 10-fold dilution, and  r2 >0.9983 for 100-fold dilution).
Sensitivity and carry-overSensitivity of the method was determined by establishing the lower limit 
of detection (LOD), defined as signal-to-noise ratio (S/N) ≥3, and the lower 
limit of quantification (LOQ), which was defined as S/N ≥10 with an accuracy 
<10%. Ideally, LOQ should be determined by analyzing the substances in their matrices. However, since no analyte-free matrix is available, both LOD 
Data is based on 3 separately measured calibration series.
0.2 µM D7-ADMA was used for the quantification of ADMA, SDMA, and MMA, 0.2 µM D4-
L-homoarginine for the quantification of L-homoarginine, and 20 µM 13C6-L-arginine for 
the quantification of L-arginine. 
0.9985-0.0077 (0.012)1.98 (0.090)0.1 – 5.0L-Homoarginine
-0.2203 (0.478)
0.0120 (0.024)
-0.0093 (0.019)
-0.0064 (0.011)
-0.0197 (0.020)
-0.0082 (0.010)
Intercept 
Mean (SD)
0.99916.56 (2.75) 0.1 – 5.0SDMA (259 – 70)
0.99814.63 (0.318)0.1 – 5.0MMA
0.99913.39 (0.111)0.1 – 5.0SDMA (259 – 228)
0.99790.157 (0.004)10 – 500L-Arginine
0.99914.87 (0.215)0.1 – 5.0ADMA (259 – 70)
0.99891.88 (0.082)0.1 – 5.0ADMA (259 – 214)
Correlation
r2
Slope
Mean (SD)
Range
(µM)
Analyte
Table 2 – Regression curves for linearity in plasma
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and LOQ were determined using matrix-free calibration samples prepared in water. For all analytes the LOD was established at 0.2 nmol/L. For ADMA (mass transition 259 → 70) and SDMA (mass transition 259 → 70) a LOQ of 0.4 nmol/L was obtained, and for all other analytes, including ADMA (mass transition 259 → 214) and SDMA (mass transition 259 → 228), the LOQ was 0.8 nmol/L. For L-arginine the lowest measured concentration was 20 nmol/L, which had a S/N of 559. From this data the LOD was estimated at 
approximately 0.1 nmol/L and the LOQ at approximately 0.4 nmol/L, which is in the same range as for ADMA and SDMA. Since such low L-arginine 
concentrations are not anticipated in biological samples, the LOD and LOQ of L-arginine were not experimentally determined.Carry-over was tested in the two blank injections measured after an injection of the highest standard. For none of the analytes peaks were found at their 
specific retention times in the two blank injections, indicating that there is no carry-over from previous injections.
Accuracy and precision
Intra-assay accuracy (% bias) and precision (expressed as CV%), and inter-assay precision were determined by using the standard addition method, for which 15 aliquots of the plasma pool were spiked at three concentration levels. In table 3 data is shown for intra-assay and inter-assay accuracy and precision of undiluted plasma. Intra-assay accuracy at the three concentration 
levels was <3% for all analytes except MMA, which was <7%. Intra-assay 
precision was ≤3.5% for all analytes, whereas inter-assay precision was <4% 
for L-homoarginine and ≤9.6% for all other analytes. Both for the 10-fold and 100-fold diluted range in plasma similar results were obtained (data not shown). Additionally, accuracy was tested by the comparison of  measurements done on 27 plasma samples using LC-MS/MS with measurements done 
using our previously validated HPLC-fluorescence method (25, 26), which 
has an inter-assay CV <4% for all analytes. Mean concentrations of ADMA, 
SDMA and L-arginine measured with HPLC-fluorescence were in line with previously reported values in healthy subjects measured with this method 
(25). Mean concentrations measured with LC-MS/MS were 0.469 ± 0.063 µmol/L for ADMA (259 → 214), 0.484 ± 0.066 µmol/L for ADMA (259 → 
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70), 0.509 ± 0.083 µmol/L for SDMA (259 → 228), 0.512 ± 0.081 µmol/L for SDMA (259 → 70), 97.8 ± 18.6 µmol/L for L-arginine, and 2.01 ± 0.647 µmol/L for L-homoarginine. For L-homoarginine and SDMA, these values 
differed by <2.5% from those measured with HPLC-fluorescence. Although values for ADMA and L-arginine, obtained with LC-MS/MS were slightly 
Table 3 – Accuracy, intra-assay precision, inter-assay precision, and recovery in plasma
2.43.7697.22.0-1.83.842.53
3.72.28100.72.60.32.340.962
5.63.1099.71.9-0.23.092.44
8.00.088NA3.5NA0.0890MMA
9.30.58593.72.3-5.40.6050.551
9.40.94895.52.3-4.20.9970.952
8.72.3092.91.8-6.92.422.51
7.6120NA1.7NA94.40L-Arginine
5.716996.61.2-1.214552.8
6.0211102.31.71.118891.2
3.835196.21.1-2.7326241
2.61.35NA1.4NA1.370L-Homoarginine
3.71.8895.01.5-1.41.900.557
NA: Not applicable
a Based on 15 samples per concentration level
2.2
2.8
1.6
2.0
1.7
3.0
1.7
1.6
2.1
1.8
1.4
1.7
2.5
1.8
2.0
Precision
(%)
1.5
0.4
NA
-0.1
1.9
-0.4
NA
-0.7
1.3
0.8
NA
-0.6
1.8
-0.1
NA
Accuracy
(%)
9.01.65102.51.610.927
9.51.66103.21.610.927
9.41.2799.11.190.537(259 - 228)
7.90.721NA0.6570SDMA
8.52.7999.12.792.24
6.73.0999.93.092.44
9.11.42102.31.440.849
8.01.06101.81.080.492(259-70)
6.40.569NA0.5760ADMA
6.90.725NA0.6620SDMA
9.61.26100.91.200.537(259-70)
2.80
1.43
1.08
0.566
Measured 
(µM)
Inter-assaya
99.3
103.0
99.8
NA
Recovery
(%)
7.52.792.24
7.81.440.849
6.91.060.492(259 - 214)
5.60.5680ADMA
Precision
(%)
Measured 
(µM)
Spike
(µM) 
Intra-assayaAnalyte
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higher compared to HPLC-fluorescence (~8% for L-arginine and ADMA 259 
→ 214, and ~11% for ADMA 259 → 70), results obtained with both methods correlated well for all analytes (Figure 3). Because MMA functions as the 
internal standard for the HPLC-fluorescence method, measurements could not be compared for this analyte.
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Figure 3
Comparison of plasma samples measured with HPLC-fluorescence and LC-MS/MSScatter plots (left) and Bland-Altman plots (right) for the comparison of concentrations (conc.) of ADMA, SDMA, L-arginine and L-homoarginine measured with HPLC-
fluorescence (HPLC-flu) and LC-MS/MS in plasma obtained from 27 healthy volunteers. The methods could not be compared for MMA, since it functions as the internal 
standard in the HPLC-fluorescence method.
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Recovery and stabilityThe recovery of the analytes was determined using a standard addition procedure (Section Analytical method validation). For ADMA and SDMA, 
recovery ranged from 99.1% to 103.2%, and for the other analytes recovery 
ranged from 92.9% to 102.3% (Table 3).
Re-injection of the derivatized samples after two weeks of storage at 4°C 
showed a deviation of <5% from the first measurement, and did not influence 
accuracy or precision. Therefore, samples that are stored at 4°C can be re-injected safely within two weeks after sample preparation.
Method implementationRat tissue samplesL-Arginine, ADMA and SDMA in rat tissue samples were previously 
determined using our HPLC-fluorescence method. However, in some of these 
samples ADMA and SDMA peaks suffered from interferences in the matrix around the same retention time (Figure 4 left panel), which made accurate 
quantification difficult. Therefore, the tissue samples were remeasured using the newly validated LC-MS/MS method (Figure 4, right panel). Because of the better selectivity and higher sensitivity the new HPLC-MS/MS method 
allowed more reliable quantification of ADMA and SDMA in rat tissue homogenates.
Plasma samples from a tracer studyPreviously we performed a tracer study (27, 28), in which D3-methyl-1-13C-methionine was given intravenously to patients with end-stage renal disease and to healthy controls. By measuring the levels of D3-methyl-labeled S-adenosyl-methionine, S-adenosyl-homocysteine and homocysteine, 
the methyl-fluxes through the three major pathways of the one-carbon metabolism (transmethylation, remethylation, and transsulfuration) were evaluated. One of the possible fates of the D3-methyl-group is its PRMT-catalyzed transfer to arginine residues in proteins, resulting in labeled MMA, ADMA, and SDMA, the latter two containing either one or two labeled methyl groups. However, the analysis of these compounds was beyond the scope of the original study. Because plasma samples from this tracer study were still 
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available, we had the opportunity to test the sensitivity of our new method for the determination of D3-MMA, D3-ADMA, D3-SDMA, D6-ADMA, and D6-SDMA. Within 60 min after starting infusion of D3-methyl-1-13C-methionine, D3-ADMA, D3-SDMA, and D3-MMA in plasma reached levels above the detection limit (Figure 5). This means that within this time frame, the supplemented D3-methyl-1-13C-methionine is transported into the cell and converted to 
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Figure 4ADMA and SDMA in rat tissue measured with 
HPLC-fluorescence and LC-MS/MS Chromatograms for ADMA and SDMA of rat tissue samples measured using the method with 
fluorescence detection are depicted on the left and using the newly developed method with mass spectrometry detection (transition 259 → 70 for ADMA and SDMA) on the right.
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S-adenosyl-methionine, from which the methyl group is transferred to an arginine residue of a protein that is subsequently degraded, releasing ADMA, SDMA or MMA into the cytosol, from where they are transported to the plasma via cationic amino acid transporters. It is remarkable how fast these subsequent processes lead to appearance of D3-methyl-labeled analytes in plasma. However, the possibility that, next to PRMT-catalyzed methylation of protein-incorporated arginine residues, also direct methylation of free L-arginine by other N-methyltransferases occurs, cannot be fully excluded.The tracer study was originally not undertaken for the determination of 
methylated arginines, but for the determination of methyl fluxes through the one-carbon metabolism. Therefore, the supplemented amount of D3-methyl-1-13C-methionine might not have been optimal for the formation of labeled ADMA, SDMA and MMA. Within the 300 min follow-up a steady state was not reached, which is probably the reason that D6-ADMA and D6-SDMA in plasma remained undetectable. 
Potential method limitations
SDMA was quantified using D7-ADMA as internal standard. SDMA has a 
different retention time than D7-ADMA and different analyte-specific mass 
spectrometric parameters, which could potentially lead to differences in ion-
suppression. However, no matrix effects were observed during post-column infusion of D7-ADMA. Furthermore, intra-assay and inter-assay precision for SDMA was similar to that of ADMA, which has its own stable isotope-labeled internal standard. The assay could be further improved by incorporating a commercially available or newly synthesized stable isotope-labeled SDMA as 
Figure 5Appearance of D3-ADMA, D3-SDMA, and D3-MMA in plasma during D3-methyl-1-13C-methionine infusion in healthy subjects. Within 60 min after start of the infusion, D3-ADMA, D3-SDMA, and D3-MMA in plasma reached detectable levels. D6-ADMA and D6-SDMA did not reach detectable levels during the 5-hour infusion period.
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internal standard (33).Plasma concentrations of ADMA and SDMA exhibit low intra-individual biological variation (34, 35), which leads to optimal imprecision goals of 
≤3% for ADMA and ≤5% for SDMA (36, 37). In contrast to our current HPLC-
fluorescence method, the inter-assay precision of the LC-MS/MS method does not meet this goal. Therefore, for the measurement of ADMA, SDMA, 
L-arginine and L-homoarginine in plasma, the HPLC-fluorescence method 
(25, 26) is preferable (CV <3% for ADMA and <4% for SDMA), whereas the 
LC-MS/MS method is more suitable for quantification of these analytes in 
small tissue samples and cultured cells, for the quantification of MMA, and in tracer studies.
ConclusionsAn LC-MS/MS method was developed for the simultaneous determination of ADMA, SDMA, MMA, L-arginine, and L-homoarginine in plasma, cells and tissues. The method was validated by determining linearity, recovery, 
lower limits of detection and quantification, accuracy, intra-assay precision, inter-assay precision, and re-injection stability. Previously, MS/MS-methods for the determination of L-arginine and its methylated forms (22, 38), and for L-homoarginine (23) in plasma and urine have been reported. Only one other group reported on a combined method for the determination of ADMA, SDMA, MMA, L-arginine, L-homoarginine, and L-citrulline in plasma and urine (24). But like most methods, because concentrations in plasma and urine are well above the detection limits, the method does not make use of chromatographic separation (21, 39). Butylation of the analytes allows chromatographic separation of ADMA and SDMA, which enables the use of their most intense common mass transition. Consequently, the separation of 
ADMA and SDMA benefits the selectivity and sensitivity for measurements in cells and tissues.Implementation of the method for analysis of rat tissue samples yielded satisfactory results, demonstrating the suitability of this method for measurements in very small tissue samples. Furthermore, the method is sensitive enough to detect appearance of D3-ADMA, D3-SDMA, and D3-MMA in plasma within 1 hour after starting infusion of labeled methionine, 
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demonstrating its potential for studying intracellular metabolism of methylated arginines with stable isotope tracer methodology.
AcknowledgementsThe authors wish to thank Rob Barto and Sigrid de Jong for their technical assistance.
References 1.  Nicholson TB, Chen T, Richard S. The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacol Res 60: 466-474, 2009. 2.  Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. 
Mol Cell 33: 1-13, 2009. 3.  Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992. 4.  Sasaki A, Doi S, Mizutani S, Azuma H. Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol Lung Cell 
Mol Physiol 292: L1480-1487, 2007. 5.  Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 78: S14-18, 2001. 6.  Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. 
Br J Pharmacol 147: S193-201, 2006. 7.  Tsikas D, Sandmann J, Savva A, Luessen P, Böger RH, Gutzki FM, Mayer B, Frölich JC. Assessment of nitric oxide synthase activity in vitro and in vivo by gas chromatography-mass spectrometry. J Chromatogr B 742: 143-153, 2000. 8.  Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. 
Am J Physiol Heart Circ Physiol 293: H3227-3245, 2007. 9.  Devés R, Boyd CA. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 78: 487-545, 1998. 10.  Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: Regulation and action. Pharmacol 
Res 60: 448-460, 2009. 11.  Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler 
Thromb Vasc Biol 23: 1455-1459, 2003.
 12.  Moali C, Boucher JL, Sari MA, Stuehr DJ, Mansuy D. Substrate specificity of NO synthases: detailed comparison of L-arginine, homo-L-arginine, their N omega-hydroxy derivatives, and N omega-hydroxynor-L-arginine. Biochemistry 37: 10453-
61
2Part II: Intracellular ADMA: metabolism and relation to plasma levels
J Chromatogr B 900 (2012) 38 - 47
10460, 1998. 13.  Pilz S, Meinitzer A, Tomaschitz A, Drechsler C, Ritz E, Krane V, Wanner C, Böhm BO, März W. Low homoarginine concentration is a novel risk factor for heart disease. Heart 97: 1222-1227, 2011. 14.  März W, Meinitzer A, Drechsler C, Pilz S, Krane V, Kleber KE, Fischer J, Winkelmann BR, Böhm BO, Ritz E, Wanner C. Homoarginine, cardiovascular risk, and mortality. 
Circulation 122: 967-975, 2010. 15.  Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA. The clinical 
significance of asymmetric dimethylarginine. Annu Rev Nutr 26: 203-228, 2006. 16.  Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 60: 481-487, 2009. 17.  Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Böhm BO, Winkelmann BR, März W. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 57: 112-121, 2011. 18.  Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, von Holten RA, Atzler D, Grant PJ, Böger RH. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 208: 518-523, 2010. 19.  Kielstein JT, Salpeter SR, Bode-Böger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial 
Transplant 21: 2446-2451, 2006. 20.  Teerlink T. ADMA metabolism and clearance. Vasc Med 10 Suppl 1: S73-81, 2005.
 21.  Martens-Lobenhoffer J, Bode-Böger SM. Chromatographic-mass spectrometric methods 
for the quantification of L-arginine and its methylated metabolites in biological fluids. 
J Chromatogr B 851: 30-41, 2007. 22.  Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. 
J Chromatogr B 851: 211-219, 2007. 23.  Atzler D, Mieth M, Maas R, Böger RH, Schwedhelm E. Stable isotope dilution assay for liquid chromatography-tandem mass spectrometric determination of L-homoarginine in human plasma. J Chromatogr B 879: 2294-2298, 2011. 24.  Di Gangi IM, Chiandetti L, Gucciardi A, Moret V, Naturale M, Giordano G. Simultaneous quantitative determination of N(G),N(G)-dimethyl-L-arginine or asymmetric 
dimethylarginine and related pathway’s metabolites in biological fluids by ultrahigh-performance liquid chromatography/electrospray ionization-tandem mass spectrometry. Anal Chim Acta 677: 140-148, 2010. 25.  Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 
62
303: 131-137, 2002. 26.  de Jong S, Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 353: 287-289, 2006. 27.  Stam F, van Guldener C, ter Wee PM, Kulik W, Smith DE, Jakobs C, Stehouwer CD, de 
Meer K. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine. Am J Physiol Renal Physiol 287: F215-223, 2004. 28.  van Guldener C, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, Donker AJ, Stehouwer CD, de Meer K. Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int 56: 1064-1071, 1999.
 29.  van der Molen EF, van den Heuvel LP, te Poele-Pothoff MT, Monnens IA, Eskes TK, Blom 
HJ. The effect of folic acid on the homocysteine metabolism in human umbilical vein endothelial cells (HUVECs). Eur J Clin Invest 26: 304-309, 1996. 30.  Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 51: 1268-1271, 2005. 31.  U.S.Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. http://www.fda.gov/cder/
guidance/index.htm. 2001. [Internet Communication] 2-1-2012.  32.  Araujo P. Key aspects of analytical method validation and linearity evaluation. 
J Chromatogr B 877: 2224-2234, 2009. 33.  Tsikas D, Beckmann B, Gutzki FM, Jordan J. Simultaneous gas chromatography-tandem 
mass spectrometry quantification of symmetric and asymmetric dimethylarginine in human urine. Anal Biochem 413: 60-62, 2011.
 34.  Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 47: 17-28, 2010. 35.  Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 43: 1130-1138, 2005. 36.  Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in 
biological fluids. J Chromatogr B 851: 21-29, 2007. 37.  Blackwell S, O’Reilly DS, Talwar D. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma. Eur J Clin Invest 37: 364-371, 2007.
 38.  Tsikas D, Schubert B, Gutzki FM, Sandmann J, Frölich JC. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-
pentafluoropropionyl) derivative. J Chromatogr B 798: 87-99, 2003.
 39.  Martens-Lobenhoffer J, Schwedhelm E, Tsikas D. Quantification of arginine and its 
mono- and dimethylated analogs NMMA, ADMA and SDMA in biological fluids by LC-
MS/MS: Is LC superfluous? J Chromatogr B 877: 3261-3266, 2009.
63
2Part II: Intracellular ADMA: metabolism and relation to plasma levels
J Chromatogr B 900 (2012) 38 - 47


Chapter 3
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Abstract
Proteolytic activity in whole blood may lead to release of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA). We investigated the role of the human erythrocyte in storage and generation of ADMA in healthy controls (n = 36) and critically ill patients (n = 38). Both free and total (sum of free and protein-incorporated) ADMA were measured. Upon incubation of intact erythrocytes with extracellular ADMA (0 to 40 µmol/L), equilibrium between intra- and extracellular ADMA was reached 
within 3 h. Compared with controls, patients had significantly higher basal concentrations of ADMA in plasma (0.88 ± 0.75 vs. 0.41 ± 0.07 µmol/L) and erythrocytes (1.28 ± 0.55 vs. 0.57 ± 0.14 µmol/L). Intracellular and plasma 
ADMA were significantly correlated in the patient group only (r = 0.834). 
Upon lysis, followed by incubation at 37°C for 2 h, free ADMA increased sevenfold (to 8.60 ± 3.61 µmol/L in patients and 3.90 ± 0.78 µmol/L in controls). In lysates of controls, free ADMA increased further to 9.85 ± 1.35 µmol/L after 18 h. Total ADMA was 15.43 ± 2.44 µmol/L and did not change during incubation. The increase of free ADMA during incubation corresponded to substantial release of ADMA from the erythrocytic protein-
incorporated pool (21.9 ± 4.6% at 2 h and 60.8 ± 7.6% at 18 h). ADMA was released from proteins other than hemoglobin, which only occurred after complete lysis and was blocked by combined inhibition of proteasomal and protease activity. Neither intact nor lysed erythrocytes mediated degradation of free ADMA. We conclude that intact erythrocytes play an important role in storage of ADMA, whereas upon erythrocyte lysis large amounts of free 
ADMA are generated by proteolysis of methylated proteins, which may affect plasma levels in hemolysis-associated diseases.
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IntroductionEndothelium-derived nitric oxide (NO), which is synthesized from arginine by nitric oxide synthase (NOS), is an important regulator of vascular homeostasis. Next to being a powerful vasodilator, NO inhibits platelet aggregation, adhesion of leukocytes to the endothelium, and proliferation of smooth muscle cells (1). Inactivation and/or reduced synthesis of NO is seen in conjunction with risk factors for cardiovascular disease and may promote endothelial dysfunction, hypertension, thrombus formation, and atherogenesis (1, 2). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NOS that, by competing with its substrate arginine, impairs NO production (3, 4). Increased plasma levels of ADMA are associated with endothelial dysfunction and atherosclerosis and have been found to predict future cardiovascular events, independent of traditional risk factors (5-7).ADMA is continuously formed during intracellular turnover of proteins. Some protein-incorporated arginine residues are posttranslationally methylated by protein arginine methyltransferases to form monomethylarginine and 
ADMA or symmetric dimethylarginine (SDMA). These modifications serve to expand the functional repertoire of the cellular proteome (8). During proteolysis of ADMA-containing proteins and peptides, ADMA is released into its free form, which inhibits NOS activity. Most free ADMA is hydrolyzed into citrulline and dimethylamine by the intracellular enzyme dimethylarginine dimethylaminohydrolase (DDAH), which has two isoforms with a wide tissue distribution (9). ADMA can be exported from the cell to the circulation via cationic amino acid transporters (CAT), which also mediate uptake by other cells or organs, thereby facilitating interorgan transport of ADMA (10).Because generation and degradation of ADMA are intracellular events, the circulation is usually considered as a passive transport medium for distribution of free ADMA between cells and tissues. Indeed, it has been shown that albumin and other plasma proteins contain virtually no protein-incorporated ADMA (11, 12). However, whole blood has been shown to contain large amounts of protein-incorporated ADMA (13-16). Billecke et al. 
(14) demonstrated that human blood is capable of releasing physiologically 
significant quantities of free ADMA from this protein-incorporated pool via 
proteolytic pathways. Although this elegant study identified the erythrocyte 
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as a likely source, ADMA concentrations in the erythrocyte cytosol were not measured directly but estimated from data in whole blood and plasma. It also remains to be established whether hemoglobin or other protein constituents of the erythrocyte are the main source of ADMA. Furthermore, DDAH-mediated degradation of free ADMA has been described in rat erythrocytes (13), but it is not clear whether active DDAH is also present in human erythrocytes. Therefore, the aim of the present study was to further delineate the role of the human erythrocyte in the transport and metabolism of ADMA. We studied the capacity of the intact erythrocyte to exchange free ADMA with its surroundings and examined the relation between intracellular free ADMA and plasma ADMA in healthy individuals and critically ill patients. We also established the size and nature of the protein-incorporated ADMA pool in erythrocytes and investigated the conditions under which free ADMA is released from this pool and the potential mechanisms involved. Finally, we investigated whether degradation of free ADMA occurs in the human erythrocyte.
Materials and methods
Study subjectsApparently healthy volunteers (n = 36) were recruited amongst laboratory personnel and students, who, after giving written informed consent, kindly donated a blood sample. In addition, blood samples were obtained from critically ill patients (n = 38) of the surgical intensive care unit of the Erasmus Medical Center Rotterdam, The Netherlands. The Institutional Review Board of the Erasmus Medical Center approved the protocol, and informed consent 
was obtained from a first-degree family member. Patients were included if they had clinical evidence of dysfunction of at least two organs. We have previously published on the relation between the plasma concentration of ADMA and mortality in these patients (17) and argued that ADMA may be a causative factor in the development of multiple organ failure (18). The present study comprises subjects from whom erythrocyte samples had been 
stored (n = 38, 71.1% male, age range 16–81). The Sequential Organ Failure Assessment (SOFA) score was calculated (19), and organ failure was defined 
as SOFA score ≥3 for any system. The number of failing organ systems 
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(number of patients) was: 0–1 (13), 2–3 (17), and ≥4 (8). Cardiovascular 
failure was most common (63.2% of patients), followed by respiratory failure 
(57.9%), renal failure (31.6%), hepatic failure (23.7%), neurological failure 
(26.3%), and coagulation failure (21.1%). During their intensive care unit 
stay, 14 patients (36.8%) died of irreversible multiple organ failure.
Isolation of erythrocytesErythrocytes were isolated from EDTA-blood by centrifugation (5 min. at 1,915 x g), separating the erythrocytes from plasma and buffy coat. After 
1 mL of plasma was acquired and removal of the remaining plasma and buffy 
coat, the erythrocytes were washed twice in 0.9% saline (Baxter, Utrecht, The Netherlands). Erythrocytes and plasma samples from individual 
subjects were stored at -80°C until further analysis. Additionally, washed erythrocytes from several individuals were pooled and used for experiments with or without prior freezing.Complete lysis of erythrocytes was accomplished by overnight freezing at 
-20°C, followed by thawing and addition of 2 volumes of water.
Measurement of ADMA release and uptake by erythrocytesADMA release from and ADMA uptake by intact erythrocytes was studied by incubating pooled erythrocytes with various concentrations of ADMA (Sigma, St. Louis, MO). To ~200 µL of packed erythrocytes (exact amount obtained by weighing), an equal volume of ADMA solution (0 to 42 µmol/L in saline) was 
added and incubated at 37°C in a water bath. At timed intervals between 0 and 180 min, tubes were taken from the water bath, rapidly chilled on ice, and centrifuged (10 min at 20,000 x g and 4°C). The supernatants were removed, and the erythrocyte pellets were washed once by resuspension in 1 mL of ice-cold saline, followed by centrifugation (10 min at 20,000 x g and 4°C). After removal of the supernatants, the erythrocyte pellets were lysed by overnight 
freezing at -20°C. After thawing, 400 µL water was added and proteins were precipitated by mixing with 600 µL ice-cold 1.2 mol/L perchloric acid (PCA; Merck, Darmstadt, Germany), followed by centrifugation (10 min at 20,000 x 
g and 4°C). Free ADMA levels were measured in the medium recovered after incubation, the saline supernatants obtained after washing the erythrocyte pellets, and in the PCA supernatants of the erythrocyte lysates.
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Generation of free ADMA induced by erythrocyte lysis 
Pooled erythrocytes were lysed by overnight freezing at -20°C. After thawing, 200 µL of the lysed cells (exact amount obtained by weighing) was mixed 
with 400 µL of water and the samples were incubated in a water bath at 37°C. After 1, 2, 3, 4, 6, and 18 h of incubation, tubes were put on ice and proteins were precipitated by mixing with 600 µL ice-cold 1.2 mol/L PCA, followed by centrifugation (10 min at 20,000 x g and 4°C). Supernatants were stored until determination of free ADMA and other amino acids. At the start and the end of the 18-h incubation period, 50-µL aliquots from the incubation mixture were taken for the determination of the total content of ADMA and other amino acids after acid hydrolysis.
To assess the effect of temperature, parallel incubations were performed at 
4°C. In addition, control incubations at 37°C with intact erythrocytes from the same pool, diluted with saline instead of water, were performed. The role of proteolysis on the release of ADMA upon in vitro lysis was studied 
by the addition of either Nα-tosyl-L-lysine-chloromethylketone (Biomol International, Plymouth Meeting, MA; 0.5 mg/mL in 62.5 mmol/L Na2HPO4, pH 6.0), an inhibitor of the (chymo)trypsin-like activity of the proteasome, or the complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany; 1 tablet/10 mL water), or both. To 200-µL aliquots from the lysed erythrocyte pool, 120 µL of one or both inhibitors was added and water to 
make a total volume of 600 µL, and the samples were incubated at 37°C for up to 18 h and processed as described above.
ADMA measurements in healthy and critically ill subjectsPlasma concentrations of ADMA and intracellular ADMA in erythrocytes were measured in both healthy subjects and critically ill patients. Erythrocytes were lysed by addition of 2 volumes of water after thawing as described above. Free ADMA in the lysates was determined at baseline and after 2 h 
incubation at 37°C. In healthy subjects, free ADMA was also determined after 18 h incubation, and at 0, 2 and 18 h aliquots were taken for determination of total (free and protein-incorporated) ADMA after acid hydrolysis.
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Acid hydrolysisFor measurement of total (i.e., the sum of free and protein-incorporated) levels of ADMA and other amino acids, proteins were hydrolyzed by acid hydrolysis. To a 50-µL aliquot of the incubation mixture, a 75-µL aliquot of a 40 µmol/L solution of the internal standard monomethylarginine (MMA) was added. Acid hydrolysis was performed by addition of 875 µL 6 mol/L hydrochloric acid (VWR International BDH Prolabo, Amsterdam, The 
Netherlands), followed by heating at 110°C for 16 h in sealed tubes. After hydrolysis, the samples were cooled and centrifuged (10 min at 20,000 x g) and the supernatant was used for analysis of ADMA and other amino acids.
Determination of ADMASupernatants obtained after deproteinization with PCA were neutralized by addition of 0.25 mol/L Na2HPO4. Plasma samples and neutralized PCA-supernatants were spiked with the internal standard MMA and then basic amino acids (including the analytes arginine, ADMA, and SDMA and the internal standard MMA) were extracted by solid-phase extraction (SPE) on polymeric cation-exchange columns (20). After SPE extraction, the samples were dried with nitrogen derivatized with ortho-phthaldialdehyde reagent containing 3-mercaptopropionic acid, and the analytes were separated by isocratic reversed-phase chromatography (HPLC) on a monolithic column as previously described (21). Total ADMA (i.e., the sum of free and protein-incorporated ADMA) was determined in acid hydrolysates. A 100-µL aliquot of the supernatant obtained after acid hydrolysis was dried under nitrogen 
at 60°C and dissolved in 100 mmol/L Na2HPO4, pH 8.0, followed by SPE and HPLC analysis as described above. For all analytes, the intra- and inter-assay 
coefficients of variation were <2% and <4%, respectively.
Determination of amino acidsConcentrations of free amino acids in the PCA-supernatants were measured with reversed-phase HPLC, using automated precolumn derivatization with ortho-phthaldialdehyde reagent containing 3-mercaptopropionic acid and 
fluorescence detection as previously described (22). The total amino acid content (i.e., the sum of free and protein-incorporated amino acids) was 
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determined in acid hydrolysates. A 100-µL aliquot of the supernatant obtained 
after acid hydrolysis was dried under nitrogen at 60°C and dissolved in 1 mL 100 mmol/L Na2HPO4, pH 8.0, followed by amino acid analysis as described 
above. For all amino acids, the intra- and inter-assay coefficients of variation 
were <4% and <7%, respectively.
Calculation of intracellular concentrationsFor calculation of intracellular concentrations of ADMA and other amino acids 
in erythrocytes, the water content was assumed to be 66% of erythrocyte weight as described by Flügel-Link et al. (23).
Statistical analysesData are presented as means ± SD, unless otherwise indicated. The paired-Student’s t-test was used for comparison of ADMA levels between plasma and erythrocytes of individual subjects and for comparison between incubation periods. ADMA levels in critically ill and healthy subjects were compared using the independent-samples t-test. Univariate relations between variables were investigated using Pearson’s correlation analysis. A two-tailed P-value 
<0.05 was considered statistically significant. Statistical analyses were performed using SPSS 19.0 (SPSS, Chicago, IL).
Results
Release and uptake of ADMA by intact erythrocytesThe capacity of erythrocytes to release and take up ADMA was studied by 
incubating a pool of intact erythrocytes for 3 h at 37°C with saline, containing increasing concentrations of ADMA. Incubation with medium devoid of ADMA resulted in a slow release of ADMA from the erythrocytes to the extracellular medium (Figure 1A). During incubation, the intra- and extracellular ADMA concentrations gradually converged, but full equilibrium was not reached during the 3-h incubation period. When the initial concentration of ADMA in the extracellular medium exceeded the intracellular ADMA concentration, net uptake of ADMA by the erythrocytes occurred (Figure 1B 
- E). At all concentrations tested, rapid inflow of ADMA resulted in ADMA concentrations being higher in the cell than in the medium at 15 min, as 
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reflected by an intracellular-to-medium concentration ratio exceeding 1 (Figure 1F). After this initial overshoot, intra- and extracellular ADMA concentrations converged and were almost equal at 3 h, irrespective of the 
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Figure 1 Asymmetric dimethylarginine (ADMA) release and uptake by intact erythrocytes. A pool of 
erythrocytes was incubated at 37°C with an equal volume of saline (A) or saline containing increasing concentrations of ADMA (B to F). Afterwards, the erythrocytes were separated from the medium by centrifugation and intracellular and medium free ADMA concentrations were measured. Intraerythrocytic-to-medium concentration ratios of ADMA were calculated (F). Values are means ± SD; n = 3.
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initial extracellular ADMA concentration. At the end of the incubation period, the calculated recovery of ADMA, i.e., the sum of ADMA in the intracellular and extracellular compartments and the saline wash, expressed as a fraction of the total amount of ADMA at the start of the incubation, ranged between 
99.3% and 103.0%.
Generation of ADMA in erythrocyte lysatesExperiments on pooled erythrocytes were performed to gain more insight in the origin and kinetics of lysis-induced ADMA generation. Lysis of 
erythrocytes followed by incubation at 37°C resulted in a rapid increase of the ADMA concentration in the lysate (Figure 2). The initial ADMA concentration 
of 0.53 ± 0.01 µmol/L more than doubled during the first hour of incubation and further rose to 4.94 ± 0.07 µmol/L at 18 h, without reaching a clear plateau. The increase of ADMA during the 18-h incubation period (4.41 ± 
0.07 µmol/L) was much smaller when incubation was performed at 4°C (0.61 ± 0.04 µmol/L) and almost negligible in intact erythrocytes incubated 
at 37°C (0.27 ± 0.12 µmol/L).
ADMA generation during incubation of lysed erythrocytes at 37°C was 
reduced by 12.2% when activity of the proteasome was inhibited and by 
56.9% when activity of proteases was inhibited. Combined inhibition of 
proteasomal and protease activity reduced ADMA generation by 87.4%, 
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Figure 2 Generation of free ADMA by erythrocytes upon lysis. Lysed erythrocytes were 
incubated at 37°C and the generation of free ADMA was measured for up to 18 h. Incubation was performed in the absence 
of inhibitors (Lysed 37°C), in the presence 
of the proteasome inhibitor Nα-tosyl-L- lysine-chloromethylketone (TLCK), in the presence of a protease inhibitor cocktail (PIC), and in the presence of both protease and proteasome inhibitors (PIC + TLCK). Control experiments were performed 
without prior lysis (Intact 37°C) and with lysed erythrocytes incubated at low 
temperature (Lysed 4°C). Values are mean ± SD; n = 3.
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which was equally effective as lowering the incubation temperature from 
37°C to 4°C (Figure 2). These results suggest that proteolysis of methylated proteins, rather than 
de novo ADMA synthesis, is the cause of the generation of free ADMA in erythrocyte lysates. To further investigate this issue, we assessed whether the increase in free ADMA was accompanied by changes in total ADMA, i.e., the sum of free and protein-incorporated ADMA. In acid hydrolysates 
of the erythrocyte lysates, we observed no significant difference between total ADMA concentrations measured in triplicate at baseline and after 18 
h incubation at 37°C (15.95 ± 0.56 vs. 16.31 ± 0.51 µmol/L, respectively; 
P = 0.45). This means that the 4.41 ± 0.07 µmol/L increase of free ADMA 
after 18 h incubation is equivalent to conversion of 27.4 ± 1.0% of the protein-incorporated ADMA pool into free ADMA. Similar calculations were performed for SDMA. The concentration of total SDMA was approximately eightfold lower compared with ADMA but, like ADMA, did not change 
significantly during incubation (1.92 ± 0.20 µmol/L at baseline vs. 2.21 ± 0.17 µmol/L at t = 18 h; P = 0.14). The increase of free SDMA during the 
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Figure 3 Comparison of the amino acid composition of erythrocytes and hemoglobin. After acid hydrolysis of an erythrocyte pool, amino acids were measured by HPLC and expressed as percentage of the total amount of amino acids recovered (grey bars). Values are mean ± SD; 
n = 3. The relative amino acid composition of human hemoglobin (α2β2) was calculated from sequence data (black bars). Amino acids that cannot be measured with the HPLC method (proline and cysteine) or that are degraded during acid hydrolysis (tryptophan and methionine) were excluded from the calculations. Because acid hydrolysis causes deamidation of asparagine and glutamine, the sum of aspartic acid and asparagine (Asx) and of glutamine and glutamic acid (Glx) is reported.
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incubation was 0.23 ± 0.01 µmol/L, corresponding to release of 10.9 ± 1.3% of protein-incorporated SDMA.
Because it seemed highly unlikely that under these conditions >10% of the erythrocyte proteome is degraded to free amino acids, we also investigated the release of common amino acids from proteins. The total amount of amino acids in the erythrocyte lysate, measured after acid hydrolysis, was 4.52 ± 0.23 mol/L (n = 3). The relative amount of the individual amino acids closely resembled the amino acid composition of human hemoglobin 
(α2β2) calculated from sequence data (Figure 3), in accord with the fact that hemoglobin almost fully accounts for the protein content of the erythrocyte. 
This was also reflected by the low content (0.34 ± 0.02%) of isoleucine, the only common amino acid that is not present in human hemoglobin and therefore originates from other proteins. The total amount of free amino acids in the erythrocyte lysate was 328 ± 8 µmol/L at baseline and increased to 982 ± 7 µmol/L after 18 h incubation. The increase of 654 ± 10 µmol/L is equivalent 
to release of 0.015 ± 0.001% of amino acids from the protein-incorporated 
AD
MA
SD
MA Il
e Ala Gl
y
Se
r
Th
r
Va
l
Ly
s
Le
u Hi
s
Gl
x
Ar
g
Ph
e Ty
r
As
x
0.00
0.02
0.04
0.06
10
20
30
R
el
ea
se
 fr
om
 p
ro
te
in
 (%
)
Figure 4 Release of free amino acids from protein after erythrocyte lysis. A pool of erythrocytes was 
lysed and incubated at 37°C. At t = 0 h and t = 18 h a sample was taken for measurement of ADMA,  symmetric dimethylarginine (SDMA) and other free amino acids. Increase in the concentration of free amino acids during incubation is expressed as percentage of the total amount (sum of free and protein-incorporated) of amino acids at t = 0 measured after acid hydrolysis. Values are means ± SD; n = 3. Amino acids that cannot be measured with the HPLC method (proline and cysteine) or that are degraded during acid hydrolysis (tryptophan and methionine) were excluded from the calculations. Because acid hydrolysis causes deamidation of asparagine and glutamine, the sum of aspartic acid and asparagine (Asx) and of glutamine and glutamic acid (Glx) is reported.
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pool. The release of individual amino acids present in hemoglobin was also 
very low, varying from almost undetectable to 0.033 ± 0.002% for alanine (Figure 4). Release of isoleucine, not present in hemoglobin, was slightly 
higher (0.063 ± 0.004%), but still >100-fold lower than the release of ADMA 
(27.4 ± 1.0%) and SDMA (10.9 ± 1.3%).To gauge potential activity of DDAH, which degrades ADMA into citrulline and dimethylamine, citrulline was also measured. Citrulline, measured in 
triplicate, did not change significantly during incubation of the erythrocyte 
lysates at 37 °C (3.36 ± 0.14 µmol/L at baseline vs. 3.52 ± 0.17 µmol/L at t = 18 h; P = 0.26), indicating absence of DDAH activity.
ADMA in erythrocytes and plasma from healthy and critically ill subjectsAs illustrated in Figure 5, the concentration of ADMA in plasma was 
significantly higher in critically ill patients than in healthy subjects (0.88 ± 0.75 vs. 0.41 ± 0.07 µmol/L; P <0.001). This was also the case for the intracellular ADMA concentration in erythrocytes (1.28 ± 0.55 vs. 0.57 ± 0.14 µmol/L; P < 0.001). In both groups, the intracellular ADMA concentration 
was significantly higher than the plasma ADMA concentration (P <0.0001; Figure 5), but this concentration gradient was more pronounced in the 
patient group, as reflected by a higher intracellular-to-plasma concentration ratio (1.78 ± 0.59 in patients vs. 1.43 ± 0.39 in controls; P = 0.003).Correlation analysis revealed that intracellular and plasma concentrations of 
ADMA were significantly related in the patient group (r = 0.834; P <0.0001; Figure 6B), but not in healthy subjects (r = 0.072; P = 0.68; Figure 6A). This might be partly caused by the wider range of ADMA concentrations in the patient group. However, when the analysis in critically ill patients 
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Figure 5 Concentration of free ADMA in plasma and erythrocytes of healthy subjects (n = 36) and critically ill patients (n = 38). Values are 
mean ± SE. * P <0.001 critically ill 
vs. healthy subjects. † P <0.0001 erythrocytes vs. plasma.
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was restricted to subjects with plasma ADMA concentrations in the range 
of healthy subjects, i.e., <0.6 µmol/L (n = 16), the association between 
intracellular and plasma ADMA was attenuated but remained significant (r = 0.529; P = 0.035).
Generation of ADMA in erythrocyte lysates of healthy and critical ill subjectsTo determine if generation of ADMA in erythrocyte lysates occurs to the same extent in critically ill patients and in healthy subjects, erythrocyte lysates 
were prepared and incubated at 37°C. In all subjects, the ADMA concentration 
increased significantly during incubation for 2h (from 0.57 ± 0.14 to 3.90 ± 0.78 µmol/L in healthy subjects and from 1.28 ± 0.55 to 8.60 ± 3.61 µmol/L in patients; both P <0.0001; Figure 7). Although the absolute increase of ADMA was much higher in the patient group, the relative increase did not 
significantly differ between both groups (7.0 ± 1.6-fold in healthy subjects vs. 6.9 ± 2.2-fold in patients; P = 0.69). In healthy subjects, incubation was continued until 18 h, and by that time the free ADMA concentration had 
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Figure 6Scatterplots of the relation between plasma ADMA and intracellular free ADMA in erythrocytes of healthy subjects (A) and critically ill patients (B). Strengths of the associations are indicated by Pearson correlation 
coefficients.
79
3
Part II: Intracellular ADMA: metabolism and relation to plasma levels
Am J Physiol Heart Circ Physiol 302 (2012) H1762 - H1770
further risen to 9.85 ± 1.35 µmol/L (P <0.0001 versus t = 2 h), almost equal to the concentration that was reached in the critically ill patients already after a 2-h incubation. Aliquots of the incubation mixture taken at baseline and 18 h were hydrolyzed for determination of total ADMA, i.e., the sum of free and protein-incorporated 
ADMA. Total ADMA did not significantly change during the incubation (15.43 ± 2.44 µmol/L at baseline vs. 14.92 ± 2.35 µmol/L at t = 18 h; P = 0.17). The increase of free ADMA after 2 and 18 h of incubation (compared to baseline 3.33 ± 0.74 and 9.27 ± 1.31 µmol/L, respectively) corresponded to conversion of a substantial fraction of the protein-incorporated ADMA pool 
into free ADMA (21.9 ± 4.6 and 60.8 ± 7.6%, respectively).
DiscussionIn this study, we investigated the role of erythrocytes in the storage and generation of the endogenous NOS inhibitor ADMA. Our results indicate that 
there is fast bidirectional traffic of ADMA across the plasma membrane of 
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Figure 7Generation of free ADMA by lysed erythrocytes of 36 healthy individuals (A) and 38 critically ill patients (B). The increase of free ADMA in erythrocyte lysates during a 2-h incubation at 
37°C is shown for each individual. Summary data are means ± SD.
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the intact erythrocyte, leading to a rapid equilibrium between intra- and extracellular ADMA. Upon lysis of erythrocytes, proteolytic activity leads to a substantial release of free ADMA from methylated proteins but without appreciable contribution from hemoglobin. No DDAH-mediated degradation of free ADMA by erythrocytes was observed. Taken together, the results of this study indicate that the erythrocyte can serve both as a reservoir and a source of free ADMA.
ADMA release and uptake by the human erythrocyteThe transport of cationic amino acids, including arginine and ADMA, across the erythrocyte membrane is facilitated by system y+, and by system y+L, which next to cationic amino acids also recognizes large neutral amino acids 
(24, 25). A family of CAT transporter proteins is responsible for the activity of system y+, whereas y+LAT transporters mediate the activity of the y+L system 
(26). Notably, CAT transporters operate as a facilitated diffusion system driven by the membrane potential. Virtually all eukaryotic cells, including erythrocytes (27), maintain a nonzero transmembrane potential, with a negative voltage in the cell interior compared with the cell exterior, thereby stimulating CAT-mediated uptake of positively charged amino acids. For arginine, it has been demonstrated that its distribution ratio, in accordance 
with the Nernst equation, accurately reflects the membrane potential (28). Under physiological conditions, the membrane potential of the erythrocyte in blood, as calculated from the Goldman-Hodgkin-Katz equation, is -14.3 mV 
(29). Application of the Nernst equation indicates that, at this potential, CAT-mediated exchange of singly charged positive amino acids will equilibrate at an intracellular concentration that is 1.71-fold higher than the extracellular concentration. Notably, this theoretical distribution ratio is close to the values we measured for ADMA in blood samples (intracellular-to-plasma ratio of 1.43 ± 0.39 in healthy subjects and 1.78 ± 0.59 in critically ill patients).
Relation between ADMA in erythrocytes and plasma in health and diseasePrevious studies (30, 31) have demonstrated that both plasma and erythrocytes contribute to the interorgan transport of amino acids. Consequently, whole blood cannot be viewed as a single compartment, but 
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the contributions of the plasma and the erythrocyte compartments should be considered separately, especially for amino acids that do not equilibrate well between plasma and blood cells (32). We studied the relation between ADMA in plasma and erythrocytes in apparently healthy individuals and critically ill patients. In line with the results of the in vitro experiments, in almost all subjects the intracellular concentration of ADMA exceeded its concentration 
in plasma. Remarkably, a significant association between intracellular and plasma concentrations of ADMA was only observed in patients and not in controls. The poor correlation in healthy individuals is in line with results of a study with stable isotope labeled amino acids in rats, showing a poor equilibration of arginine between plasma and erythrocytes (32). Possibly, the closer relation between intra- and extracellular ADMA in critical illness is caused by upregulation of CAT in the plasma membrane. Upregulation of CAT in erythrocytes has indeed been demonstrated in patients with chronic renal or heart failure (33-36) and also in pregnant women with preeclampsia 
(37). Next to changed expression levels of CAT in the erythrocyte membrane, 
also uptake of ADMA from the plasma by tissues may affect the plasma-erythrocyte equilibrium. Kidneys and liver have a high DDAH activity and both organs contribute to clearance of ADMA from the circulation (38-43). Rapid clearance of ADMA from the circulation has been demonstrated by Kielstein et al. (44) by infusion of ADMA into healthy subjects. In these experiments, a mean plasma half-life of 24 ± 7 min was calculated from the plasma ADMA decay curves. Clearance-induced attenuation of the correlation between ADMA in plasma and erythrocytes will likely be substantial in healthy individuals but may be less pronounced in critically ill patients, in whom DDAH activity and thus clearance is impaired. 
Generation of ADMA in erythrocyte lysatesThe rapid increase of free ADMA during incubation of erythrocyte lysates at 
37 °C was due to enzymatic degradation of methylated proteins, because the process was temperature dependent and almost completely blocked in the presence of inhibitors of proteases and the proteasome. During maturation, 
erythrocytes undergo a series of differentiations, including loss of nucleus, ribosomes, and mitochondria. Consequently, all capacity for cell division and 
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protein synthesis is lost. Therefore, mature erythrocytes would be expected to have minimal turnover of proteins, since replacement of degraded proteins by de novo synthesis is not possible. However, erythrocytes are capable to degrade (oxidatively) damaged proteins by the catalytic action of the 20S proteasome (45-47). Lysis of erythrocytes, by inducing oxidative damage or conformational changes of intracellular proteins, probably triggers proteasomal degradation. The proteasome generates peptides of seven to nine amino acids long, which subsequently can be degraded into single amino acids by proteases (48, 49). Therefore, release of free ADMA from methylated proteins requires the combined action of the 20S proteasome 
and a number of different proteases, which is consistent with our observation 
that ADMA generation was most effectively blocked by combined inhibition of proteasomal and protease activities.
In erythrocyte lysates, >25% of protein-incorporated ADMA was released as free ADMA after 18h incubation. This is in strong contrast with common 
amino acids that are present in hemoglobin, of which <0.04% was released during incubation (Figure 4). The low degradation rate of hemoglobin may 
reflect stability of its compact quaternary structure. Isoleucine, that is not 
present in human hemoglobin, was released at a slightly higher rate (0.06%), indicating that proteins other than hemoglobin may be more sensitive towards proteasomal degradation. However, the rate of release of ADMA and SDMA was >100-fold higher, indicating that proteins methylated at arginine residues may be degraded at an extremely high rate. We (50) have previously also observed very high rates of release of ADMA and SDMA from methylated proteins during incubation of rat kidney homogenates. In contrast to other 
posttranslational modifications that are reversible, such as phosphorylation, arginine methylation is virtually irreversible. This implies that if arginine methylation is considered as a switch that turns on a particular function of a protein, degradation of the entire protein may be the only way to switch 
off that function. A high intrinsic sensitivity of arginine-methylated proteins 
towards proteasomal degradation may thus enhance flexibility of arginine methylation as a tool to modulate protein function.Several other investigators (13-16) have previously provided evidence for release of ADMA from whole blood or erythrocytes. Hemoglobin is by far 
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the most abundant protein constituent of the erythrocyte, but there is some controversy whether or not it is a likely source of ADMA (12, 15). Our data clearly demonstrate that hemoglobin is not the main source of free ADMA released upon erythrocyte lysis. However, proteomic analysis has revealed the existence of >750 proteins within the human erythrocyte (47, 51), and a recent study (45) identified 28 proteins whose content was affected by proteasomal activity in intact erythrocytes. In our opinion, the source of ADMA should be sought among one of these nonhemoglobin members of the complex erythrocyte proteome.
Absence of DDAH activity in erythrocytesOur results strongly suggest the absence of active DDAH in the erythrocyte. First, in the experiments in which we examined exchange of free ADMA across the erythrocyte membrane, the recovery of ADMA at the end of the incubation period was essentially complete at all ADMA concentrations tested. Second, although a substantial fraction of protein-incorporated ADMA was released into its free form during incubation of erythrocyte lysates, the total amount of ADMA remained constant. This is in line with the results obtained by Billecke et al. (14), who also observed an increase of free ADMA without a change of total ADMA during incubation of whole blood lysates. Finally, DDAH-mediated degradation of ADMA would lead to production of citrulline, but the concentration of citrulline in the erythrocyte lysates did 
not increase during incubation. Taken together, our results do not confirm the presence of active DDAH in human erythrocytes as previously reported by Kang et al. (52). On a parallel note, Böhmer et al. (53), using a sophisticated gas chromatography-mass spectrometry assay, convincingly demonstrated lack of NOS activity in erythrocytes. The absence of active DDAH and NOS enzymes indicates that intraerythrocytic ADMA probably has no functional role in the regulation of NO production by the erythrocyte.
Study limitationsTo study uptake and release of ADMA by intact erythrocytes, washed erythrocytes were incubated with ADMA in isotonic saline solutions. In whole blood, the rate of exchange of ADMA across the plasma membrane 
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will be different, because other cationic amino acids, such as SDMA, arginine, lysine, and ornithine, compete with ADMA for CAT-mediated transport. In addition, the rate of transport may be enhanced by the presence of cationic amino acids on the opposite side of the membrane, a phenomenon known as transstimulation (24, 25). Therefore, the results of these experiments merely reveal the capacity of erythrocytes for rapid exchange of ADMA across their membrane but should not be regarded to quantitatively model the in vivo process.We deliberately chose to investigate healthy volunteers and critically ill patients as representatives of the extremes of the (patho)physiological 
spectrum. Our data clearly show differences between these groups with respect to cytosolic ADMA in intact erythrocytes and generation of free ADMA upon lysis. However, because both groups were not matched in any 
way, we cannot draw any definitive conclusions on the potential clinical 
significance of these differences. This would require further experiments in a well-controlled clinical study.
Potential clinical consequencesOur data show that the erythrocyte is an important player in the generation, storage, and transport of ADMA. Intact erythrocytes can take up and store ADMA from their surroundings and are also able to release ADMA when extracellular concentrations are lower. In healthy subjects, the concentration of ADMA in the erythrocyte cytosol is higher than in plasma and in critically ill patients this contrast is even more pronounced. This implies a role for the erythrocyte in the temporary storage and interorgan transport of free ADMA and indicates that this faculty of the erythrocyte may be most conspicuous in critical illness.Lysis of erythrocytes results in generation of substantial amounts of free ADMA, released from methylated proteins by rapid proteasomal and proteolytic degradation. In critically ill patients, this process occurs in vitro at a higher rate than in healthy individuals (Figure 7), consistent with previous studies (54, 55) showing increased levels of the 20S proteasome in the circulation and increased proteasomal activity in skeletal muscle of critically ill patients. Upon intravascular lysis of erythrocytes, the cytosolic ADMA 
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that was originally present in the erythrocyte before lysis, as well as the free ADMA generated during lysis-associated proteolysis, is spilled into the plasma compartment from where it may be taken up by other cells, including intact erythrocytes. Considering the large reservoir of protein-incorporated ADMA in erythrocytes, lysis of even a small fraction of erythrocytes may therefore lead to a clinically relevant rise of ADMA concentrations, not only in plasma and erythrocytes, but also in tissues that are in intimate contact with the blood compartment, like the vascular endothelium. ADMA generation by hemolysis may contribute to the high plasma ADMA levels observed in patients with sickle cell disease (56-58) and HELLP syndrome 
(59) and possibly also in other hemolysis-associated diseases. Release of ADMA from lysed erythrocytes may also occur as a consequence of ex vivo shear stress during hemodialysis of patients with end-stage renal failure. This might explain the observations that the decrease of plasma ADMA after hemodialysis is less than might be expected from its molecular weight (60, 
61) and that plasma ADMA levels appear to be lower in patients treated with peritoneal dialysis compared to patients on hemodialysis (62, 63).The dual role played by erythrocytes and hemoglobin in the metabolism of NO is increasingly recognized. On the one hand, the erythrocyte may limit the bioavailability of NO, either by reducing its production through arginase-catalyzed consumption of arginine (64) or by hemoglobin-mediated scavenging of NO (65). On the other hand, under hypoxic conditions, the erythrocyte may contribute to NO production, via hemoglobin-catalyzed reduction of nitrite (65, 66). Storage and generation of the NOS inhibitor ADMA further add to the portfolio of the erythrocyte with respect to regulation of NO metabolism.
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Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness
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Abstract
High plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are associated with adverse outcome in critically ill patients. ADMA is released within cells during proteolysis of methylated proteins and is either degraded by dimethylarginine dimethylaminohydrolase (DDAH) or exported to the circulation via cationic amino acid transporters. We aimed to establish the role of DDAH activity in the regulation of tissue and plasma concentrations of ADMA. In 33 critically ill rabbits, we measured DDAH activity in kidney, liver, heart, and skeletal muscle and related these values to concentrations of ADMA in these tissues and in the circulation. Both DDAH activity and ADMA concentration were highest in kidney and lowest in skeletal muscle, with intermediate values 
for liver and heart. Whereas ADMA content was significantly correlated 
between tissues (r = 0.40 - 0.78), DDAH activity was not. Significant inverse associations between DDAH activity and ADMA content were only observed 
in heart and liver. Plasma ADMA was significantly associated with ADMA in the liver (r = 0.41), but not in the other tissues. In a multivariable regression model, DDAH activities in muscle, kidney, and liver, but not in heart, were negatively associated with plasma ADMA concentration, together explaining 
approximately 50% of its variation. In critical illness, plasma ADMA poorly 
reflects intracellular ADMA. Furthermore, tissue DDAH activity is a stronger predictor of plasma ADMA than of intracellular ADMA, indicating that, compared with DDAH activity, generation of ADMA and cationic amino acid transporter-mediated exchange may be more important regulators of intracellular ADMA.
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IntroductionNitric oxide (NO), produced from arginine by NO synthase (NOS), plays an important role in the cardiovascular system by regulating vascular tone, reducing the interaction of white blood cells and platelets with the endothelium, and inhibiting proliferation of vascular smooth muscle cells 
(1). Asymmetric dimethylarginine (ADMA) is an endogenously produced inhibitor of NOS (2); and several prospective studies have shown that elevated plasma concentrations of ADMA, independent of traditional risk factors, predict cardiovascular events and mortality (3). Especially in critically ill patients, ADMA levels may rise to high levels and plasma ADMA is a strong independent predictor of adverse outcome (3, 4).
The metabolism of ADMA and its exchange between different organ systems via the plasma compartment are illustrated in Figure 1. ADMA is released within cells upon proteolysis of proteins that have been posttranslationally methylated at arginine residues by protein arginine methyltranferases. Cytosolic ADMA is either degraded by 1 of the 2 isoforms of dimethylarginine dimethylaminohydrolase (DDAH) or exported via cationic amino acid transporters (CAT) to the circulation, from where it is taken up by other cells or excreted by the kidneys (5). It has been estimated that whole-body 
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Figure 1 Metabolism and transport of ADMA. Free ADMA is generated during proteolysis of proteins that have been methylated at arginine residues. Intracellular ADMA, which is an inhibitor of NOS, is actively degraded by DDAH or exported from the cell to the plasma compartment via CAT. 
The plasma concentration of ADMA reflects a dynamic equilibrium and is the net result of release into and uptake from the plasma compartment by liver, kidney, heart, muscle, and other organs. In addition, a relatively small fraction of ADMA is cleared from the plasma by renal excretion.
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production of ADMA in humans is around 300 µmol/d, of which more than 
80% is metabolized by DDAH (6). There is strong evidence that both type 1 and 2 isoforms of DDAH are of critical importance in the metabolism of ADMA 
(7). Experiments in which either DDAH-1 or DDAH-2 was overexpressed in transgenic mice led to decreased plasma levels of ADMA (8, 9). Conversely, reduction of DDAH activity by deleting the gene or inhibiting its transcription with small inhibitory RNAs led to increased plasma ADMA levels (10-12). Next to DDAH activity, also the activities of protein arginine methyltranferases and proteolytic enzymes, and CAT-mediated exchange between intra- and extracellular ADMA play a role in the regulation of intracellular ADMA levels, although the relative contributions of these processes are currently not known (13).Both generation and DDAH-mediated metabolism of ADMA as well as inhibition of NOS activity by ADMA are intracellular processes; but most studies report on plasma ADMA levels, based on the underlying assumption 
that the concentration of ADMA in plasma accurately reflects intracellular ADMA levels. Although there are strong indications that, under pathological 
conditions, intracellular ADMA is elevated and may reach levels sufficient to inhibit NOS function (14), reports on the relation between plasma and intracellular ADMA levels are scarce.Hyperglycemia caused by insulin resistance is a common metabolic disorder during critical illness and is associated with complications. Normalization of blood glucose levels with intensive insulin therapy reduced morbidity and mortality among critically ill patients in the surgical intensive care unit 
(15). We observed that intensive insulin therapy prevented the early rise in plasma ADMA levels in these patients, suggesting that modulation of ADMA 
metabolism may contribute to the beneficial effects of intensive insulin therapy (16). Using an animal model of prolonged critical illness, in which plasma insulin and glucose levels were independently manipulated, we were able to show that normoglycemia rather than glycemia-independent actions of insulin maintained physiological ADMA levels by preserving DDAH activity 
(17).The aim of the present study was to investigate in detail the relation between plasma and intracellular concentrations of ADMA and the role of tissue DDAH 
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activity in the regulation of ADMA concentration in both compartments in this animal model of prolonged critical illness.
Methods
Animal modelAnimals were treated according to the Principles of Laboratory Animal Care formulated by the US National Society for Medical Research and the Guide for 
the Care and Use of Laboratory Animals prepared by the US National Institutes of Health. The protocol was approved by the local ethics committee for animal research. In brief, in male, adult New Zealand white rabbits, endogenous 
insulin deficiency was induced by alloxan; and critical illness was brought about by a third-degree burn injury. Insulin was administered via continuous 
fixed-speed intravenous infusion to receive either low or high physiologic plasma insulin levels. On each insulin level, blood glucose was manipulated by adjusting the speed of a supplementary intravenous glucose infusion to receive either normoglycemia or hyperglycemia. This resulted in a design with 4 experimental arms: normal insulin levels and normoglycemia (n = 8), high insulin levels and normoglycemia (n = 8), normal insulin levels and hyperglycemia (n = 9), and high insulin levels and hyperglycemia (n = 8). Seven days post-burn injury, blood was collected and animals were killed to allow harvesting of tissue samples of myocardium, skeletal muscle (quadriceps femoris), kidney, and liver. The entire procedure has been described in more detail in a previous publication (17). The analyses described in the current article are based on pooled data from the 4 experimental groups.
Tissue workup and measurement of DDAH activityFrozen tissue samples were homogenized in 4 volumes (4 mL/g wet weight of 
tissue) of ice-cold sodium phosphate buffer (100 mmol/L; pH 6.5) containing protease inhibitors (Complete protease inhibitor cocktail from Roche Applied Science, Mannheim, Germany) with an OMNI-2000 homogenizer (OMNI International, Waterbury, CT). Immediately after homogenization, a part of the homogenate was mixed with an equal volume of 1.2 mol/L perchloric acid; and after centrifugation (10 minutes at 2000 x g at 4°C), the 
supernatant was stored at 4°C until analysis of ADMA. The remainder of the 
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homogenate was used for determination of DDAH activity by measurement of citrulline formation during incubation with excess of ADMA (18). After a dual centrifugation procedure (10 minutes at 2000 x g, followed by 30 minutes at 10.000 x g, both at 4°C) to remove cellular debris, 160 µL of the supernatant was mixed with 240 µL of a 4-mmol/L ADMA solution in sodium phosphate 
buffer (100 mmol/L; pH 6.5). Before and after incubation for 2 hours at 37°C, the reaction was stopped; and proteins were precipitated by transferring 200 µL of the incubation mixture to vials containing 8 mg sulfosalicylic acid. After vortex mixing, the vials were centrifuged (10 minutes at 3000 x g at 4°C); and citrulline was measured in the clear supernatant with high-performance liquid chromatography as previously described (19). The increase in citrulline concentration during incubation was used to calculate DDAH activity (expressed as nanomoles per minute per gram wet weight of tissue). 
The within-assay coefficient of variation was less than 5%. To ensure the validity of the assay procedure, several control experiments were performed. When incubation was performed in the absence of either tissue homogenate or exogenous ADMA, no change of citrulline concentration was observed, 
demonstrating that citrulline formation indeed reflects DDAH activity. Upon 
incubation of tissue homogenates with excess exogenous citrulline (final concentration of 100 µmol/L), no decrease in citrulline concentration was observed, showing that metabolic enzymes that could potentially interfere with the DDAH assay by consuming the generated citrulline were not active under the assay conditions. To improve measurement precision in tissues with low DDAH activity, such as skeletal muscle, a relatively long 2-hour incubation time was used. Potentially, this might lead to deviation from assay linearity, especially in tissues with high DDAH activity, such as kidney. However, in none of the tissues examined in this study, was deviation from linearity observed using incubation times up to 3 hours, as illustrated in Figure 2 for kidney and liver.
Measurement of ADMABefore analysis, the supernatants obtained after deproteinization of tissue homogenates with perchloric acid were neutralized by adding 400 µL of 0.5 mol/L Na2HPO4 to 200 µL of the supernatant. The concentration of 
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ADMA in neutralized tissue extracts and plasma was determined using high-performance liquid chromatography as previously described (20) with 
modified chromatographic separation conditions (21). Intra- and interassay 
coefficients of variation were 1.5% and 3.0%, respectively.
Statistical analysesData are presented as mean ± standard deviation or median and interquartile range (P25 – P75). Because the concentration of ADMA in tissues had a right-skewed distribution, statistical analyses were performed after natural logarithmic transformation. Univariate relations between variables were investigated using Pearson correlation analysis. Because the plasma concentration of ADMA is the net result of the release into and uptake from the plasma compartment by various organs (Figure 1), we used multivariable regression models to assess the individual contributions of these organs. The relation between tissue levels of ADMA and the concentration of ADMA in plasma was explored by multivariable linear regression analysis with plasma ADMA as dependent variable and tissue content of ADMA in kidney, liver, heart, and muscle as independent explanatory variables. A similar multivariable linear regression model was used to explore the relation 
between tissue DDAH activity and plasma ADMA. Regression coefficients were expressed as change in plasma ADMA concentration in micromoles per liter per 1-standard deviation increase of the independent explanatory 
variables. To obtain sufficient statistical power, the main analyses were 
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Figure 2Linearity of citrulline formation by DDAH activity. Homogenates of kidney and liver 
were incubated at 37 ˚C in the presence of 2.4 mmol/L ADMA. After incubation, proteins were precipitated; and the concentration of citrulline in the supernatant was measured. Data points represent the means of 3 replicate incubations of a single tissue preparation. 
The coefficient of variation was less than 3% 
at each time point. No significant deviation from linearity was observed for incubation times up to  3 hours. Calculated DDAH activities were 31.59 ± 0.43 and 3.75 ± 0.04 nmol/(min g wet weight) for the kidney and liver sample, respectively. 
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performed on pooled data from all experimental groups. To assess whether treatment allocation altered the overall predictive value of the models or altered the strengths of the associations between the explanatory variables and plasma ADMA concentration, we added treatment modality (high or low glucose and high or low insulin, both added as dummy [0/1] variables) to the models. A two-sided P value <0.05 was considered to indicate statistical 
significance. Statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL).
ResultsMean plasma concentration of ADMA was 0.85 ± 0.27 µmol/L. Concentrations of ADMA and DDAH activity in tissue homogenates are summarized in Table 1. Of all tissues investigated, the highest mean DDAH activity was observed in kidney. Mean DDAH activities were approximately 3 to 4-fold lower in heart and liver than in kidney, and the lowest activity was observed in muscle tissue. A similar pattern was observed for the tissue content of ADMA, with a 6-fold higher level in kidney compared with muscle, and intermediate levels in heart and liver.
Relation between tissue ADMA and tissue DDAH activity
Despite the rather large differences between ADMA concentrations in various organs, correlation analysis revealed that the ADMA concentrations 
were positively and significantly associated between all organs. Particularly strong relations were found amongst organs with a relatively high ADMA 
0.920-0.0220.49 (0.35 – 0.83) 2.33 ± 0.63Muscle
Data are presented as mean ± SD or median (P25 – P75).
a Pearson correlation between DDAH activity and logarithmically transformed ADMA.
0.027-0.4111.09 (0.71 – 1.62)7.36 ± 2.45Liver
0.039-0.3850.69 (0.58 – 0.92)11.19 ± 3.67Heart
0.700-0.0793.00 (2.74 – 4.71)30.62 ± 8.48Kidney
P valuer(nmol/g)(nmol/[min g])
Correlation aADMA 
concentration
DDAH 
activity
Table 1 – Tissue DDAH activity and ADMA content, and their relation
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content, that is, kidney, liver, and heart (r = 0.65 - 0.78, all P <0.001) and also between kidney and muscle (r = 0.61; P = 0.002), whereas the relations between muscle ADMA and ADMA in liver and heart were weaker but still 
significant (r = 0.44, P = 0.024 and r = 0.40, P = 0.045, respectively).In contrast to the tissue content of ADMA, DDAH activities in the various 
organs were not significantly related. Correlation coefficients varied from r = -0.30 (P = 0.12) for the relation between DDAH activity in kidney and heart to r = 0.20 (P = 0.29) for the relation between DDAH activity in kidney and liver.Because DDAH hydrolyzes ADMA, a negative association between DDAH activity and ADMA content at the organ level was anticipated. However, these 
associations (shown in Table 1) were only significant in heart (r = -0.385, P = 0.039, Figure 3A) and liver (r = -0.411, P = 0.027, Figure 3B).
Relation between plasma ADMA and tissue ADMANext, we examined whether the concentration of ADMA in plasma was 
associated with tissue levels of ADMA. Plasma ADMA was only significantly 
A
B
r = -0.385
P = 0.039
r = -0.411
P = 0.027
Figure 3Relation between ADMA content and DDAH activity in heart (A) and liver (B). The natural logarithm of the measured ADMA content is plotted. Strengths of the associations are indicated by Pearson correlation 
coefficients. Treatment allocation: normal insulin (circles), high insulin (squares), normoglycemia (open symbols), and 
hyperglycemia (filled symbols). 
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associated with ADMA in liver (r = 0.406, P = 0.029, Figure 4) and not in the other tissues (all P >0.2). To assess the independent predictive value of tissue ADMA levels to the plasma ADMA concentration, a multivariable linear regression model was built with plasma ADMA as dependent variable and tissue ADMA levels as independent predictor variables. In this model the association between ADMA in the liver and in plasma was slightly attenuated 
and lost significance (P = 0.061); and the ADMA content of none of the other 
tissues contributed significantly to the model (all P >0.5).
Relation between plasma ADMA and tissue DDAH activityFinally, we examined the associations between the ADMA concentration in 
plasma and DDAH activity in the various tissues. There were a significant negative relation between plasma ADMA and DDAH activity in the kidney (r = -0.501, P = 0.006, Figure 5) and weaker inverse associations with DDAH activity in liver (r = -0.334, P = 0.077) and muscle (r = -0.317, P = 0.11). A weak positive association between plasma ADMA concentration and DDAH activity in the heart was observed (r = 0.283, P = 0.14). To assess the independent 
r = 0.406
P = 0.029
r = -0.501
P = 0.006
Figure 4Relation between plasma ADMA and liver ADMA. The natural logarithm of the liver ADMA content is plotted. Strength of the association is indicated by Pearson 
correlation coefficient. Treatment allocation: normal insulin (circles), high insulin (squares), normoglycemia (open symbols), 
and hyperglycemia (filled symbols).
Figure 5Relation between plasma ADMA and kidney DDAH activity. Strength of the association is 
indicated by Pearson correlation coefficient. Treatment allocation: normal insulin (circles), high insulin (squares), normoglycemia 
(open symbols), and hyperglycemia (filled symbols).
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contributions of tissue DDAH activities to plasma ADMA, a multivariable linear regression model was built (Table 2). This model revealed independent and 
significant associations of DDAH activities in kidney, liver, and muscle with the plasma ADMA concentration. The strongest association was observed for 
muscle DDAH activity with a regression coefficient of -0.118, indicating that an increase of DDAH activity in skeletal muscle by 1 standard deviation is associated with a decrease of 0.118 µmol/L plasma ADMA. The contributions from DDAH activities in liver and kidney to the model were almost equal (-0.098 and -0.097 µmol/L ADMA per standard deviation, respectively) and slightly less than the contribution of muscle DDAH activity. The DDAH activity 
in heart did not significantly contribute to the model. Overall, this model 
accounted for 49% of the variability in plasma ADMA concentrations, with a P value for the whole model of 0.002. The addition of treatment modality (high glucose or high insulin entered as dummy variables) to the model neither altered the associations between organ DDAH activity and plasma ADMA concentration nor improved the predictive value of the model.
DiscussionTo gain more insight into the role of tissue DDAH activity in the regulation of intracellular and plasma ADMA levels, we analyzed data from a rabbit model of critical illness, in which ADMA metabolism was modulated by independently 
manipulating plasma glucose and insulin levels. The most salient findings of our study are as follows: (1) DDAH activities in muscle, kidney, and liver, 
Table 2 - Multivariable linear regression model for plasma ADMA with 
DDAH activity in liver, kidney, heart, and muscle as independent
predictor variables
0.13-0.021 to 0.1540.066Heart DDAH activity
R2 model = 0.49; P = 0.002
aRegression coefficients are expressed as change in plasma ADMA (micromoles per liter) 
per 1-standard deviation increase of the organ DDAH activity.
0.033-0.185 to -0.008-0.097Kidney DDAH activity
0.028-0.184 to -0.011-0.098Liver DDAH activity
0.011-0.206 to -0.029-0.118Muscle DDAH activity
P
value
95% Confidence 
interval
Regression 
coefficientaIndependent variables
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but not in heart, were inversely and independently associated with plasma 
ADMA and together explained approximately 50% of the variation in the concentration of plasma ADMA. (2) At the organ level, DDAH activity was only inversely associated with ADMA in the heart and liver, but not with ADMA in kidney and muscle, suggesting that, in the latter organs, DDAH activity is not a major determinant of intracellular ADMA levels. (3) Although ADMA levels in the various organs were strongly correlated, plasma ADMA was only 
significantly associated with ADMA in the liver and not in the other organs, indicating that plasma ADMA is a poor indicator of tissue levels of ADMA.Over the past years, both type 1 and 2 isoforms of DDAH have emerged as a critical regulators of NO bioavailability (7). Overexpression of either DDAH-1 or DDAH-2 in transgenic mice led to decreased plasma ADMA levels (8, 9), whereas reduction of DDAH activity by deleting the gene or by inhibiting its transcription with small inhibitory RNAs led to increased plasma ADMA levels 
(10-12). Overall, the data from our rabbit model confirm that DDAH is a major player in the regulation of plasma ADMA levels. The plasma concentration of ADMA was negatively associated with DDAH activity in muscle, kidney, 
and liver; and multivariable linear regression analysis confirmed that DDAH activities in these tissues all independently contributed to the plasma level 
of ADMA, together explaining 49% of its variation. The major contribution of renal DDAH activity to this regression model is in line with previous studies showing that the kidneys play a prominent role in the clearance of ADMA. 
By measurement of arteriovenous concentration differences, net renal extraction of ADMA has been demonstrated in humans and rats (22, 23). The kidney clears ADMA from the circulation both by degradation via DDAH and 
by urinary excretion. It should be noted that urinary ADMA excretion differs between species, being prominent in healthy humans (2, 24, 25) and mice 
(25), but almost absent in rats (24, 25) and rabbits (26). Therefore, in the present rabbit model, renal DDAH activity was probably the sole route of renal ADMA clearance. However, there is evidence that, in healthy humans, urinary excretion constitutes only a minor pathway for elimination of ADMA 
(6). In accord with this notion, plasma ADMA levels are already elevated during early stages of chronic kidney disease, that is, before the decline of 
glomerular filtration rate (27, 28).
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The contribution of hepatic DDAH activity to regulation of plasma ADMA levels is in agreement with previous studies showing that, next to the kidney, the liver also plays an important role in ADMA metabolism (3, 29, 30). Hepatic clearance of ADMA from the circulation, estimated from measurement of 
blood flow and arteriovenous concentration differences across the liver, was shown to be only slightly lower than renal clearance in both humans and rats 
(31, 32). Plasma ADMA levels are increased in patients with liver cirrhosis 
(33), alcoholic hepatitis (34), and acute liver failure (35) and have also been shown to increase after a major hepatic resection (36). Moreover, plasma levels of ADMA in patients with liver failure decrease upon successful liver transplantation (37, 38).Although DDAH activity in skeletal muscle was much lower than in the other 
tissues investigated, it was a significant and independent predictor of plasma ADMA concentration; and its contribution to the multivariable regression model was even slightly higher than the contributions of kidney and liver. 
The most likely explanation for this surprising finding is that the total mass of skeletal muscle is far higher than the mass of kidney or liver. Already in 1979, Lou (39) described that urinary excretion of ADMA, but not symmetric dimethylarginine (SDMA), was strongly elevated in children with muscular dystrophy, which is consistent with an important role of muscular DDAH in the regulation of circulatory ADMA. Diminished clearance of circulating ADMA by skeletal muscle tissue might help explain the elevation of plasma ADMA levels associated with insulin resistance and type 2 diabetes reported in a number of studies (40-43). Insulin has been shown to stimulate uptake of glucose in skeletal muscle by inducing vasodilation (44). A blunted vasodilatory response to insulin in insulin-resistant individuals may reduce uptake not only of glucose but also of ADMA. Because insulin-induced vasodilation is partly NO-dependent (44), increased ADMA levels may then exacerbate the impairment of the vasodilatory response. Despite the fact that DDAH activity in the heart was intermediate between activities in kidney and liver and approximately 5-fold higher than in skeletal 
muscle, cardiac DDAH activity was not a significant predictor of plasma 
ADMA. Conversely, DDAH activity in the heart showed a significant negative association with its ADMA content. This suggests that cardiac DDAH is very 
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important for regulation of ADMA levels at the local level, but plays no major role in the regulation of circulatory ADMA. This is consistent with results from several studies in humans and animals. Myocardial proteome analysis in dogs revealed that expression of DDAH is related to local perfusion, with 
high expression of DDAH and low ADMA levels in areas of low local flow 
(45). Decreased myocardial DDAH expression and/or activity were found in humans with coronary heart disease and in dogs with congestive heart 
failure or atrial fibrillation (46-48).There are several indications that DDAH activity is not a major determinant 
of ADMA content at the organ level. First, differences in mean ADMA levels between organs changed in parallel with DDAH activity; for example, the highest DDAH activity and ADMA levels were observed in the kidney, whereas in muscle, both DDAH activity and ADMA were lower than in the other tissues. Second, although we observed a strong correlation between 
the ADMA content of various tissues, DDAH activities were not significantly correlated. Finally, DDAH activity was not related to ADMA content of muscle and kidney; and the inverse associations between DDAH activity and 
ADMA content of heart and liver were significant but not very strong (r = ~0.4), indicating that, in these tissues, variation in DDAH activity explains 
approximately 16% (r2) of the variation in ADMA content.The liver excepted, our data do not support the concept that plasma ADMA 
closely reflects intracellular ADMA levels. The concentration of ADMA in 
the circulation was not significantly associated with ADMA levels in heart, kidney, and muscle. The high blood content of the liver and the fact that the hepatic sinusoids are lined by a relatively permeable fenestrated endothelium may explain the positive association between ADMA in the liver and the 
circulation. However, this association was attenuated and lost significance in the multivariable regression model. We have previously shown that, in this 
rabbit model, plasma levels of SDMA closely reflect intracellular SDMA levels in heart, kidney, and liver (17). This strong association between plasma and 
tissue levels of SDMA possibly reflects efficient CAT-mediated exchange of SDMA between both compartments. Although transport by CAT is probably 
equally effective for ADMA as for SDMA, extensive intracellular degradation of the former by DDAH may attenuate the association between intra- and 
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extracellular ADMA. Different behavior of ADMA and SDMA has previously 
been demonstrated in animal and human models of acute inflammation. Induction of endotoxemia by injection of lipopolysaccharide into rats lowered plasma levels of both arginine and ADMA, whereas plasma levels of SDMA increased (23). In patients undergoing elective knee arthroplasty, the post-
operative systemic inflammatory response was accompanied by a transient decrease of plasma ADMA, whereas the concentration of SDMA remained unchanged (49). Possibly, tissue-specific increases in CAT activity provoked 
by inflammatory stimuli contribute to the differential behavior between both methylated arginines (13).It is striking that DDAH activities in liver, kidney, and muscle together explained a large portion of the variation in circulatory ADMA levels; but in 
the latter 2 organs, DDAH activity was not significantly related to intracellular ADMA levels. It should be noted that the pool of circulatory ADMA is much smaller than the intracellular ADMA pools. This implies that DDAH-mediated degradation of a small amount of circulatory ADMA can strongly lower plasma ADMA levels, whereas a similar relative reduction of intracellular ADMA requires degradation of much larger amounts of ADMA. Another potential explanation is that ADMA from the plasma compartment has better access to DDAH compared with intracellular ADMA. Immunostaining of rat mesenteric vessels for DDAH-2 was positive in cytoplasmic vesicles and the apical membrane of endothelial cells (12). The presence of DDAH-2 in the plasma membrane may provide ADMA from the plasma compartment, possibly after CAT-mediated cellular uptake, with direct access to cellular DDAH, explaining preferential metabolism of circulatory ADMA. Endothelial NOS and CAT-1 are both located in caveolae in the plasma membrane (50), providing a mechanism for direct delivery of plasma arginine to NOS and thereby explaining the “arginine paradox”, that is, the observation that extracellular rather than intracellular arginine concentrations are critical to NO production (50, 51). Close proximity of DDAH to, or association of DDAH 
with, the caveolar CAT – NOS complex would place together all key players involved in NO production within the microenvironment of the plasma membrane. This would explain why DDAH has a larger impact on plasma ADMA than on intracellular ADMA. In addition, this model implies that 
108
plasma ADMA rather than intracellular ADMA is critical in regulating NOS activity, consistent with many studies that have found plasma ADMA to be an independent predictor of cardiovascular morbidity and mortality (3).Some limitations of the present study deserve comment. First, this study was designed to investigate the modulation of arginine and ADMA levels by glycemic control (17). For the present analysis, animals from all treatment groups were pooled because the number of animals per group was too small to allow separate analysis. However, the result of the multivariable regression model was not altered if treatment allocation was included as additional predictor variable. Moreover, for the present purpose, the pooling of treatment groups was advantageous because the inclusion of ill animals 
treated with different regimens ensured a fairly wide range of DDAH activities 
and ADMA levels, thereby increasing the likelihood of detecting significant associations with a low number of observations. Second, we acknowledge that regulation of the DDAH-ADMA system and the response of this system 
to metabolic changes during critical illness may differ between species; and therefore, the results of this study in rabbits cannot be directly extrapolated to humans. A third limitation is that ADMA content and DDAH activity were measured in tissue homogenates and therefore we obtained no information on intraorgan heterogeneity of ADMA content and DDAH activity, which is very prominent in the kidney (7, 25) and possibly in other organs as well. Fourth, measurement of DDAH activity does not discriminate between both 
isoforms of DDAH. Recent evidence has indicated that the effect of DDAH-1 on endothelial NO production is largely ADMA dependent, whereas the 
effect of DDAH-2 is mainly ADMA independent (52). Finally, it is very likely that other organs that were not evaluated in the present study, such as the lung (53, 54), also contribute to the generation and metabolism of ADMA.In conclusion, the results from this animal model of prolonged critical illness show that DDAH activities in several organs in concert determine 
plasma levels of ADMA, confirming that DDAH is an important player in the 
regulation of circulatory ADMA. Novel findings include the contribution of muscle DDAH as a potential determinant of plasma ADMA levels and the fact that tissue DDAH activity is a stronger predictor of circulatory ADMA than of 
intracellular ADMA levels. The latter finding indicates that, compared with 
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DDAH activity, the generation of ADMA by protein methylation/proteolysis and CAT-mediated exchange between intracellular and extracellular ADMA may be more important regulators of intracellular ADMA levels.
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Chapter 5
Plasma concentrations of arginine and asymmetric dimethylarginine do not 
reflect their intracellular concentrations in peripheral blood mononuclear cells
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Abstract
Production of nitric oxide (NO) from arginine is inhibited by endogenously produced monomethylarginine (MMA) and asymmetric dimethylarginine (ADMA). Elevated levels of ADMA, by limiting NO production, may lead to endothelial dysfunction and cardiovascular disease. Symmetric dimethylarginine (SDMA) and the arginine homolog homoarginine have also been associated with cardiovascular disease. Although NO synthesis, as well as generation of MMA, ADMA, SDMA and homoarginine occurs intracellularly, these biomarkers are usually measured in plasma. Despite extensive transmembrane transport, it is not clear whether plasma levels of these biomarkers are a valid proxy for their intracellular levels in the 
cardiovascular system. Since it is difficult to obtain vascular tissue from healthy humans, we explored the relations between concentrations of these biomarkers in plasma and intracellular concentrations in peripheral blood mononuclear cells (PBMC).In PBMC and plasma of 27 healthy subjects, concentrations of arginine, MMA, ADMA, SDMA, and homoarginine were determined using stable isotope dilution liquid chromatography tandem mass spectrometry.
In PBMC, significant positive correlations were observed among arginine 
and its methylated forms (ρ = 0.43 to 0.81) and these correlations were 
slightly less pronounced in plasma. Homoarginine was not significantly correlated with (methylated) arginine in either PBMC or plasma. Plasma 
concentrations of arginine and its methylated forms showed non-significant inverse associations with their respective intracellular concentrations in PBMC and only for homoarginine a weak positive association was observed 
(ρ = 0.37). In healthy individuals, plasma levels of arginine, MMA, ADMA, and SDMA 
poorly reflect their intracellular levels in PBMC.
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IntroductionHigh plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the enzyme nitric oxide (NO) synthase (NOS), are associated with endothelial dysfunction (1), atherosclerosis (2), and cardiovascular disease 
(3, 4), and with increased mortality in critically ill patients (5). Symmetric dimethylarginine (SDMA), the inactive isomer of ADMA, has been established as a risk marker for renal failure (6). Furthermore, low plasma levels of homoarginine, a homolog of the NOS substrate arginine, have recently been associated with cardiovascular mortality and stroke (7, 8). Although these metabolites are measured as biomarkers in plasma, most of the processes in their generation and degradation, as well as the inhibition of NOS are intracellular events (9).ADMA and SDMA are formed intracellularly through the methylation of arginine residues in proteins by protein arginine methyltransferases (PRMT) 
(10), with monomethylarginine (MMA) formed as an intermediate product. After proteolysis, arginine and its methylated forms are released into their free forms, of which both ADMA and MMA, but not SDMA, can inhibit NO formation from arginine by NOS. Diminished basal NO production may lead to vasoconstriction, elevated blood pressure and thrombus formation 
(2). Cells can clear ADMA and MMA either through their hydrolysis by dimethylarginine dimethylaminohydrolase (DDAH), or through their export to the plasma via cationic amino acid transporters (CAT), which also mediate transmembrane transport of SDMA, arginine, and homoarginine between the cell interior and the plasma (11). Because both production and degradation of free ADMA, as well as ADMA-mediated inhibition of NOS occur intracellularly, the intracellular concentration of ADMA is clearly most relevant with respect to cardiovascular disease. Nevertheless, most clinical studies rely on measurement of ADMA in plasma, which is often regarded 
as cellular spill over and assumed to reflect intracellular concentrations. Recently, we challenged this notion by showing in an animal model of prolonged critical illness that intracellular ADMA content correlated 
significantly between different tissues, but not with ADMA levels in plasma 
(12). However, data on the relation between plasma and intracellular ADMA levels in humans is scarce.
Since it is difficult to obtain tissue from healthy humans, we explored the 
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relations between ADMA levels in plasma and intracellular levels in blood cells, which are easily obtained. In a previous report we showed that in healthy humans ADMA concentrations in erythrocytes and plasma were 
not correlated, whereas in critically ill patients a significant correlation between ADMA levels in plasma and erythrocytes was observed (13). Since the mature erythrocyte lacks a nucleus, and therefore its capacity for protein synthesis (14), it may behave differently than other cells that do contain the full protein synthesis machinery. Therefore, in the present study the relation between plasma ADMA levels and ADMA in peripheral blood mononuclear cells (PBMC), which do contain all protein synthesis mechanisms and have been shown to produce ADMA and SDMA (15), was explored. In parallel, we also report on the relation between plasma concentrations and intracellular PBMC concentrations of SDMA, MMA, arginine and homoarginine.
Methods
SubjectsFrom 27 apparently healthy volunteers, recruited amongst laboratory personnel, 8 mL whole blood was obtained using a BD vacutainer® cell preparation tube (CPT™) from Becton, Dickinson and Company (Franklin Lakes, NJ, USA), after they gave their informed consent.
Isolation of PBMC and plasmaWithin 2 hours after venipunture, PBMC and plasma were separated from erythrocytes and granulocytes by centrifugation (30 min, 1500 x g, 20 °C). PBMC were resuspended in the plasma and transferred to a clean 15-mL volumetric tube. After centrifugation (10 min, 600 x g, 4 °C) a 1-mL aliquot 
of plasma was acquired from the supernatant and stored at -80 °C, and the excess supernatant was discarded. The PBMC-pellet was washed twice in 
14 mL ice-cold phosphate buffered saline, pH 8.0. From the second wash a 250-µL aliquot was taken for a cell count (CBC WBC extended count, CellDyn 4000, Abbott, Hoofddorp, The Netherlands), and after centrifugation (10 min, 600 x g, 4 °C) the PBMC-pellet was stored at -80 °C until further analysis.
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Measurement of ADMA, SDMA, MMA, arginine and homoarginine in PBMC and 
plasmaPBMC-pellets were thawed on ice and resuspended in 500 µL 100 mmol/L NaH2PO4, pH 7.3. Subsequently they were lysed using an ultrasonic probe (Bandalin Sonopuls mini 20 with MS 1.5 titanium microtip) for 3 x 10 sec at 
~0.250 kJ (= 90% of maximum power) while kept on ice. In a 20-µL aliquot from the PBMC lysate, protein content was determined using the bicinchoninic acid protein assay method (16). Next, to a 200-µL aliquot from the PBMC lysate 200 µL 1.2 mol/L perchloric acid was added to precipitate proteins. After centrifugation (10 min, 20100 x g, 4 °C), 200 µL of the supernatant was used for the determination of ADMA, SDMA, MMA, arginine and homoarginine. In parallel, 200 µL of matched plasma samples were analyzed after thawing on ice. The analytes were extracted from both plasma and PBMC samples using Oasis MCX solid phase extraction cartridges (Waters, Milford, MA, USA) and their butyl-esters were determined using our recently described method which is based on stable isotope dilution liquid chromatography tandem mass spectrometry (17).
Calculations and statistical analysesTo allow comparison of intracellular and plasma levels, the intracellular analyte concentrations were expressed in µmol/L. To this end, the measured concentrations were corrected for the amount of cells and for a mean corpuscular volume of 282.9 fL per PBMC, described by Simiele et al (18). For the determination of associations among intracellular analytes, intracellular concentrations were expressed as nmol/mg protein. Because this ratio does not depend on cell count and mean cell volume it is slightly more accurate than the estimated analyte concentration. The arginine/ADMA ratio was calculated as well, because NO production is determined by both substrate availability (arginine) and the presence of inhibitor (ADMA), which may be 
adequately reflected by this ratio.Intracellular concentrations of ADMA, SDMA, MMA, arginine, and homoarginine in the PBMC were compared to plasma levels by paired-Student’s t-test, and the strengths of associations between their concentrations were assessed using Spearman rank correlation. A two-tailed 
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P-value <0.05 was considered statistically significant. Statistical analyses were performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
ResultsADMA, SDMA, MMA, arginine, and homoarginine levels, measured in plasma and in PBMC lysates, are listed in Table 1. Additionally, the PBMC/plasma concentration ratio is listed. ADMA, SDMA, MMA and arginine levels were 
significantly higher in PBMC than in plasma (P <0.001), whereas homoarginine 
levels were not significantly different (P = 0.44). In PBMC, mean levels of both ADMA and arginine were 7.6-fold higher than levels measured in plasma. This resulted in a similar arginine/ADMA ratio in PBMC (181.4 ± 36.3) and plasma (186.1 ± 31.8), an indicator of possible NO production by NOS. Mean MMA levels in PBMC were approximately 18-fold higher compared to mean plasma levels. SDMA and homoarginine levels were only 1.5-fold and 1.3-fold higher, respectively, in PBMC versus plasma.In PBMC, positive correlations were observed among intracellular levels of arginine and its methylated forms, ADMA, SDMA and MMA. All of these 
associations were significant, with Spearman correlation coefficients 
ranging from ρ = 0.434 for the relation between SDMA and MMA to ρ = 0.813 for the relationship between ADMA and MMA (Figure 1). In the plasma compartment, the association between ADMA and MMA was of similar 
strength (ρ = 0.814, P <0.001), but most of the other correlations were 
less pronounced than in PBMC, although still significant (ADMA-arginine: 
(1.3)
(0.6)
(2.8)
(7.5)
(3.1)
(0.67)
(0.081)
(0.072)
(0.016)
(18.6)
(0.42)
(1.30)
(0.339)
(2.28)
(261)
(0.0060)
(0.0008)
(0.0044)
(0.0018)
(0.67)
- 1.32.012.370.0086Homoarginine
0.783
3.95
1.29
717
mol/L
1.50.5120.0029SDMA
Data are presented as mean (SD)
7.60.5280.0153ADMA
17.80.0770.0051MMA
7.697.82.69Arginine
ratiomol/Lnmol/mg protein
PBMC/Plasma-PlasmaPBMCAnalyte
Table 1 – Levels of arginine, its methylated forms and homoarginine in 
PBMC and plasma 
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Figure 1Relationships between intracellular concentrations of arginine, ADMA, SDMA and MMA in PBMC. The concentrations of the metabolites were expressed as nmol/mg protein and the strengths of the associations were assessed by Spearman correlation.
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ρ = 0.491, P = 0.009; arginine-MMA: ρ = 0.393, P = 0.043), or of borderline 
significance (SDMA-ADMA: ρ = 0.356, P = 0.069; SDMA-arginine: ρ = 0.340, P 
= 0.083; SDMA-MMA: ρ = 0.310, P = 0.12). Homoarginine was not significantly correlated with arginine or the methylated arginines in either PBMC or 
plasma (ρ = 0.078 to 0.297 in PBMC, and ρ = -0.077 to 0.349 in plasma).In contrast to these moderate to strong positive associations amongst arginine metabolites within both the intracellular and plasma compartments, the relationship between their concentrations in plasma and in PBMC was 
weak. For ADMA an inverse non-significant association (ρ = -0.263, P = 0.19) was observed (Figure 2A). Similarly, for arginine, SDMA and MMA inverse 
non-significant associations were observed (arginine: ρ = -0.164, P = 0.41; 
SDMA: ρ = -0.027, P = 0.90; MMA: ρ = -0.120, P = 0.55). Only homoarginine 
(Figure 2B) exhibited a positive association of borderline significance (ρ = 0.374, P = 0.055).
DiscussionThis study shows that there is neither a relation between plasma ADMA and intracellular ADMA in PBMC, nor between plasma and intracellular concentrations of arginine, MMA, SDMA and homoarginine. In its relation to cardiovascular disease, ADMA is commonly measured in plasma. Yet, ADMA 
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Figure 2Correlations between ADMA and homoarginine concentrations in PBMC and plasma. For 
ADMA (A) an inverse non-significant association was observed (ρ = -0.263, P = 0.19), whereas homoarginine (B) was the only analyte that exhibited a positive association of borderline 
significance (ρ = 0.374, P = 0.055).
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synthesis by PRMT, its release into the cytosol after proteolysis, its inhibition of NOS, and its clearance by DDAH are all intracellular processes. It is usually assumed that ADMA in the circulation originates from cellular spillover and, 
thus, the concentration of ADMA in plasma accurately reflects its intracellular concentration. The results of our study challenge the general validity of this assumption, at least in healthy individuals.
Concentrations of arginine and its methylated forms were significantly higher in PBMC than in plasma (P <0.001), whereas homoarginine levels 
were not significantly different (P = 0.44). For SDMA, the mean PBMC/plasma 
concentration ratio was five to tenfold lower than for ADMA and MMA, which may be due to a lower intracellular production rate of SDMA compared to ADMA and MMA. The PRMT family comprises two classes, with type 1 PRMTs catalyzing formation of ADMA and type 2 PRMTs producing SDMA (10). In many tissues, including lung, heart, liver and kidney, protein-incorporated levels of ADMA are several-fold higher than protein-incorporated SDMA levels, consistent with higher activity of type 1 compared to type 2 PRMTs 
(9, 19). Furthermore, differences in clearance of SDMA, compared to ADMA and MMA, may contribute to its lower PBMC/plasma concentration ratio. Whereas ADMA and MMA are mainly degraded intracellularly by the enzyme DDAH, the sole route for clearance of SDMA is through cellular export by CAT and subsequent excretion by the kidneys (9).In contrast to arginine and its methylated forms, the mean intracellular 
concentration of homoarginine was not significantly higher than in plasma, 
which may be explained by differences in formation and clearance between these metabolites. Intracellular proteolysis is the sole source of free MMA, ADMA, and SDMA, and a major source of free arginine, but homoarginine, being a non-proteinaceous amino acid, is not generated during proteolysis. There are two likely routes for de novo synthesis of homoarginine, both using lysine as precursor. In one pathway lysine is converted into homoarginine by enzymes of the urea cycle, in a sequence of reactions that is analogous to the conversion of ornithine into arginine (20, 21). In the other pathway, lysine is directly converted into homoarginine by addition of an amidinogroup derived from arginine (22). We have recently shown that the latter pathway, which is catalyzed by promiscuous activity of arginine:glycine amidinotransferase (AGAT; EC 2.1.4.1.), a key enzyme in the synthesis of creatine, is probably 
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mainly responsible for synthesis of homoarginine in humans (23). AGAT activity is high in tissues involved in creatine synthesis, i.e., kidney and liver, and is probably negligible in PBMC. Taken together, intracellular homoarginine in PBMC most likely originates from CAT-mediated uptake from the circulation. Intracellular homoarginine can to some extent be consumed by catabolic pathways shared with arginine. Arginine is hydrolyzed to ornithine and urea by the enzyme arginase, which has been shown to be present in PBMC (24). Although homoarginine can also serve as substrate for arginase, enzyme activity is approximately 1000-fold lower compared to arginine (25). Likewise, homoarginine can serve as substrate for NOS, but 
with much lower catalytic efficiency compared to arginine (26). Therefore, intracellular catabolism of homoarginine is probably not very extensive and the main route for clearance of homoarginine is through CAT-mediated export.Because arginine and its methylated forms share pathways of formation and cellular uptake and disposal, i.e., proteolysis and CAT-mediated membrane transport, it is not surprising that their intracellular levels were strongly correlated. A particular strong association was observed between ADMA and MMA, which, on top of the mechanisms mentioned above, also share DDAH-mediated degradation as catabolic pathway. This strong association between ADMA and MMA was also observed in plasma, but the strengths of most other 
associations was slightly attenuated in plasma, reflecting differences in rates and pathways of clearance from the plasma compartment between individual 
metabolites. Homoarginine was not significantly correlated to arginine and 
its methylated forms, reflecting that its formation and degradation routes 
are different from that of arginine, ADMA, SDMA and MMA, as described in the previous paragraph.
The absence of a significant correlation between plasma and intracellular levels of ADMA in PBMC of healthy subjects is in line with our previous 
report that showed no significant relation between plasma and intracellular ADMA levels in erythrocytes of healthy subjects (13). Furthermore, in an animal model of prolonged critical illness we showed that ADMA levels in 
different tissues were correlated to each other, whereas tissue levels were not correlated to plasma levels (12). The lack of a correlation between 
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ADMA in PBMC and in the plasma compartment may be due to the fact 
that the concentration of ADMA in plasma reflects a complex and dynamic equilibrium and is the net result of release into and uptake from the plasma compartment by circulating cells, including erythrocytes and PBMC, and by skeletal muscle and organs such as liver, kidney, heart, and lung. In fact, plasma and intracellular concentrations of ADMA were inversely associated and similar inverse associations were observed for arginine, MMA, and SDMA. Although the fact that these associations were weak and 
non-significant does not allow drawing definitive conclusions, their negative sign may hint to involvement of CAT-mediated transmembrane transport. Diminished CAT expression or activity will slow cellular egress of ADMA, thereby increasing intracellular, but decreasing extracellular ADMA levels, potentially leading to an inverse association between ADMA concentrations in both compartments (11). The same mechanism may apply to arginine, MMA, and SDMA, which like ADMA are formed inside the cell. In contrast, it would not hold for homoarginine which is neither formed nor metabolized 
inside the cell. Indeed, for homoarginine a borderline significant positive association between intracellular and plasma concentrations was observed. Interestingly, upregulation of CAT in erythrocytes, platelets and PBMC has been demonstrated in patients with chronic renal or heart failure (27, 28). 
Upregulation of CAT in specific patient groups may lead to a closer association between intra- and extracellular concentrations of cationic amino acids. It may explain our previous observation of a close correlation between ADMA levels in plasma and erythrocytes of critically ill patients, which was not seen in healthy subjects (13). Therefore, it would be interesting to extend the experiments in healthy individuals as conducted in the present study 
to specific patient groups. In fact, a study in patients undergoing coronary artery bypass grafting, in which plasma, PBMC and samples of cardiac and aortic tissue are collected, is underway (29). That study will also be useful to 
establish whether ADMA levels in PBMC, better than plasma levels, reflect ADMA levels in cardiovascular tissue.In conclusion, our data show that, at least in healthy individuals, plasma concentrations of the NOS substrate arginine and the NOS inhibitor ADMA 
poorly reflect their intracellular concentrations in PBMC.
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Rationale and design of a proof-of-
concept trial investigating the effect of uninterrupted perioperative (par)enteral 
nutrition on amino acid profile, cardiomyocytes structure, and cardiac perfusion and metabolism of patients undergoing coronary artery bypass graftingMarlieke Visser, Mariska Davids, Hein J. Verberne, Wouter E.M. Kok, Hans W.M. Niessen, Lenny M.W. van Venrooij, Riccardo Cocchieri, Willem Wisselink, Bas A.J.M. de Mol, and Paul A.M. van LeeuwenJ Cardiothorac Surg 6 (2011) 36
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Abstract
Malnutrition is very common in patients undergoing cardiac surgery. Malnutrition can change myocardial substrate utilization which can induce 
adverse effects on myocardial metabolism and function. We aim to investigate 
the hypothesis that there is a disturbed amino acids profile in the cardiac surgical patient which can be normalized by (par)enteral nutrition before, during and after surgery, subsequently improving cardiomyocyte structure, cardiac perfusion and glucose metabolism.
This randomized controlled intervention study investigates the effect of uninterrupted perioperative (par)enteral nutrition on cardiac function in 48 patients undergoing coronary artery bypass grafting. Patients are given enteral nutrition (n = 16) or parenteral nutrition (n = 16), at least two days before, during, and two days after coronary artery bypass grafting, or are treated according to the standard guidelines (control) (n = 16). We will 
illustrate the effect of (par)enteral nutrition on differences in concentrations of amino acids and asymmetric dimethylarginine and in activity of dimethylarginine dimethylaminohydrolase and arginase in cardiac tissue and blood plasma. In addition, cardiomyocyte structure by histological, immuno-histochemical and ultrastructural analysis will be compared between 
the (par)enteral and control group. Furthermore, differences in cardiac perfusion and global left ventricular function and glucose metabolism, and their changes after coronary artery bypass grafting are evaluated by electrocardiography-gated myocardial perfusion scintigraphy and 18F-
fluorodeoxy-glucose positron emission tomography respectively. Finally, fat free mass is measured before and after intervention with bioelectrical impedance spectrometry in order to evaluate nutritional status.Trial registration: Netherlands Trial Register (NTR): NTR2183
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BackgroundMalnutrition is very common in patients undergoing cardiac surgery as well as other types of surgery. For example, in a population of cardiac and 
abdominal surgical patients, respectively 10-25% (1, 2) and 44% (3) was malnourished. Malnutrition is an independent risk factor resulting in more complications, and increased mortality rates, length of hospital stay and costs (1-3). The lack of optimal nutrition can change myocardial substrate 
utilization which can have adverse effects on myocardial metabolism such as adenosine triphosphate (ATP) production and utilization (4). For that reason, malnutrition might be an underlying risk factor for the perioperative cardiac complications observed in patients undergoing non-cardiac surgery 
(5). In addition to cardiac complications, the lack of optimal nutrition can 
induce nutrient deficiencies which in turn can lead to the impairment of the immune system (6). It is still common practice that patients receive only clear 
fluids during the period prior to surgery and the day after surgery leading to starvation of the patient over a longer period of time. As this occurs, glycogen reserves that last only a few hours will deplete with the result that further fasting induces gluconeogenesis. As this gluconeogenesis mainly 
depends on catabolism of body proteins it furthers the negative effects of malnutrition. We hypothesize that avoidance of malnutrition and starvation can improve cardiac metabolism and function, and might prevent protein 
catabolism, which would be beneficial for both cardiac and non-cardiac surgical patients.Nitric oxide (NO), created from the amino acid arginine, is a regulator of cardiac and vascular function. However, the actions of NO can be disturbed by elevated levels of the NO synthase (NOS) inhibitor, asymmetric dimethylarginine (ADMA), a condition reported in patients with failing hearts (7). Moreover, ADMA has been indicated as marker of circulatory function and as predictor of outcome in patients with cardiac dysfunction (7, 8). As NO availability 
might be reflected by the ratio between substrate (arginine) and inhibitor 
(ADMA), the negative effects of ADMA might be relieved by supplementation 
of arginine. However, the effect of arginine supplementation is complicated as studies have shown both positive and negative results in critically ill patients (7). Probably, the ratio between arginine and ADMA might play a 
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role as NO availability needs to be perfectly balanced in order to guarantee proper cardiac contraction and vascular dynamics. We hypothesize that nutrition containing arginine is a safe method that might improve the whole 
amino acid profile in patients with cardiac dysfunction.
Therefore, in this proof-of-concept study, we aim:
1. To evaluate the effect of uninterrupted perioperative (par)enteral nutrition supplementation versus no supplementation on amino 
acid profile and cardiomyocytes structure in patients undergoing coronary artery bypass grafting (CABG).
2. To study the effect of uninterrupted perioperative (par)enteral nutrition supplementation versus no supplementation on myocardial perfusion, left ventricle function and glucose metabolism before and after CABG.
3. To study the effect of uninterrupted perioperative (par)enteral nutrition supplementation versus no supplementation on fat free mass (FFM, as a marker of nutritional status) before and after CABG.
Methods/Design
DesignThis is a randomized controlled intervention study. The research protocol of this clinical trial (NTR2183, EudraCTnr 2009-017812-33) has been reviewed and approved by the Medical Ethical Committee of the Academic Medical Center of the University of Amsterdam (AMC) (MEC 09/304) and the Competent Authority of the Netherlands (Centrale Commissie Mensgebonden Onderzoek) (NL28231.018.09).
Participants
Patients undergoing cardiac bypass surgery are selected to study the effects of (par)enteral nutrition on human cardiac tissue. In order to prevent 
cardioplegic effects on cardiomyocytes, selected patients are undergoing 
an off-pump CABG-procedure. Forty-eight patients with stable anginal complaints planned for an elective CABG who meet all inclusion criteria and 
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do not have any of the exclusion criteria (Table 1) will be randomized by computer-generated block randomization (each block including six patients) to one of the three study groups.
Setting
Figure 1 depicts a flow chart of the study protocol. The study is currently performed at the department of cardio-thoracic surgery of the AMC. Patients are informed about the study by a cardiologist and nutritionist who hand over the information letter as well as the informed consent form. A patient is included in the study when the informed consent form is signed. Subsequently, the patient can be randomized to one of the three groups: the “enteral group” (n = 16), the “parenteral group” (n = 16), or the control group (n = 16). During visits at the hospital outpatient clinic (approximately two weeks before surgery), patients are subjected to baseline measurements including blood sampling, measurement of body weight and height, bioelectrical impedance spectrometry (BIS), ECG-gated myocardial perfusion scintigraphy (MPS) and a 18F-fluorodeoxy-glucose positron emission tomography (18F-FDG PET) scan (Table 2). As part of the preoperative evaluation, patients will also undergo preoperative assessments by a cardiothoracic surgeon and an anesthesiologist.Patients allocated to the enteral and parenteral group will be admitted at the hospital three days before surgery (Table 2). Patients allocated to the control group will be admitted one day before surgery.
• Combined valve and CABG procedure
• Age  <18 and ≥80 years
• Diabetes mellitus type I
• Pregnancy
• Renal insufficiency defined as creatine  
>95 µmol/L for women and >110 µmol/L for men
• Liver insufficiency defined as ALAT 
>34 U/L for women and >45 U/L for men 
Exclusion criteria:
ALAT, alanine aminotransferase; CABG, coronary artery bypass grafting.
• Undergoing off-pump  CABG-surgery
• Age 18 till 80 years
Inclusion criteria:
Table 1 – Inclusion & exclusion criteria
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Approximately three weeks after surgery patients will visit the outpatient clinic for measurements including blood sampling, measurement of body weight, BIS, MPS and 18F-FDG PET. In addition, as part of the routine clinical postoperative care patients will be seen by a cardiothoracic surgeon.
Nutrition and administering devicesEnteral nutritionDuring the four days before hospital admission, the enteral group will take 125 mL per day of a nutrient drink (Nutridrink Compact, Nutricia, Zoetermeer, The Netherlands) consisting of proteins, carbohydrates, fats, vitamins and minerals (Table 3). When admitted to the hospital, patients in the enteral group will receive a solution containing amino acids (PeptoPro, DSM, Delft, The Netherlands), carbohydrates (Fantomalt, Nutricia, Zoetermeer, The Netherlands), and vitamins and minerals (Phlexy-Vits, SHS International Ltd., Liverpool, United Kingdom) which will be prepared at the hospital each day. 
Enteral group
Home
• Nutrient drink
Informed consent
Randomization
Parenteral group
Outpatient clinic
• Blood sampling
• MPS
• 18F-FDG PET
• BIS
Hospital
• Parenteral nutrition
• CABG
• Blood sampling
• Tissue sampling
Outpatient clinic
• Blood sampling
• MPS
• 18F-FDG PET
• BIS
Outpatient clinic
• Blood sampling
• MPS
• 18F-FDG PET
• BIS
Outpatient clinic
• Blood sampling
• MPS
• 18F-FDG PET
• BIS
Control group
Hospital
• CABG
• Blood sampling
• Tissue sampling
Outpatient clinic
• Blood sampling
• MPS
• 18F-FDG PET
• BIS
Hospital
• Enteral nutrition
• CABG
• Blood sampling
• Tissue sampling
Outpatient clinic
• Blood sampling
• MPS
• 18F-FDG PET
• BIS
Figure 1Flow chart of study protocol.BIS, bioelectrical impedance spectrometry; CABG, coronary artery bypass grafting; 18F-FDG PET, 18F-fluorodeoxy-glucose positron emission tomography; MPS, myocardial perfusion scintigraphy.
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An amount of 1050 mL of the enteral nutrition will be given during 24 hours. This nutrition will be given two days before, during and two days after CABG by a computerized guidance system-placed nasoduodenal tube (Cortrak®, Viasys Healthcare, Wheeling, IL, USA). At the morning of surgery the position 
of the duodenal tube is verified. Patients are permitted to eat and drink in addition to their supplemental nutrition.
Parenteral nutrition
Patients in the parenteral group will receive 1250 mL of nutrition (Nutriflex 
Table 2 – Study schedule
E,PE,PE,PE,PE,PE,PE,PE,PNutrition
BIS, bioelectrical impedance spectrometry; C, control group; CABG, coronary artery bypass grafting; E, enteral group; 
18F-FDG PET, 18F-fluorodeoxy-glucose positron emission tomography; MPS, myocardial perfusion scintigraphy; 
P, parenteral group.
CE,PHospital admission
EEEENutrient drink
E,P,CAortic tissue
E,P,CE,P,CCardiac tissue
E,P,CE,P,CBIS
E,P,CE,P,C18F-FDG PET
E,P,CE,P,CMPS
E,P,CE,P,CE,P,CE,P,CE,P,CE,P,CE,P,CBlood sampling
E,P,CRandomization
E,P,CInformed consent
endstartBefore
>21321000-1-2-3-4-5-6-7-14
AfterCABGBeforeDays
Table 3 – Composition of enteral and parenteral nutrition
YesYesYesVitamins and minerals
955745300Energy (kcal)
501.511.6Fat (g)
809537.1Carbohydrates (g)
4080.512Amino acids (g)
12501050125Volume (mL)
Nutrition 
(at hospital) 
per day
Nutrition 
(at hospital) 
per day
Drink 
(at home) 
per day 
Parenteral groupEnteral group
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Lipid peri, B.Braun, Oss, The Netherlands) containing amino acids, lipids and glucose. An amount of 1250 mL of the amino acid infusion (840 mOsm/L) will be given in 24 hours for 5 days (Table 3). In addition, vitamins (Cernevit, Baxter, Utrecht, The Netherlands) and trace elements (Nutritrace, B.Braun, Oss, The Netherlands) will be added to the parenteral nutrition. This nutrition will be given two days before, during and two days after CABG. Patients are permitted to eat and drink in addition to their supplemental nutrition.
Controls The control group follows the standard protocol of the department of cardio-thoracic surgery of the AMC allowing patients to eat and drink until six hours before surgery. The day after surgery, this standard protocol prescribes a (clear) liquid diet. On the second day after surgery patients are recommended a normal diet.
Outcome measures
The main study outcomes are amino acid profile and cardiomyocytes 
structure at the time of cardiac surgery. Amino acid profile will be studied in blood plasma and cardiac tissue and includes determining the concentrations of all amino acids, ADMA and symmetric dimethylarginine (SDMA, ADMA’s isomer that lacks direct NOS inhibitory activity). In addition, the arginine/ADMA ratio (an indicator of potential NO production) will be calculated. In cardiac tissue, also the activity of dimethylarginine dimethylaminohydrolase (DDAH, an enzyme which degrades ADMA) and arginase (an enzyme which metabolizes arginine) are measured. Cardiomyocytes structure will be assessed by histological analysis, immuno-histochemistry, and by electron microscopy.The secondary study outcomes are cardiac perfusion, left ventricular function and cardiac glucose metabolism. ECG-gated MPS will be used for the measurement of cardiac perfusion and left ventricular function. Cardiac glucose metabolism will be measured with 18F-FDG PET.BIS measured FFM will be used as parameter of nutritional status. A high FFM is related to better nutritional status and improved post-surgical outcome 
(9). Other outcome parameters are cardiac muscle damage and signs of 
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failure as measured by blood plasma biomarkers (Troponin T, CK-MB, and NT-proBNP). Blood plasma will be stored for future study of metabolic switch biomarkers. Baseline characteristics (including European System for Cardiac Operation Risk Evaluation score (EuroSCORE) (10), and unintended weight loss) will be recorded, as well as clinical parameters (intensive care unit (ICU) stay, length of hospital stay, time of mechanical ventilation, organ failure, infections, bleeding, and postoperative mortality). Finally, the concentration of ADMA will be measured in a sample of the aortic wall to investigate the relation between tissue ADMA concentrations in the aorta, and both intracellular concentrations from peripheral blood mononuclear cells (PBMC) and plasma levels.
Blood and tissue samplesBlood sampling will be done at baseline (approximately two weeks before CABG during a visit at the hospital outpatient clinic), at the day of surgery 
(once before and twice during surgery), at the first and third day after surgery, and approximately three weeks after surgery (during a visit at the hospital outpatient clinic) (Table 2).During surgery, two tissue samples of the appendix of the right atrium will be taken by the surgeon. One sample will be taken prior to the start of the anastomosic connection of the bypass graft, and one sample at the end of the procedure before closing of the pericardium. Half of each sample is placed in an aluminum box which will be immediately frozen in liquid nitrogen and 
stored at -80°C until the amino acid profile is analyzed. The other half of each sample is immediately placed in formalin and will be analyzed within two weeks for the assessment of cardiomyocytes structure. In addition, a sample of aortic tissue is taken by the surgeon at the end of the CABG-procedure 
which becomes available due to fixation of the proximal anastomosis needed for the bypass and is in routine clinical practice discarded. The sample is 
immediately frozen in liquid nitrogen and stored at -80°C until the ADMA concentration is measured.
Nuclear medicine imaging techniquesAn ECG-gated MPS and a 18F-FDG PET scan are performed at baseline 
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(approximately two weeks before CABG) and more than three weeks after CABG. Stress and rest myocardial perfusion scintigraphy (with single-photon emission computed tomography (SPECT)) is performed with 99mTc labeled Tetrofosmin. Symptom limited exercise is the preferred stress modality. Pharmacological vasodilatory stress with adenosine will be applied if there 
is an insufficient increase of heart rate (<85% age predicted maximal heart-rate) during physical exercise, in the presence of a left bundle branch block, or if the anti-anginal medication had not been adequately discontinued. Dobutamine stress testing is performed in patients with a contra-indication for adenosine. The type of stress test applied for MPS before surgery is maintained at the MPS post-surgery. ECG-gated image acquisition is performed for the assessment of parameters of left ventricular function (end-systolic and end-diastolic volumes and ejection fraction). Two experienced nuclear medicine physicians analyze the images in a total of 17 myocardial segments. Segments are scored with a 5-point scoring system (0 = normal; 1 = equivocal; 2 = moderate reduction; 3 = severe reduction; 4 = absent activity). Summed stress score (SSS) and summed rest score (SRS) are obtained by adding the scores of all segments of respectively stress and rest images. The 
summed difference score (SDS) is calculated by subtracting the SRS from the SSS. Reversible myocardial perfusion defects, indicative for inducible 
myocardial ischemia, are defined as SDS ≥3. Fixed defects, indicative for 
scarring are defined as a SRS-score of ≥3. The presence of either reversible 
or fixed defects is defined as the presence of any perfusion defect.18F-FDG is a glucose analogue that after cellular uptake via the GLUT-4 transporter and phosphorylation by hexokinase is not further metabolized. Therefore the imaged concentration of 18F-FDG in the heart reflects its glucose metabolism. Patients are imaged after suppression of the free fatty acid metabolism by oral administration of acipimox. The glucose metabolism in the myocardium is analyzed by standardized uptake values, both regional as for the total myocardium.
Bioelectrical impedance spectrometryA BIS-measurement (BodyScout, Fresenius Kabi, ‘s-Hertogenbosch, The Netherlands) is performed at baseline and approximately three weeks after 
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CABG for the assessment of body composition. The principle of the BIS is 
based on the conductance through body fluid of an electric current (5-800 
μA, 5 kHz-1 MHz). The BIS measures the impedance at a range of frequencies from which the resistances of extra-cellular water and intracellular water are extrapolated. Resistance is measured on the right side while patients in supine position. Subsequently, FFM is calculated (FFM is linearly related to height2/body resistance) (11).
Anesthetic and (post-)surgical procedures
Anaesthesia is induced with sufentanil 3 μg kg-1 (Suftena®, Janssen-Cilag, Tilburg, The Netherlands) and propofolol 50-100 mg (Fresenius Kabi, Den Bosch, The Netherlands). Pancuronium bromide 0.1 mg kg-1 (Pavulon®, Organon, Oss, The Netherlands) is given for muscle relaxation. Morphine 20 mg is given as a slow bolus injection before start of surgery. Anaesthesia is maintained with a continuous infusion of propofolol 2-5 mg kg-1 h-1.
The off-pump technique is used for all patients. After a median full sternotomy, 
a few superficial and deep pericardial sutures are placed to facilitate cardiac displacement. During anastomosis, a suction-type mechanical stabilizer (Octopus 4.3, Medtronic, Minneapolis, MN, USA) is used to immobilize the target site of coronary artery. Distal myocardial perfusion is maintained 
using intracoronary shunt tube (Anastaflo, Edwards Life-science, Irvine, CA, USA). The basic strategy for myocardial revascularization is in situ grafting of the internal thoracic artery to the left coronary system with complementary saphenous vein. Vein-to-aorta proximal anastomosis is performed using partial clamping or an anastomotic device.After surgery, patients are admitted to the ICU and treated according to a 
standardized clinical protocol. Fluid administration consists of NaCl 0.9% 
and hydroxyethyl starch 6% of molecular weight 200 kDa (Haes-Steril, Fresenius Kabi, Den Bosch, The Netherlands).
Blood laboratory analysesIn blood plasma, the concentrations of amino acids, ADMA and SDMA will be 
analyzed by high performance liquid chromatography (HPLC)/fluorescence as described previously (12, 13). Briefly, solid-phase extraction is used to 
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isolate ADMA, SDMA and arginine, and subsequently all amino acids and ADMA and SDMA are converted into stable adducts by derivatization with 
ο-phthaldialdehyde reagent containing mercaptopropionic acid. Derivatives are then separated by reversed-phase HPLC using isocratic elution and 
fluorescence detection.Blood plasma, concentrations of Troponin T, CK-MB, and NT-proBNP will be analyzed with standard laboratory tests.PBMC are isolated from whole blood by centrifugation after which cells are washed with PBS, are counted (Cell Dyn 4000, Abbott, Hoofddorp, The Netherlands), and lysed. Finally, the intracellular ADMA concentration in 
PBMC will be measured by HPLC/fluorescence.
Tissue laboratory analysisAfter homogenization of cardiac or aortic tissue (OMNI 2000 homogenizer, OMNI international Inc., Gainesville, Virginia, USA), concentrations of amino 
acids, ADMA and SDMA will be analyzed by HPLC/fluorescence. In cardiac tissue, also the activity of DDAH will be determined by measuring citrulline formation during incubation of tissue homogenates with an excess of ADMA. Furthermore, the activity of arginase will be determined by measurement of ornithine formation during incubation of tissue homogenates with an excess of arginine. Both citrulline and ornithine formation will be analyzed 
by HPLC/fluorescence.
Tissue pathological evaluation
The cardiac tissue sample will be fixated in formaline. It then will be studied by histological, immuno-histochemical and ultrastructural analysis. For histological analysis, tissue samples will be stained with hematoxylin and eosin (HE) and Elastica van Gieson (EVG). Subsequently, cardiomyocytes 
diameter, thickness of the endocardium, level of fibrosis (interstitial, replaced and perivascular) and the percentage of fat tissue contribution (replacement 
and perivascular) will be analyzed. Periodic acid Schiff digested (PAS/D) stained tissue segments will be evaluated to detect and quantify glycogen stacking. Finally, the presence of iron and amyloid will be established by ferron and Congo-red staining respectively. The immuno-histochemical part 
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of the study includes analysis/quantification of lymphocytes, macrophages, 
neutrophil granulocytes, myocytolysis, and pro-inflammatory vessel damage by antibodies CD45, CD68, myeloperoxidase (MPO), C3d, and carboxymethyl lysine (CML) respectively. Using electron microscopy, we will determine 
myofibril density, cytosolic glycogen, expanded sarcoplasmatic reticulum (as marker of cellular damage), amount of mitochondria, damage to mitochondria (stacking as reversible damage, protein dots as irreversible damage), and thickness of the basal membrane of capillaries.All analysis in this study will be done by analysts that are blinded to group assignment.
Baseline and Clinical characteristics
Unintended weight loss before surgery is defined as [(current weight) - 
(weight 1 month ago)] >5% or [(current weight) - (weight 6 months ago)] 
>10%. Clinical characteristics (including risk score, length of stay at the ICU and hospital, time of mechanical ventilation, organ failure, infections, and bleeding) are extracted from medical case notes and an electronic database. This database includes the risk score based on EuroSCORE (10). Organ failure after intervention will be aggregated from the presence of 
cardiac damage defined as CK-MB isoenzyme ≥100 μg/L and/or acute renal 
failure defined as postoperative serum creatinine ≥200 μmol/L or as need 
for dialysis, and/or neurologic failure defined as cerebrovascular accident or 
peripheral neuropathy. Bleeding is defined as abdominal bleeding or need 
for reoperation because of bleeding, and infection is defined as respiratory tract infection, urinary tract infection, mediastinitis, sternal wound infection, leg wound infection, and other infections (such as phlebitis and rare cases 
of intra-abdominal and dermatologic conditions). Mortality is defined as mortality during the period from hospital admission until the postoperative visit at the outpatient clinic.
Statistical analysisThe results of the enteral and parenteral group will be compared with results 
of the control group. Differences between the (par)enteral and control group will be analyzed with Chi-square tests for categorical variables, with unpaired 
144
t-tests for continuous variables, and with the Mann-Whitney U test for non-normally distributed data. Correlations will be analyzed with Pearson’s 
correlation or with the Spearman rank correlation coefficient. Multiple linear and multiple logistic regression models will be used to determine if 
differences between groups can be explained by the effect of (par)enteral 
nutrition, by confounders or by both. A p-value of ≤0.05 will be considered 
statistically significant.
DiscussionMalnutrition and starvation in surgical patients can have a negative impact on cardiac function and metabolism. We will investigate if this problem can be relieved by supplementation of uninterrupted perioperative enteral or 
parenteral nutrition. To the best of our knowledge, this is the first randomized 
controlled trial that examines the effect of uninterrupted (par)enteral nutrition on cardiac function in cardiac surgical patients. In this proof-of-concept study we will explore the hypothesis that there is a disturbed amino 
acids profile in the cardiac surgical patient and that our uninterrupted 
perioperative nutrition will normalize this profile with a subsequent improvement in cardiomyocytes structure, and in cardiac perfusion and metabolism. The results from this study will increase knowledge about the 
effect of nutrition and about avoiding starvation in cardiac surgical patients and thereby improving cardiac metabolism and function which might improve outcome. Additionally, as perioperative starvation is common practice in all surgical patients, and malnutrition might be an underlying risk factor for the perioperative cardiac complications in non-cardiac surgeries, the results of this study will be valuable for the treatment of all surgical patients.
Previous studiesRandomized controlled trials in humans in which arginine (14-16), aspartate 
(17), or glutamate (18) was administered, have shown improved cardiac 
flow (15, 16), cardiac function (measured as plasma troponine T, creatine kinase (CK), and CK-MB) (14, 17, 18) and/or cardiac metabolism (measured as myocardial acidosis, ATP and lactate in myocardial biopsies) (17, 18). In animal studies, amino acid supplementation minimized cardiomyocytes 
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apoptosis probably by increasing ATP production and myocardial oxygen consumption (19), by reducing myocardial ischemic damage, and by increasing diastolic pressure (20). Parenteral amino acid supplementation increased esophageal core temperature, shortened duration of postoperative mechanical ventilation, ICU stay and hospitalization, and speeded tracheal extubation in patients undergoing CABG (21). Enteral nutrition in cardiac surgical patients, repleted cardiomyocytes with nutrients, improved left ventricular end-diastolic volume before surgery (22), improved preoperative host defense, reduced the number of postoperative infections, and preserved renal function (23).
The results of the aforementioned studies show favorable effects of nutrition 
on cardiac function. However, the effect of uninterrupted perioperative supplementation of amino acids, glucose, vitamins and minerals on cardiac 
amino acid profile, cardiomyocytes structure, cardiac perfusion, left ventricular function and metabolism of cardiac surgical patients have never been investigated.
Rationale for nutrients and administration devicesThe enteral and parenteral nutrition used in this study contain amino acids, glucose, vitamins and minerals. Besides their function as precursors for protein synthesis, amino acids are able to replenish components of the tricarboxylic acid cycle which can increase ATP production in heart cells, 
with positive effects on cardiomyocytes metabolism (4). Many of these amino acids are essential amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) that cannot be synthesized by the human body and therefore need to be supplied by nutrition. The non-essential amino acids glutamate and aspartate are important compounds of nutrition since they are abundant intracellular free amino acids in the heart (24) which have been shown to be cardioprotective by enhancing ATP production (25). Furthermore, in previous studies depleted levels of aspartate and glutamate in cardiomyocytes (26) and low plasma levels of arginine (27) have been found in patients with heart failure. Importantly, the semi-essential amino acid arginine is the precursor of NO, 
a dominant compound that influences blood flow and endothelial function, 
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is involved in myocardial relaxation and distensibility, and might improve left ventricular function (7). Furthermore, arginine supplementation might improve the arginine/ADMA ratio, an indictor of potential NO production.The addition of glucose to (par)enteral nutrition can avoid conversion of the supplemented amino acids into glucose through gluconeogenesis, and can prevent protein catabolism (28). Vitamins and minerals are essential ingredients of the nutrition because they prevent from micronutrient 
deficiency and they have antioxidant qualities (29).
Acknowledgements
MV was supported by the Egbers Foundation. PeptoPro, Phlexyvits, Nutriflex lipid peri and Nutritrace were supplied free of charge by DSM (Delft, The Netherlands), Nutricia (Zoetermeer, The Netherlands) and B. Braun (Oss, The Netherlands) respectively.
References 1.  Van Venrooij LM, De Vos R, Borgmeijer-Hoelen MM, Haaring C, De Mol BA. Preoperative unintended weight loss and low body mass index in relation to complications and length of stay after cardiac surgery. Am J Clin Nutr 87: 1656-1661, 2008. 2.  Engelman DT, Adams DH, Byrne JG, Aranki SF, Collins JJ, Jr., Couper GS, Allred EN, Cohn LH, Rizzo RJ. Impact of body mass index and albumin on morbidity and mortality after cardiac surgery. J Thorac Cardiovasc Surg 118: 866-873, 1999.
 3.  Sungurtekin H, Sungurtekin U, Balci C, Zencir M, Erdem E. The influence of nutritional status on complications after major intraabdominal surgery. J Am Coll Nutr 23: 227-232, 2004. 4.  Neubauer S. The failing heart--an engine out of fuel. N Engl J Med 356: 1140-1151, 2007. 5.  Damen J, Hagemeijer JW, Van den Broek L, Poldermans D. [Prevention of perioperative cardiac complications in non-cardiac surgery: an evidence-based guideline]. Ned 
Tijdschr Geneeskd 152: 2612-2616, 2008. 6.  Bengmark S, Andersson R, Mangiante G. Uninterrupted perioperative enteral nutrition. 
Clin Nutr 20: 11-19, 2001. 7.  Visser M, Paulus WJ, Vermeulen MA, Richir MC, Davids M, Wisselink W, De Mol BA, Van Leeuwen PA. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail 12: 1274-1281, 2010. 8.  Visser M, Vermeulen MAR, Richir MC, Teerlink T, Van Leeuwen PA, Oudemans-Van Straaten HM. Arginine/ADMA as a predictor of cardiac output  in septic shock patients [abstract]. JPEN J Parenter Enteral Nutr 34: 203, 2010. 9.  Van Venrooij LM, Verberne HJ, Van Leeuwen PA, De Vos R, Borgmeijer-Hoelen MMMJ, 
147
6a
Part II: Intracellular ADMA: metabolism and relation to plasma levels
J Cardiothorac Surg 6 (2011) 36
De Mol BA. Skeletal muscle mass changes in patients undergoing cardiac surgery. Clin 
Nutr Suppl 4:94, 2009. 10.  Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16: 9-13, 1999. 11.  Kyle UG, Schutz Y, Dupertuis YM, Pichard C. Body composition interpretation. Contributions of the fat-free mass index and the body fat mass index. Nutrition 19: 597-604, 2003. 12.  Teerlink T, Van Leeuwen PA, Houdijk A. Plasma amino acids determined by liquid chromatography within 17 minutes. Clin Chem 40: 245-249, 1994. 13.  Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in 
biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 851: 21-29, 2007. 14.  Colagrande L, Formica F, Porta F, Brustia M, Avalli L, Sangalli F, Muratore M, Paolini 
G.  L-arginine effects on myocardial stress in cardiac surgery: preliminary results. Ital 
Heart J 6: 904-910, 2005.
 15.  Quyyumi AA, Dakak N, Diodati JG, Gilligan DM, Panza JA, Cannon RO, III. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. 
J Am Coll Cardiol 30: 1220-1227, 1997.
 16.  Wallace AW, Ratcliffe MB, Galindez D, Kong JS. L-arginine infusion dilates coronary vasculature in patients undergoing coronary bypass surgery. Anesthesiology 90: 1577-1586, 1999. 17.  Uyar I, Mansuroglu D, Kirali K, Erentug V, Bozbuga NU, Uysal G, Yakut C. Aspartate and glutamate-enriched cardioplegia in left ventricular dysfunction. J Card Surg 20: 337-344, 2005. 18.  Bitzikas G, Papakonstantinou C, Lazou A, Bougioukas G, Toumpouras M, Tripsianis G, Spanos P. The supportive value of pre-bypass L-glutamate loading in patients undergoing coronary artery bypass grafting. J Cardiovasc Surg (Torino) 46: 551-557, 2005. 19.  Scarabelli TM, Pasini E, Stephanou A, Chen-Scarabelli C, Saravolatz L, Knight RA, Latchman DS, Gardin JM. Nutritional supplementation with mixed essential amino acids enhances myocyte survival, preserving mitochondrial functional capacity during ischemia-reperfusion injury. Am J Cardiol 93: 35A-40A, 2004.
 20.  Pasini E, Scarabelli TM, D’Antona G, Dioguardi FS. Effect of amino acid mixture on the isolated ischemic heart. Am J Cardiol 93: 30A-34A, 2004. 21.  Umenai T, Nakajima Y, Sessler DI, Taniguchi S, Yaku H, Mizobe T. Perioperative amino 
acid infusion improves recovery and shortens the duration of hospitalization after off-pump coronary artery bypass grafting. Anesth Analg 103: 1386-1393, 2006. 22.  Jeejeebhoy F, Keith M, Freeman M, Barr A, McCall M, Kurian R, Mazer D, Errett L. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. 
Am Heart J 143: 1092-1100, 2002. 23.  Tepaske R, Velthuis H, Oudemans-Van Straaten HM, Heisterkamp SH, Van Deventer 
SJ, Ince C, Eysman L, Kesecioglu J. Effect of preoperative oral immune-enhancing 
148
nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet 358: 696-701, 2001. 24.  Venturini A, Ascione R, Lin H, Polesel E, Angelini GD, Suleiman MS. The importance of myocardial amino acids during ischemia and reperfusion in dilated left ventricle of patients with degenerative mitral valve disease. Mol Cell Biochem 330: 63-70, 2009. 25.  Taegtmeyer H, Harinstein ME, Gheorghiade M. More than bricks and mortar: comments on protein and amino acid metabolism in the heart. Am J Cardiol 101: 3E-7E, 2008. 26.  Suleiman MS, Fernando HC, Dihmis WC, Hutter JA, Chapman RA. A loss of taurine and other amino acids from ventricles of patients undergoing bypass surgery. Br Heart J 69: 241-245, 1993. 27.  Kaye DM, Ahlers BA, Autelitano DJ, Chin-Dusting JP. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 102: 2707-2712, 2000. 28.  Wolfe BM. Substrate-endocrine interactions and protein metabolism. JPEN J Parenter 
Enteral Nutr 4: 188-194, 1980. 29.  Witte KK, Clark AL, Cleland JG. Chronic heart failure and micronutrients. J Am Coll 
Cardiol 37: 1765-1774, 2001.
149
6a
Part II: Intracellular ADMA: metabolism and relation to plasma levels
J Cardiothorac Surg 6 (2011) 36
0

Chapter 6b
The concentration of asymmetric dimethylarginine in plasma, better than in peripheral blood mononuclear cells, 
reflects its concentration in cardiac tissue
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Abstract
Elevated plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), have been associated with cardiovascular risk. ADMA is formed intracellularly through methylation of arginine residues in proteins, and released into its free form upon proteolysis. Cellular ADMA is cleared either through intracellular hydrolysis by dimethylarginine dimethylaminohydrolase (DDAH), or through export to the plasma. Inhibition of NOS by ADMA is an intracellular event, but clinical studies often report on plasma ADMA, assuming that 
plasma concentrations result from cellular spillover and accurately reflect intracellular concentrations. However, studies on the relation between plasma and intracellular levels of ADMA are scarce.This study explored the relations between ADMA levels in plasma, peripheral blood mononuclear cells (PBMC), heart and aortic tissue, obtained from 33 patients undergoing coronary artery bypass grafting (CABG). In addition, the relation between intracellular ADMA and DDAH activity was investigated.
ADMA concentrations in plasma were significantly related to intracellular ADMA in PBMC (r = 0.434; P = 0.013) and heart tissue (r = 0.380; P = 0.029), 
but ADMA in PBMC was not significantly related to ADMA in heart tissue (r = 0.113; P = 0.54).DDAH activity was positively associated with ADMA in heart tissue (r = 0.767, 
P <0.001) and PBMC (r = 0.457, P = 0.014).We conclude that in patients undergoing CABG, plasma levels of ADMA, 
better than ADMA in PBMC, reflects cardiac ADMA. Upregulation of DDAH may be a compensatory response to elevated intracellular ADMA levels in coronary artery disease.
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IntroductionElevated plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase (NOS), have been associated with atherosclerosis (1), endothelial dysfunction (2), cardiovascular disease (3, 4), and ICU mortality (5). Although clinical studies report on plasma concentrations of ADMA in association with cardiovascular disease, all processes responsible for generation and degradation of ADMA, as well as the inhibitory action of ADMA towards NOS, are intracellular events 
(6). ADMA and its inactive isomer symmetric dimethylarginine (SDMA) are formed intracellularly through the methylation by protein arginine methyltransferases (PRMT) of arginine residues in proteins (7), in which monomethylarginine (MMA) is formed as an intermediate product. Upon proteolysis, arginine and its methylated forms are released into their free forms, of which both ADMA and MMA can inhibit the production of NO from arginine by NOS. Reduced basal NO synthesis may lead to vasoconstriction, elevated blood pressure and thrombus formation (1). Clearance of cellular ADMA and MMA is established either through their hydrolysis by dimethylarginine dimethylaminohydrolase (DDAH), or through export to the plasma by cationic amino acid transporters (CAT), which also transport other cationic amino acids such as SDMA and arginine (8). ADMA in plasma 
is often regarded as cellular spill over and assumed to reflect intracellular concentrations, but data on the relation between intracellular and plasma concentrations is limited.In an animal model of prolonged critical illness we previously observed that 
ADMA content correlated significantly between different tissues, but not with ADMA levels in plasma. In addition, DDAH activity was correlated with ADMA levels in plasma rather than with ADMA levels in tissue (9). Extension 
of such experiments to humans is hampered by the fact that it is difficult to 
obtain tissue samples from healthy individuals. Therefore, we first explored the relation between ADMA levels in plasma and intracellular levels in blood cells, which are more easily obtained. We showed that ADMA levels in erythrocytes of healthy humans were not related to levels found in plasma, 
whereas in critically ill patients a significant correlation between ADMA in plasma and erythrocytes was observed (10). Because the mature erythrocyte 
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lacks a nucleus, and therefore its capacity for protein synthesis (11), it may 
behave differently than other cells that do contain the full protein synthesis machinery, such as peripheral blood mononuclear cells (PBMC). The present study was performed to test the hypothesis that intracellular ADMA in PBMC, 
better than ADMA in plasma, reflects ADMA content at the tissue level. To this end we measured ADMA and related compounds in plasma, PBMC, heart and aortic tissue from patients undergoing coronary artery bypass grafting (CABG).
Materials and methods
Subjects and samplesPatients were recruited in a randomized controlled intervention study for which the rationale and design have been described previously (12). In short, 
the study investigates the effect of uninterrupted perioperative (par)enteral nutrition on cardiac function in 33 patients undergoing CABG. Patients were given either enteral nutrition (n = 11) or parenteral nutrition (n = 11), two days before, during, and two days after CABG. The control group (n = 11) was treated according to the standard guidelines for CABG surgery. Clinical characteristics of the patients are shown in Table 1.During surgery, at the end of the CABG-procedure before closing of the pericardium, a tissue sample of the appendix of the right atrium (heart) and, when possible (n = 20), a tissue sample of the aorta, which becomes 
available due to fixation of the proximal anastomosis, were obtained by the 
[1.0 – 3.0]
(10)
[26.2 – 30.6]
(33)
(6.1)
2.0EuroSCORE
27.7kg/m2Body mass index
Data is presented as mean (SD) or when distributions were skewed as median 
[interquartile range].
EuroSCORE: European System for Cardiac Operation Risk Evaluation (21).
30.3% (N)Diabetes mellitus
100% male (N)Gender
65.4yearsAge
33N
UnitVariable
Table 1 – Patient characteristics
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surgeon and immediately frozen in liquid nitrogen before storage at -80°C. Simultaneously, 8 mL whole blood was obtained using a BD vacutainer® cell preparation tube (CPT™) from Becton, Dickinson and Company (Franklin Lakes, NJ, USA).
Isolation of PBMC and plasmaWithin 2 hours after venipuncture, PBMC and plasma were separated from erythrocytes and granulocytes by centrifugation (30 min, 1500 x g, 20°C). PBMC were resuspended in the plasma and transferred to a clean 15-mL volumetric tube. After centrifugation (10 min, 600 x g, 4°C) a 1-mL aliquot 
of plasma was acquired from the supernatant and stored at -80°C, and the excess supernatant was discarded. The PBMC-pellet was washed twice in 14 
mL ice-cold phosphate buffered saline, pH 8.0. From the second wash a 250-µL aliquot was taken for a cell count (CBC WBC extended count, CellDyn 4000, Abbott, Hoofddorp, The Netherlands), and after centrifugation (10 min, 600 x g, 4°C) the PBMC-pellet was stored at -80°C until further analysis.
Sample preparation After weighing, the frozen tissue samples were homogenized in 1 mL ice-cold 100 mmol/L NaH2PO4, pH 6.5 containing protease inhibitors (Complete protease inhibitor cocktail from Roche Applied Science, Mannheim, Germany) using an OMNI-2000 homogenizer (OMNI International, Waterbury, CT). Immediately after homogenization, part of the homogenate was mixed with an equal volume of 1.2 mol/L perchloric acid and, after centrifugation (10 min, 2000 x g, 4°C), the supernatant was stored at 4°C until analysis of ADMA, SDMA, MMA, arginine, and homoarginine. The remainder of the homogenate was used for determination of DDAH activity.PBMC-pellets were thawed on ice, and resuspended in 500 µL 100 mmol/L NaH2PO4, pH 6.5 containing protease inhibitors. Subsequently, they were lysed using an ultrasonic probe (Bandalin Sonopuls mini 20 with MS 1.5 titanium 
microtip) for 3 x 10 sec at ~0.250 kJ (= 90% of maximum power) while kept on ice. From a 100-µL aliquot of the PBMC lysate proteins were precipitated by addition of 100 µL 1.2 mol/L perchloric acid. After centrifugation (10 min, 20100 x g, 4°C), the supernatant was stored at 4°C until analysis of ADMA, 
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SDMA, MMA, arginine, and homoarginine. The remainder of the lysate was used for determination of DDAH activity.
Measurement of ADMA, SDMA, MMA, arginine, and homoarginineFor the determination of ADMA, SDMA, MMA, arginine, and homoarginine in plasma, tissue-homogenates and PBMC-lysates, samples were thawed on ice. After addition of the internal standards D7-ADMA, 13C6-arginine, and D4-homoargarginine, the cationic amino acids were extracted using Oasis MCX solid phase extraction cartridges (Waters, Milford, MA, USA), and their butyl-esters were determined using our recently validated LC-MS/MS method 
(13). The arginine/ADMA ratio was calculated as well, since NO production by NOS is determined by the combination of substrate availability and the 
presence of inhibitor, which is reflected by this ratio.
Determination of DDAH activityDDAH activity was determined in tissue-homogenates and PBMC-lysates a by measurement of citrulline formation during incubation with excess of ADMA (9, 14). After a dual centrifugation procedure (10 min, 2000 x g, 4°C followed by 30 min, 10.000 x g, 4°C) to remove cellular debris, 80 µL of the supernatant was mixed with 120 µL of a 4 mmol/L ADMA solution in 100 mmol/L NaH2PO4, pH 6.5. In a baseline sample and in a sample incubated 
for 2 hours at 37°C, the reaction was stopped by transferring the incubation mixture to vials containing 8 mg sulfosalicylic acid, which precipitates the proteins. After vortex mixing, the vials were centrifuged (10 min, 3000 x g, 4°C) and citrulline was measured in the clear supernatant with high-performance liquid chromatography as previously described (15). The increase in citrulline concentration during incubation was used to calculate the DDAH activity.  Validation data of the assay procedure have been published 
(9).
Calculations and statistical analyses Amino acid concentrations in heart and aorta were expressed as nmol/g tissue, and intracellular levels in PBMC were expressed in µmol/L. To this end, the measured concentration was corrected for the amount of cells and 
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for a mean corpuscular volume of 282.9 fL per PBMC, described by Simiele et al (16). DDAH activity in heart and aorta was expressed as nmol citrulline per min per g tissue and in PBMC as µmol/L citrulline per min.  Intracellular concentrations of ADMA, SDMA, MMA, arginine, and homoarginine in PBMC, heart and aorta were compared to plasma levels by paired-Student’s t-test, and strengths of associations between their concentrations were assessed using Pearson correlation. A two-tailed P-
value <0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA).
ResultsConcentrations of arginine, ADMA, SDMA, MMA, and homoarginine in plasma, PBMC, heart and aorta are listed in Table 2. Mean levels of ADMA in PBMC were 13.1-fold higher than in plasma, and concentration gradients were observed for all other amino acids as well, with ratios of mean intracellular over mean plasma concentrations of 7.4 for arginine, 5.5 for MMA, 4.0 for SDMA, and 1.6 for homoarginine. In heart all amino acids had a 2-fold higher concentration compared to aorta. The arginine/ADMA ratio, an indicator for possible NO production by NOS, was highest in plasma (163.2 ± 43.4) and 
significantly lower in PBMC (94.5 ± 27.7), heart (112.0 ± 31.9) and aorta (110.5 ± 35.4).
In heart strong and highly significant positive correlations were observed between levels of arginine, its methylated forms and homoarginine (Table 
0.036 (0.030)0.078 (0.055)4.00 (2.79)2.57 (1.14)Homoarginine
0.010 (0.003)0.026 (0.004)0.520 (0.428)0.094 (0.015)MMA
0.041 (0.012)
0.047 (0.021)
5.63 (4.40)
Heart
(nmol/g tissue)
Data is presented as mean (SD). 
n = 33 for plasma, PBMC and heart, and n = 20 for aorta.
0.024 (0.009)3.05 (2.11)0.753 (0.134)SDMA
0.024 (0.011)8.57 (6.26)0.653 (0.085)ADMA
2.79 (1.92)782 (512)0.105 (21).00Arginine
Aorta
(nmol/g tissue)
PBMC
(µmol/L)
Plasma
(µmol/L)
Analyte
Table 2 – Concentrations of arginine, ADMA, SDMA, MMA, and 
homoarginine in plasma, PBMC, heart, and aorta
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3). In aorta most of these analytes were also strongly correlated. The association between arginine and homoarginine was stronger than in heart (r = 0.749 versus r = 0.451, respectively). Only the relations with MMA were 
less strong than in heart, but still highly significant with the exception of the relation between homoarginine and MMA (r = 0.321, P = 0.17). Also in PBMC strong correlations were found between arginine, its methylated forms and homoarginine. Again, the correlations with MMA were less strong, 
and between ADMA and MMA borderline significant (r = 0.331, P = 0.064). In 
plasma significant correlations were only observed between ADMA and MMA (r = 0.892, P <0.001), ADMA and SDMA (r = 0.681, P <0.001) and between SDMA and MMA (r = 0.483, P = 0.004). Additionally, a borderline significant relation between arginine and homoarginine in plasma was observed.
As shown in Figure 1, ADMA concentrations in plasma were significantly related to intracellular ADMA in PBMC (r = 0.434; P = 0.013) and heart tissue (r = 0.380; P = 0.029), but ADMA in PBMC was not significantly related to ADMA in heart tissue (r = 0.113; P = 0.54). For homoarginine these associations were stronger than for ADMA (Figure 1), and both plasma 
homoarginine and intracellular homoarginine in PBMC were significantly 
<0.0010.7490.0080.451<0.0010.8420.0680.321ARG - HARG
<0.0010.793<0.0010.9180.0640.331<0.0010.892ADMA - MMA
<0.0010.925<0.0010.923<0.0010.936<0.0010.681ADMA - SDMA
0.0090.566<0.0010.782<0.0010.7000.76-0.054ARG - MMA
<0.0010.855<0.0010.751<0.0010.8610.750.058ARG - SDMA
<0.001
0.001
0.001
<0.001
0.170.001
<0.001
<0.001
<0.001
<0.001<0.001
<0.001
0.020
<0.001
<0.0010.98
0.58
0.004
0.53
0.78
PPPP rrrr
0.8130.7110.6540.101SDMA – HARG
0.6920.8420.4020.483SDMA – MMA
0.555
0.661
0.853
Heart
0.599
0.706
0.827
PBMC
n = 33 for plasma, PBMC and heart, and n = 20 for aorta. 
ARG = arginine, HARG = homoarginine
0.321-0.005MMA - HARG
0.6730.113ADMA - HARG
0.859-0.051ARG - ADMA
AortaPlasma
Table 3 – Pearson correlations between arginine, ADMA, SDMA, MMA, 
and homoarginine in plasma, PBMC, heart, and aorta
159
6b
Part II: Intracellular ADMA: metabolism and relation to plasma levels
   
 
 
 
 
 
  
  
   


 

 







    
 
 
 
 
  
  
   






 

 







   
 
 
 
 
  
  
   


 

 






 



    
 
 
 
 
 
 
  
  
   






 

 






 



    
 
 
 
 
  
  
   


 

 






 



   
 
 
 
 
 
 
  
  
   






 

 






 



Figure 1Scatter plots for the associations of ADMA and homoarginine in plasma, PBMC, and heart. The strengths of the associations were assessed by Pearson’s correlation. Open symbols 
represent the control group, crossed symbols the parenteral group and filled symbols the enteral group.
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related to homoarginine in heart (r = 0.819, P <0.001 and r = 0.476, P = 0.005). 
For SDMA only a significant relation was observed between heart and plasma (r = 0.374, P = 0.032). Neither for arginine nor for MMA, significant associations were observed between their concentrations in plasma, PBMC, and heart tissue. Concentrations of ADMA, SDMA, MMA, arginine, 
and homoarginine in aortic tissue were not significantly related to their respective concentrations in heart tissue, PBMC, or plasma.Mean DDAH activity in heart (12.2 ± 9.9 nmol/g tissue min) was approximately 2-fold higher than in aortic tissue (5.6 ± 3.8 nmol/g tissue min) and mean DDAH activity in PBMC was 0.287 ± 0.229 µmol/L min. No 
significant relations were observed between DDAH activities in heart, aorta or PBMC. In heart tissue strong positive correlations between DDAH activity and concentrations of both ADMA (r = 0.767, P <0.001) and MMA (r = 0.650, 
P <0.001) were observed (Figure 2). In PBMC, DDAH activity and ADMA concentration were positively correlated as well, but less strong than in heart (r = 0.457, P = 0.014), and DDAH activity and MMA concentration were not 
significantly correlated. DDAH activity in aortic tissue was not significantly correlated with either ADMA or MMA (Figure 2).
Discussion
This study offered the unique opportunity to measure ADMA levels in heart, 
aorta, plasma, and PBMC from patients undergoing CABG. The main finding 
of this study is that ADMA concentrations in plasma were significantly related 
to intracellular ADMA in PBMC, but only plasma ADMA was significantly related to ADMA in heart tissue, whereas ADMA in PBMC was not. Therefore, determination of ADMA in plasma, rather than measurement in PBMC, seems suitable to assess cardiac ADMA in patients with coronary artery disease. In addition, in cardiac tissue positive correlations between DDAH activity and concentrations of both ADMA and MMA were observed.
PBMC of patients undergoing CABG showed strong significant relations between arginine and its methylated forms. This is similar to previous 
findings in PBMC of healthy subjects (unpublished data, Thesis Chapter 5 
(17)), that also showed strong significant relations between arginine and 
its methylated forms. Also in heart and aorta strong significant associations 
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Figure 2: Scatter plots for the associations between local DDAH activity and ADMA or MMA  in heart, PBMC, and aorta. The strengths of the associations were assessed by Pearson’s correlation. 
Open symbols represent the control group, crossed symbols the parenteral group and filled symbols the enteral group.
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were present between these analytes. Theses strong positive correlations 
reflect the shared cellular pathways, between the methylated arginines, of formation by PRMT and proteolysis, uptake through CAT, and disposal through either CAT or DDAH. In plasma of CABG patients only ADMA, SDMA and MMA 
were significantly correlated, whereas no significant relation was observed 
between arginine and the different methylated forms. In contrast, in plasma of healthy subjects the relation between arginine and its methylated forms 
was weaker than in PBMC but still significant (17). Differences between the 
relations in healthy subjects and CABG patients may reflect differences in clearance rates by CAT, DDAH activity, PRMT activity, or protein turnover in these two groups. For instance, CAT in erythrocytes, platelets and PBMC is upregulated in patients with chronic renal failure or heart failure (18, 
19). Upregulated CAT may result in faster egress of ADMA from the cell, leading to closer associations between intracellular and extracellular levels. Furthermore, it was shown that in patients with myocardial infarction, 
arginase activity in serum increases within a few hours after the first attack of coronary pain (20). This may explain why in plasma of CABG patients the associations between arginine and the methylated arginines were no longer 
significant.Clinical studies on cardiovascular disease often report on plasma concentrations of ADMA, assuming that ADMA in plasma originates from 
cellular spillover and accurately reflects cellular concentrations. However, synthesis of ADMA by PRMT, its release into its free form after proteolysis, its inhibition of NO synthesis, and hydrolysis of ADMA by DDAH are all processes that occur intracellularly. In previous reports we challenged the general 
validity of the assumption that plasma ADMA accurately reflect intracellular 
levels in healthy subjects, showing the absence of significant correlations between ADMA in plasma and intracellular ADMA in erythrocytes (10). Likewise, in healthy subjects no relation was found between plasma ADMA and intracellular ADMA in PBMC (17). In contrast, in the present study we 
showed that ADMA in PBMC of CABG patients was significantly correlated to 
ADMA in plasma. Furthermore, a significant correlation was present between ADMA in heart and in plasma. It seems that, in line with what we previously reported for intracellular ADMA in erythrocytes, which showed a strong 
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significant association with plasma levels in critically ill patients, whereas it was not seen in healthy subjects, also for intracellular ADMA levels in PBMC of CABG patients a relation with plasma ADMA is present. The closer association between intra- and extracellular concentrations of ADMA, as well as other cationic amino acids such as SDMA, in heart and in plasma, may be indicative of increased CAT expression observed in PBMC, platelets and 
erythrocytes of patients suffering from chronic renal or heart failure (18, 19), which would lead to faster exchange between both compartments, resulting in a positive relation between concentrations in both compartments (8).In healthy subjects we found that mean levels of both arginine and ADMA in PBMC were 7.6-fold higher than in plasma (17). Therefore, the PBMC/plasma ratio was the same for arginine and ADMA, leading to a similar arginine/ADMA ratio in both PBMC (181.4 ± 36.3) and plasma (186.1 ± 31.8). The arginine/ADMA ratio is an indicator for NO production by NOS. In the present study in CABG patients, the PBMC/plasma ratio for arginine (7.4) was similar to the ratio in healthy subjects, but the PBMC/plasma ratio for ADMA (13.1) was 1.7-fold higher than in healthy subjects (17), resulting in a 
different arginine/ADMA ratio in plasma compared to PBMC. In plasma the arginine/ADMA ratio was slightly lower (163.2 ± 43.4) compared to healthy 
subjects. However, in PBMC of CABG patients a significantly lower arginine/ADMA ratio was observed (94.5 ± 27.7). The intracellular arginine/ADMA 
ratios in heart (112.0 ± 31.9) and aorta (110.5 ± 35.4) were not significantly 
different from the ratio in PBMC. The lower arginine/ADMA ratio in CABG patients, compared to healthy subjects, which is especially pronounced 
intracellularly, reflects the impaired NO metabolism in these patients. Reduction in NO formation by NOS, due to the lower arginine/ADMA ratio, results in endothelial dysfunction, vasoconstriction, elevated blood pressure and thrombus formation (1). Reduced NO production, by accelerating atherosclerosis, may ultimately lead to the necessity of CABG.In a previous report on the role of DDAH activity in an animal model we showed that DDAH activity might be a more important determinant in the regulation of plasma ADMA concentrations than in the regulation of tissue ADMA (9). In contrast to the significant association between intracellular ADMA levels in heart, lung, liver kidney and muscle observed in that study, 
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the current study showed no correlation between intracellular ADMA levels in heart, aorta, and PBMC of CABG patients. In the current study DDAH activity was measured in heart, aorta and PBMC and compared to both ADMA and MMA levels in these compartments. Surprisingly, in heart, DDAH 
activity showed significant positive correlations with both its ADMA and MMA content, whereas inverse relations would be expected. Increased DDAH activity should lead to increased degradation of both ADMA and MMA and thus a decrease in their content. The apparent reversal of the association between DDAH activity and ADMA content could be a result of the upregulation of DDAH as a reaction to the high ADMA and MMA concentrations in the heart. In PBMC the relation between DDAH activity and ADMA was also positive 
although less strong than in heart, whereas there was no significant relation 
with MMA. In aorta neither ADMA nor MMA were significantly associated with the local DDAH activity, which may be related to the fact that levels of ADMA and MMA as well as DDAH activity were 2-fold lower in aortic tissue compared to heart tissue. This study has some limitations. First, because it is virtually impossible to obtain cardiac tissue specimens from healthy subjects, our study was conducted in patients undergoing CABG. Therefore, the conclusions may also pertain to patients with other stages of coronary artery disease, but possibly not to healthy individuals. Second, the study was designed to 
investigate the effect of perioperative (par)enteral nutrition compared to standard treatment on cardiomyocyte structure, cardiac perfusion and metabolism. For the present analysis, patients from all three treatment groups were pooled because the number of patients per group was too small 
to allow separate analysis. The pooling of patients under different nutritional regimens may have increased the range of ADMA levels and DDAH activities, 
thereby increasing the likelihood of detecting significant associations with a relatively low number of observations. Third, successful sampling of aortic tissue was performed in only 20 out of 33 patients, severely limiting the statistical power of analyses performed on aortic tissue.In conclusion, our results show that, in patients undergoing CABG, 
intracellular levels of ADMA in heart and PBMC correlate significantly with ADMA levels in plasma, possibly due to upregulation of CAT. Notably, 
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concentrations of ADMA in plasma, better than in PBMC, reflect cardiac ADMA. Furthermore, upregulation of DDAH may be a compensatory response to elevated intracellular ADMA levels in coronary artery disease.
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Abstract
Homoarginine, a homolog of arginine, is a naturally occurring cationic amino acid, which is formed in vivo from lysine. Recently, serum homoarginine has emerged as a potential new risk marker for cardiovascular disease (CVD). However, knowledge on the physiological role of homoarginine in health and CVD is limited.This review discusses metabolic routes for homoarginine synthesis and utilization, bio-analytical aspects, and potential mechanisms underlying its association with CVD.Both high and low homoarginine levels appear to be associated with increased CVD risk. In order to better understand the role of homoarginine in health and disease it is necessary to fully understand all possible metabolic processes in which homoarginine is involved. Although involvement of urea cycle enzymes cannot be excluded, arginine:glycine amidinotransferase (AGAT), a key enzyme in creatine synthesis, seems to be the main actor in homoarginine synthesis from lysine. Homoarginine is a competitive substrate for nitric 
oxide synthase (NOS), but being a less efficient substrate than arginine, high homoarginine levels may lead to reduced nitric oxide formation, resulting in endothelial dysfunction and increased vascular resistance. In contrast, 
the relation between low homoarginine and CVD may reflect impairment of myocardial creatine metabolism, caused by low AGAT activity which also 
results in reduced homoarginine synthesis. It therefore seems that different mechanisms underlie the relations of CVD with high and low homoarginine levels. High homoarginine may, by impairing nitric oxide production, be causally involved, whereas low homoarginine may be an innocent bystander 
reflecting failing creatine metabolism.
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IntroductionHomoarginine, is a naturally occurring cationic amino acid that is structurally 
similar to arginine. The only difference between the two amino acids is the additional methylene group (-CH2-) in the carbon chain of homoarginine 
(Figure 1). DL-homoarginine was first synthesized chemically from DL-lysine by Greenstein in 1937 (1) and the synthesis of L-homoarginine from L-lysine 
was first successfully accomplished in 1950 by Stevens and Bush (2).In 1962 the natural presence of homoarginine in the seeds of Lathyrus cicera was described by Bell (3). Non-protein amino acids like homoarginine are commonly found in plants, which are sometimes used as animal feed or for human consumption. 
Different suggestions have been made on the possible metabolic routes involved in its in vivo synthesis from lysine (4). Furthermore, its ability to interact with enzymes that use arginine as substrate, such as arginase and nitric oxide synthase (NOS), has been studied widely (5-7). In several inherited urea cycle disorders, altered levels of homoarginine in serum and urine have been reported (8-10), and recently low serum homoarginine has surfaced as potential new risk marker for stroke (11) and cardiovascular mortality (12, 13). However, research on the physiological role of homoarginine and on its synthesis and metabolism is limited. Therefore, in the following sections we describe homoarginine synthesis and metabolism, and its potential role in the cardiovascular physiology, and discuss some 
issues on the determination of homoarginine in biological fluids.
OH
NH
O
NH2
NH2
NH
OH
O
NH2
NH
NH2
NH
Arginine Homoarginine
Figure 1Chemical structures of arginine and its structural homolog homoarginine, which 
differs only from arginine by lengthening of the carbon chain by one methylene-group (-CH2-).
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Homoarginine synthesis from lysine
The first report on the existence of a metabolic route for the in vivo synthesis of homoarginine and homocitrulline from lysine dates from 1964 (4). This report described detection of 14C-labeled homoarginine and 14C-homocitrulline in rat kidney after injection of 14C-labeled lysine. Furthermore, it showed increased urinary homoarginine excretion in healthy adults after oral lysine administration. Although the metabolic route for its synthesis from lysine has not yet been unraveled completely, three pathways have been suggested in literature 
(Figure 2). The first uses the subsequent reactions of the enzymes in the urea cycle, in the second protein-lysine carbamoylation leads to homoarginine synthesis, and in the third pathway homoarginine is synthesized from lysine by arginine:glycine amidinotransferase (AGAT), an enzyme essential for creatine synthesis.An alternate urea cycleThe possible existence of an alternate urea cycle, in which the enzymes of the urea cycle are used to convert lysine into homoarginine was already postulated in 1974 (10). In several urea-cycle disorders, such as citrullinemia, and the hyperornithinemia, hyperammonemia and homocitrullinuria (HHH)-syndrome, elevated levels of homoarginine and homocitrulline are found (8, 10). These elevations were especially pronounced upon the administration of additional ammonium chloride, which represses lysine degradation (9), leaving more available for the synthesis of homoarginine and homocitrulline. 
In the alternate urea cycle lysine is first converted into homocitrulline by ornithine transcarbamoylase (OTC), which normally converts ornithine into citrulline. The use of lysine as substrate, however, results in a 50-fold lower OTC activity than for the reaction with its native substrate ornithine 
(10). In the next step of the urea-cycle, homocitrulline can be converted into homoargininosuccinate by argininosuccinate synthase (ASS), and subsequently into homoarginine by argininosuccinate lyase (ASL). Finally, arginase can convert homoarginine into lysine, thereby completing the alternate urea cycle.
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Protein-lysine carbamoylationIn addition to the enzymatic conversion of lysine into homocitrulline by OTC, 
non-enzymatic posttranslational modification of lysine residues in proteins may contribute to homocitrulline generation. Cyanate and isocyanate, 
reactive species in equilibrium with urea, can react with the ε-amino group of protein-incorporated lysine, thereby generating protein-incorporated homocitrulline, which can be released during proteolysis (Figure 2). The urea cycle enzymes ASS and ASL subsequently convert homocitrulline into homoarginine. Urea levels increase with declining renal function and homocitrulline formation by carbamoylation is well recognized in patients with uremia (14). More recently it has been shown that the inflammatory enzyme myeloperoxidase (MPO) may also accelerate protein carbamoylation 
AGAT
Homoarginine
Arginine
Ornithine
Arginase
Urea
Homocitrulline
HomoargininosuccinateNOS
NO
Protein-
Lysine
Protein-
Homocitrulline
Cyanate
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Isocyanate
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Glycine
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Guanidino
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Creatine
Arginine
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Figure 2 Overview of homoarginine metabolism. Homoarginine is synthesized from lysine by the subsequent reactions of urea-cycle enzymes (center), or by arginine:glycine amidinotransferase (left). Additionally, protein-incorporated lysine may be converted into homocitrulline through MPO-mediated or urea-induced carbamoylation (right), which, after proteolysis, can be further converted into homoarginine. Homoarginine can be utilized by nitric oxide synthase (NOS), or converted into lysine by arginase.
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(15). MPO is abundantly expressed in neutrophils, monocytes and tissue 
macrophages, including those found in the inflamed vascular wall (16). MPO-catalyzed oxidation of thiocyanate to cyanate may drive the carbamoylation reaction in a urea-independent way. Plasma levels of thiocyanate vary depending upon dietary intake and are especially high in smokers. Taken together, carbamoylation may link the cardiovascular risk factors uremia, 
inflammation, and smoking to elevated homoarginine production.
Arginine:glycine amidinotransferaseIn the third proposed metabolic route for the synthesis of homoarginine, the enzyme AGAT is involved. AGAT is responsible for the production of guanidino acetic acid (GAA) and ornithine from arginine and glycine (Figure 2). This 
is the first step in the synthesis of creatine, which is subsequently formed from GAA by guanidinoacetate methyltransferase (GAMT). Creatine and its phosphorylated form phosphocreatine are important for energy metabolism in many tissues (17, 18). When AGAT uses lysine instead of glycine as amidino-acceptor, homoarginine is formed instead of GAA (Figure 2).In homoarginine synthesizing plants an amidinotransferase similar to AGAT has been described (19). After isolation from Pseudomonas syringae 
pv. phaseolicola, this enzyme (arginine:lysine amidinotransferase; ALAT; not to be confused with alanine aminotransferease) showed its capacity for homoarginine synthesis in vitro. Besides the similarity in enzyme structure and function between ALAT in plants and AGAT in mammals, also the gene 
encoding for ALAT is very similar to the gene that encodes AGAT (50.4% similarity to AGAT from mitochondria in humans) (19). Amidinotranferase genes are well conserved throughout plants, but similarity decreases when 
the plant genes are compared to mammalian genes. However, the specific amino acids that are related to the enzymes substrate binding site are conserved.In rat kidney it was shown that homoarginine is synthesized by a reaction similar to that of AGAT, in which glycine was replaced by lysine (20). The homoarginine producing reaction was less favorable, since the optimal glycine to arginine ratio was 1.6:1 and the optimal lysine to arginine ratio 3:1. AGAT produced 0.5 µmol ornithine per hour per mg protein for the 
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reaction with glycine and only 0.012 µmol homoarginine per hour per mg protein with lysine (20). Using stable-isotope labeled arginine and lysine, 
we recently showed that lymphoblasts from patients with AGAT deficiency lacked the capacity for de novo homoarginine synthesis, whereas control 
lymphoblasts were able to form homoarginine, confirming that in humans AGAT is responsible for homoarginine synthesis as well (21).
AGAT versus an alternate urea cycleAlthough the coexistence of both enzymatic pathways for the synthesis of homoarginine, through the alternate urea cycle or through AGAT, cannot be excluded, we think that AGAT rather than an alternate urea cycle is mainly responsible for the formation of homoarginine. Kato et al showed that during the hours after oral lysine administration, homoarginine levels in plasma increased before homocitrulline levels did (8, 9). This data is in line with direct single step formation of homoarginine from lysine by AGAT, because if homoarginine were to be formed through the urea cycle, homocitrulline 
would be formed first, before its conversion into homoarginine. If AGAT is indeed the main enzyme involved in homoarginine synthesis, homocitrulline formation may be due to activity of NOS, which normally produces nitric oxide (NO) and citrulline from arginine, but can also use homoarginine as substrate (Figure 2).Homoarginine and homocitrulline are both formed from lysine. However, homoarginine is formed mainly in the kidney, whereas homocitrulline is formed in both kidney and liver (4). AGAT is mainly present in the kidney 
(17), and the urea cycle enzymes are predominantly located in the liver, indicating that AGAT, rather than the urea cycle enzymes, is likely responsible for the generation of homoarginine in vivo. This is in line with the decrease in plasma homoarginine levels in nephrectomized mice, which remained low during 4 months follow-up. Homoarginine levels in urine were below the detection limit and in the brain levels remained unchanged (22). In addition, 
it was shown that in patients with renal insufficiency the serum levels of both homoarginine and GAA were decreased (23), supporting the idea that homoarginine and GAA share AGAT for their biosynthesis. Also in male epileptic patients both homoarginine and GAA were decreased compared to 
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healthy controls (24). Furthermore, homoarginine, GAA, and creatinine are lower in women than in men, while creatine is higher (23). The differences in GAA, creatine and creatinine are due to the higher energy demand in men (17). In women less creatine is converted into phosphocreatine and subsequently into creatinine (17). This leaves more creatine available for the inhibition of AGAT (17), which might lead to the lower GAA and homoarginine levels in women. 
Homoarginine uptake from dietIn addition to the synthesis of homoarginine from lysine, the consumption of certain homoarginine containing legumes may also contribute to the endogeous homoarginine pool. Grass pea (Lathyrus cicera) and Lentil (Lens 
Culinaris), for instance, contain a considerable amount of homoarginine 
(3, 25). However, to what extent homoarginine from diet contributes to 
plasma levels, and the effect of homoarginine intake from these plants on cardiovascular disease (CVD) is not yet fully understood, and needs further investigation.
Homoarginine utilizationBecause homoarginine is structurally similar to arginine, several studies have been devoted to homoarginine as a possible alternative substrate for enzymes that use arginine as native substrate, such as arginase and NOS 
(5-7). 
ArginaseOne of the enzymes that can use homoarginine as alternative substrate is arginase (6). It can convert homoarginine into lysine, thereby completing the alternate urea cycle (Figure 2). In patients with hyperargininemia, elevated levels of arginine, homoarginine, creatine, and GAA in plasma have been reported. Furthermore, homoarginine and arginine in these patients 
are elevated in cerebrospinal fluid as well (26). In this condition the lack of arginase activity leads to reduced degradation of arginine and homoarginine, resulting in an increase in their levels. GAA and creatine may subsequently be increased because more arginine is available for the creatine synthesis 
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pathway (17). Although homoarginine can function as a substrate for 
arginase, the catalytic efficiency of this enzyme is higher (lower Km) with arginine as substrate (Km = 1.0 ± 0.1 mmol/L) than with homoarginine (Km = 7.2 ± 1.7 mmol/L) (6), which means that arginase has a much higher 
affinity for arginine than for homoarginine.
Nitric oxide synthaseAnother enzyme that may use homoarginine instead of arginine as substrate is NOS. Abu-Soud et al.   demonstrated that homoarginine can be utilized by neuronal NOS, resulting in the formation of NO and homocitrulline instead of citrulline (7). This is in line with a report in salt sensitive rats, demonstrating lowering of the mean arterial pressure and an increase in urinary nitrate upon homoarginine infusion (27), and a study in pregnant women, showing a positive correlation between homoarginine levels and both brachial artery 
diameter and flow mediated dilation, indicating increased NO production 
(28).
However, a study by Moali et al. on the substrate specificity and kinetics 
of NOS showed that the catalytic efficiency of NO formation was lower with homoarginine compared to arginine (5). This implies that in the simultaneous presence of both substrates, as under normal physiological conditions, NO production may decrease when the homoarginine-arginine ratio is increased. Furthermore, the study by Moali et al. revealed that NO production from homoarginine was accompanied by increased NADPH consumption, suggesting partial uncoupling of NOS, leading to the formation of superoxide instead of NO (5). 
Homoarginine in bio-analytical methodsSince the discovery of homoarginine, several bio-analytical methods have been developed that use homoarginine. Homoarginine has been used as 
a specific inhibitor of alkaline phosphatase (29) allowing differentiation 
between the different tissue-specific isoforms of this enzyme. Conversion of terminal lysine residues of tryptic peptides into homoarginine, using o-methylisourea, has been used to increase their sensitivity towards mass spectrometric detection in proteomics (30). Furthermore, homoarginine has 
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been used as an internal standard in chromatographic analysis of methylated 
arginine species. Finally, methods have been developed specifically for the 
measurement of homoarginine levels in biological fluids. 
Homoarginine as internal standardIn many chromatographic methods for the determination of arginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine 
(SDMA) in biological fluids, homoarginine is used as an internal standard. Homoarginine is an endogenous compound and although levels have been shown to be very low in a number of physiological and pathological conditions (26), it may significantly increase in certain disease states (31). 
Since this could lead to inaccurate quantification, the use of homoarginine as internal standard cannot be recommended. Mass spectrometry based techniques use stable isotope-labeled internal standards instead (32), and for 
methods using fluorescence detection monomethylarginine (MMA) is often used as an alternative (33). MMA is also endogenously present in plasma, but in much lower concentrations than homoarginine. With the addition of an excess MMA as internal standard, the contribution of endogenous MMA is negligible. Blackwell et al. compared MMA to monoethylarginine, which is not endogenously present, as internal standard in the determination of homoarginine and methylated arginines. They showed that MMA and monoethylarginine are equally accurate in determining homoarginine, arginine, ADMA, and SDMA (34).
Homoarginine determination with mass spectrometrySince interest in homoarginine and its role in CVD is rising, it is important 
to have a reliable method for its quantification in biological samples. Recently, we developed an accurate, precise, and highly sensitive method for the simultaneous determination of homoarginine, arginine, ADMA, SDMA, and MMA, in biological samples using LC with tandem mass spectrometry detection (32). This method is able to discriminate between homoarginine and other endogenous compounds with the same mass, like 
MMA, because they produce different fragments (m/z = 84 for homoarginine and m/z = 70 for MMA). Furthermore, homoarginine can be separated 
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chromatographically from acetyllysine and trimethyllysine, which have the same mass and produce the same fragment as homoarginine (31, 32).
Homoarginine in plasma, serum, CSF, and urine of healthy individualsReported homoarginine levels in plasma range from 1.93 ± 0.77 µmol/L 
(34) to 2.5 ± 1.0 µmol/L (35). In serum similar concentrations have been reported (24, 28). In plasma and serum, as well as in urine, homoarginine concentrations are higher in men than in women (24, 35). Furthermore, homoarginine increases during pregnancy (28), presumably by the activation of AGAT by increased estrogen levels. The only report on homoarginine levels in CSF was made by Marescau et al. in 1985. In the CSF of 19 healthy controls homoarginine levels ranging from 0.05 to 0.59 µmol/L were observed (26).Only a few studies published data on urinary homoarginine, which ranged from below the detection limit to 12.2 µmol/g creatinine in 24-hour urine 
(23, 26). Kato et al. showed that elevated levels of homoarginine are excreted by the kidneys after lysine supplementation (8). Compared to adults, small children have elevated urinary levels of homocitrulline, which is also formed from lysine (36). However, there are no reports on the comparison between homoarginine levels in urine or plasma of children and adults. Furthermore, 
the influence of different biological matrices and sample pretreatment on 
homoarginine levels should be evaluated. For instance, possible differences between levels in serum, heparin-plasma, and EDTA-plasma have not yet been explored.
Homoarginine and cardiovascular diseaseFigure 3 gives an overview of potential mechanisms by which homoarginine is related to pathways and risk factors involved in cardiovascular health and disease. Homoarginine infusion in salt sensitive rats led to lowering of the mean arterial pressure and an increase in urinary nitrate (27), suggesting that, like arginine, homoarginine can stimulate NO production (Figure 3A). However, homoarginine may also interfere with the regular NO production 
from arginine, because it is a less efficient NOS substrate than arginine (Figure 3B) (5). In addition, homoarginine, by competing with arginine for 
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cellular uptake, may limit the amount of intracellular arginine (Figure 3C). In an isolated perfused rat kidney model, homoarginine led to a decrease in NO production and increased renal vascular resistance, and these 
effects were reversed by coadministration of excess arginine, confirming the antagonistic relation between both amino acids (37). Furthermore, the use of homoarginine instead of arginine as substrate may result in uncoupling (Figure 3D), which means that NOS switches from production of NO to production of superoxide, which, by avidly reacting with NO to form peroxynitrite, further reduces the available amount of NO. In addition to the increased cardiovascular risk caused by the reduced bioavailability of NO, the production of superoxide and peroxynitrite contributes to oxidative stress, which is itself also associated with endothelial dysfunction, elevated blood pressure and increased cardiovascular risk (16, 38). Oxidative stress may also 
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potentiate the activity of the enzyme MPO, which can reduce NO availability by using it as substrate or through NO-scavenging by MPO-derived reactive substances (16). Furthermore, MPO is known to oxidize LDL and to impair HDL function, two important steps in atherosclerotic plaque formation. As described in a previous section, MPO may also contribute to homoarginine production by stimulation of carbamoylation of protein-incorporated lysine residues (15). In this scenario MPO may be causally related to CVD, whereas homoarginine is merely an innocent bystander formed as byproduct. Recently, Pilz et al. reported that low serum homoarginine is a novel risk marker for stroke (Figure 3E) and that low levels are associated with a history of cerebrovascular events. In the Ludwigshafen Risk and Cardiovascular 
Health (LURIC)-study people suffering from stroke had a mean serum homoarginine of 2.07 ± 0.83 µmol/L at baseline, whereas the remaining study population had a mean serum homoarginine level of 2.58 ± 1.06 µmol/L (11). In the same cohort a relationship between low homoarginine and sudden cardiac death, heart failure and fatal myocardial infarction was found (13). Additionally, a strong relation was observed between low homoarginine levels in serum at baseline and the risk for cardiovascular and all-cause mortality, both in the LURIC-study and in the 4D-study (Die Deutsche Diabetes Dialyse Study). In this study homoarginine was positively 
associated with glomerular filtration rate, lysine, arginine and the arginine/ornithine ratio (an indicator for arginase activity), and negatively with alkaline phosphatase. Furthermore, homoarginine was negatively associated 
with fibrinogen and D-dimers, (both related to platelet aggregation), and with adhesion molecules (related to endothelial dysfunction) (12).In 2006, Cullen et al. reported elevated AGAT mRNA expression and enzyme activity in heart failure patients (18), suggesting that the local creatine synthesis is responsive to intracellular creatine availability.  The low local creatine availability may be caused by low AGAT expression or activity in the myocardium, which could also lead to low homoarginine levels. When creatine reaches too low levels the heart fails (in heart failure levels are up 
to 70% lower) and AGAT expression is upregulated in response (18). When during recovery creatine levels return to normal, AGAT expression is lowered again, since creatine inhibits AGAT expression at the pre-translational level 
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(39). Since Cullen et al. did not report on homoarginine levels, the question remains whether low homoarginine is just an innocent bystander in the local failing creatine metabolism (18).
ConclusionSo far, homoarginine has been implicated as an important player in CVD. Remarkably, both high and low homoarginine levels have been linked 
to detrimental effects. High homoarginine levels have been found to induce increased vascular resistance, whereas in prospective studies low homoarginine levels were associated with cardiovascular mortality and 
stroke. It seems that two different mechanisms underlie these seemingly contradicting outcomes. The relation between low homoarginine and heart 
failure can be a side effect of the local failing creatine metabolism in the myocardium. The relation between high homoarginine and cardiovascular risk factors such as hypertension, hyperglycemia and oxidative stress, on 
the other hand, may reflect its interference with NO synthesis. Although homoarginine may act as an alternate substrate for NOS, it can reduce NO 
synthesis from arginine since it is utilized less efficiently. Homoarginine may even result in superoxide production and oxidative stress, due to NOS uncoupling. In order to better understand the physiological and pathological role of homoarginine in health and disease it is necessary to fully understand all possible metabolic processes in which homoarginine may be involved. Especially the enzymatic roles of AGAT and the urea cycle enzymes should be further explored, to provide essential information on the role of homoarginine synthesis in CVD. Although we previously showed that AGAT plays a pivotal role in homoarginine synthesis, the possibility of an alternate urea cycle cannot be excluded. Homoarginine seems to be an interesting new risk marker for CVD, but further mechanistic and epidemiological studies are required to determine if and to what extent homoarginine is causally involved in atherogenesis.
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Measurement of nitric oxide-related amino 
acids in serum and plasma: effects of blood clotting and type of anticoagulant
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Abstract
Analysis of circulatory amino acids is performed in diverse fields of research, 
but very often without justification or even specification of specimen type. We investigated the impact of coagulation and anticoagulants on amino acid concentrations, with emphasis on amino acids involved in nitric oxide metabolism.Plasma, using either heparin or EDTA as anticoagulant, and serum were collected from 23 apparently healthy subjects. Amino acids were measured with high precision using high-performance liquid chromatographic techniques.Compared to heparin-plasma, the concentrations of almost all amino acids were lower in EDTA-plasma and higher in serum. For EDTA-plasma the 
mean difference was highest for tryptophan (5.3%). The mean difference between serum and heparin-plasma was much higher for some amino acids, 
including taurine (42.3%), arginine (36.4%), glutamic acid (16.2%) and 
serine (5.6%).
Differences in amino acid concentrations between EDTA- and heparin-plasma are small and clinically most likely irrelevant. Concentrations of amino acids in serum are higher than in heparin-plasma, which is probably caused by poorly controllable ex vivo release from blood cells during clotting. We advocate 
using plasma rather than serum and not using different anticoagulants interchangeably in a single study. In addition, we urge editors and reviewers to demand adequate description of specimen type in manuscripts.
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IntroductionApart from their role as building blocks of proteins, amino acids are involved in cell signaling, regulation of gene expression, and synthesis of hormones, neurotransmitters and nitric oxide (NO) (1). NO produced from L-arginine by the endothelial isoform of NO synthase (NOS) is a powerful vasodilator that plays an important role in the regulation of vascular tone and tissue perfusion (2). In addition, NO strongly inhibits platelet aggregation, adhesion of circulatory cells to the vascular endothelium and proliferation of smooth muscle cells in the vascular wall. By virtue of these functions, adequate basal production of NO is required for the maintenance of cardiovascular health. Besides the NOS substrate arginine, several other amino acids are also relevant to NO metabolism. The kidneys synthesize arginine from citrulline, which in turn is generated by intestinal conversion from glutamine (3, 4). Many tissues contain arginase, which hydrolyzes arginine to ornithine (1). NOS activity may be diminished by the endogenous inhibitor asymmetric dimethylarginine (ADMA) and also by symmetric dimethylarginine (SDMA), which competes with arginine for cellular uptake (5). Homoarginine, a homolog of arginine synthesized from lysine (6), can modulate NO production and is related to cardiovascular disease (7). Finally, taurine has 
beneficial cardiovascular effects by serving as antioxidant and stimulating NO production (8).
In the field of inborn errors of metabolism, amino acids are usually measured in heparin-plasma, because coagulation may lead to changes in amino acid concentrations and the anticoagulant EDTA may interfere with chromatographic separation (9, 10). We have noted that in a fairly large 
proportion of publications the anticoagulant was not specified, serum instead of plasma was used, or information about the specimen type was not provided at all. Because little quantitative information on concentration 
differences between serum, heparin-plasma and EDTA-plasma is available 
(11, 12), we performed this comparison in healthy individuals, using high-precision analytical techniques. We focused on amino acids involved in NO metabolism, because relatively small changes in their concentration may already have clinical consequences.
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Materials and methods
Subjects and blood samplingBlood samples were obtained from 23 apparently healthy volunteers recruited amongst medical students, after obtaining written informed consent according to institutional guidelines. Venous blood was obtained by venipuncture and collected in plastic Vacutainer tubes of Becton, Dickinson and Company (Franklin Lakes, NJ). For preparation of serum, tubes with spray-dried clot activator (product nr. 368815) were used, and for preparation of plasma, tubes with spray-dried lithium heparin (product nr. 368886) or K2EDTA (product nr. 367864) were used. The tubes were kept on ice and centrifuged within 2 h (10 min at 1900 x g). Part of the plasma and serum was immediately deproteinized by pipetting 0.5-mL aliquots in cryovials containing 20 mg solid 5-sulfosalicylic acid, followed by vigorous mixing (13). These vials, as well as cryovials containing non-deproteinized 
plasma and serum, were stored at -80 °C until analysis.
Amino acid analysisTwo high-performance liquid chromatography (HPLC) procedures for 
analysis of amino acids were employed. The first HPLC method is routinely used in our laboratory for analysis of amino acids in plasma (13). After thawing and centrifugation of deproteinized plasma and serum samples (15 min at 3000 x g and 4°C), the supernatants were put in the refrigerated autosampler. The HPLC method is based on fully automated precolumn derivatization of amino acids with o-phthaldialdehyde reagent containing 3-mercaptopropionic acid, separation of the derivatives by reversed-phase 
chromatography, and quantification by fluorescence detection. The intra-
assay coefficient of variation (CV) of this method is less than 4% for all amino 
acids. The second HPLC method has been specifically designed for analysis of arginine, homoarginine, ADMA and SDMA (14). Non-deprotenized plasma and serum samples were thawed and centrifuged (5 min at 1900 x g), and after addition of the internal standard monomethylarginine, basic amino acids were extracted by fully automated solid-phase extraction on polymeric cation-exchange columns. After derivatization with o-phthaldialdehyde reagent containing 3-mercaptopropionic acid, the derivatives were analyzed 
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by isocratic reversed-phase chromatography on a monolithic column with 
fluorescence detection (15). The intra-assay CV of this method is less than 
2% for all amino acids. Using both HPLC methods, care was taken that the heparin-plasma, EDTA-plasma and serum samples of each individual were analyzed in the same analytical series.
Statistical analysesFor each volunteer, amino acid concentrations measured in EDTA-plasma and serum were compared to their respective concentrations in heparin-plasma. 
Both absolute and relative differences were calculated and paired t-tests 
were performed to test for significant differences between sample types. The Bonferroni correction was applied to adjust for multiple comparisons (n = 46), and accordingly a two-tailed P-value <0.001 was considered to indicate 
statistical significance. SPSS version 19 (SPSS, Chicago, IL) was used for statistical analyses.
Results and discussionThe amino acids measured in this study are listed in Table 1 in descending order of their mean concentrations in heparin-plasma, which were in good agreement with published values obtained in heparin-plasma from healthy subjects (4, 13, 14, 16). The concentrations of almost all amino acids were slightly lower in EDTA-plasma compared to heparin-plasma. Notably, we used K2EDTA, which is spray-dried on the wall of the tubes, in contrast to K3EDTA, which is present as a liquid. Therefore, the lower amino acid concentrations were not caused by dilution, but more likely resulted from shrinkage of red blood cells caused by K2EDTA-induced hypertonicity of the plasma. This notion is supported by the fact that the concentrations of arginine, homoarginine, ADMA, and SDMA were higher, rather than lower, in EDTA- compared to heparin-plasma. These basic amino acids are present in the cytosol of erythrocytes in concentration exceeding their concentration in plasma and are rapidly exchanged across the cell membrane by cationic amino acid transporters (17). Hence, redistribution of these amino acids between the erythrocyte cytosol and the plasma may attenuate or even 
reverse the effect of cell shrinkage on their concentrations in plasma.
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Although the difference in absolute concentrations between EDTA- and 
heparin-plasma was significant (P <0.001) for 7 amino acids (glutamine, threonine, histidine, ornithine, phenylalanine, asparagine, and tryptophan), 
the magnitude of the differences was rather small. Expressed as percentage, 
the mean absolute differences between EDTA- and heparin-plasma were 
below 4% for 6 of these amino acids. For tryptophan a slightly higher 
value of 5.3% was observed. Tryptophan is unique among amino acids in that it is largely bound to plasma albumin (18, 19), which may play a role 
in the rather large concentration difference between EDTA- and heparin-plasma. Although protein precipitation with 5-sulfosalicylic acid results in a 
tryptophan recovery of >85% from both heparin- and EDTA-plasma (13, 20), it cannot be excluded that the equilibrium between free and protein-bound 
tryptophan slightly differs between these matrices.In serum, the concentrations of all amino acids, ADMA excepted, were 
higher than in heparin-plasma (Table 1). For 8 amino acids the difference in 
absolute concentrations was significant (P <0.001), but, with the exception of 
asparagine, these were other amino acids than those that differed significantly between EDTA- and heparin-plasma. In contrast to the relatively small 
differences between EDTA- and heparin-plasma, the concentration difference between serum and heparin-plasma in terms of percentage was appreciable 
for a number of amino acids (Figure1). The largest mean difference was 
observed for taurine and arginine (42.3% and 36.4%, respectively). Also for 
glutamic acid and serine rather large differences were observed (16.2% and 
5.6%, respectively), but for alanine, glycine, phenylalanine, and asparagine 
the relative differences were significant but modest (<4%). The high concentrations of taurine and arginine in serum may be caused by release of these amino acids from red blood cells and platelets during clotting (9, 10, 19). 
Notably, the concentration of homoarginine differed less then 1% between 
serum and heparin-plasma. This striking difference between arginine and 
its homolog homoarginine probably reflects differences in their metabolic pathways and intracellular levels (6).It is unlikely that mixing up of serum and plasma-samples would compromise 
diagnosis of inborn errors of metabolism by amino acid profiling, because these diseases are usually associated with grossly changed concentrations 
196
of one or more amino acids. For example, in patients with hyperargininemia 
due to liver arginase deficiency, plasma levels of arginine are increased 5- to 15-fold (22). In the fields of nutrition and nitric oxide metabolism, however, 
more subtle differences in amino acid concentrations may be clinically relevant. Because plasma concentrations of arginine are rate-limiting for nitric oxide production (5), a rise in arginine levels of 20% or more may certainly increase nitric oxide output.It should be noted that concentrations of other metabolites related to the L-arginine/nitric oxide pathway, such as nitrite and nitrate, may also be 
affected by anticoagulation, most likely due to contaminations present in commercially available blood collection tubes (23). Dimethylamine, which is 
endogenously formed by enzymatic hydrolysis of ADMA, has been identified as an abundant contaminant in EDTA-containing vacutainer tubes (24). Taken together, investigators should be aware that anticoagulantdependent generation as well as contamination may contribute to ex vivo artefactual 
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Figure 1Amino acid concentrations in serum compared to heparin-plasma. Bars represent the mean 
percent difference in amino acid concentrations between serum and paired heparin-plasma 
samples; error bars represent SEM. * P < 0.001 indicating statistical significance (adjusted for multiple comparisons by Bonferroni correction)
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rises in concentrations of nitric oxide-related metabolites. Our study has some limitations. Proline and cysteine were not analyzed because they do not react with the derivatization reagent. However, all amino acids that are closely related to NO metabolism were included. We did not evaluate citrate as anticoagulant, because it is present as a liquid in the blood collection tubes, leading to dilution of the plasma, which is poorly controllable because 
it depends on the level of filling of the tube and hematocrit. A major strength of our study is the very good precision of both HPLC methods, allowing 
reliable detection of very small concentration differences.
ConclusionsIn conclusion, our data show that in EDTA-plasma amino acids concentrations 
are lower than in heparin-plasma, but the differences are relatively small and clinically most likely irrelevant. In contrast, concentrations of amino acids in serum are higher than in heparin-plasma. For some amino acids 
the effect is considerable and probably caused by poorly controllable ex 
vivo release from blood cells during clotting. Important examples include arginine, a key player in NO metabolism, and taurine, which is receiving increasing attention as a physiologically relevant anti-oxidant and may also enhance NO production (8). Considering these data, we strongly advocate using either EDTA- or heparin-plasma for amino acid analysis and to not use 
different anticoagulants interchangeably in a single study. In addition, we urge editors and reviewers to demand adequate description of specimen type in manuscripts.
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Chapter 9
L-Homoarginine and L-arginine are antagonistically related to blood pressure 
in an elderly population – The Hoorn Study
Leonard P. van der Zwan, Mariska Davids, 
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Abstract
Production of nitric oxide (NO) by the vascular endothelium is crucial for the maintenance of vascular tone, an important determinant of blood pressure. L-Arginine and its homolog L-homoarginine are competitive substrates of NO synthase (NOS), whereas asymmetric dimethylarginine (ADMA) is a NOS inhibitor. We evaluated the relationships between physiological levels of these amino acids and blood pressure.The relationship between blood pressure and plasma levels of L-arginine, L-homoarginine, and ADMA was studied in participants of the Hoorn Study, a population-based cohort study of elderly subjects (n = 746, aged 50 to 87, 
49.5% male).In linear regression models adjusted for age, sex, L-arginine and ADMA, a positive association was observed between L-homoarginine and systolic 
blood pressure (3.90 mmHg per 1-SD increment of L-homoarginine [95% CI: 2.28 to 5.52]) and diastolic blood pressure (1.83 [0.95 to 2.72]). In these 
models, L-arginine was not significantly associated with systolic blood 
pressure (-0.68 mmHg per 1-SD increment of L-arginine [95% CI: -2.23 to 
0.88]), but a significant inverse association with diastolic blood pressure was observed (-1.17 [-2.02 to -0.32]). These associations were slightly attenuated after further adjustment for glucose or body mass index, but not after adjustment for other cardiovascular risk factors (lipids, smoking, 
inflammation markers, microalbuminuria, prior cardiovascular disease, and 
anti-hypertensive medication). ADMA was not significantly associated with either systolic or diastolic blood pressure. In elderly subjects, plasma levels of L-homoarginine and L-arginine are 
independently associated with clinically relevant differences in blood pressure in an antagonistic fashion.
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IntroductionProduction of nitric oxide (NO) from L-arginine by the endothelial isoform of NO synthase (NOS) is crucial for the maintenance of vascular tone, an important determinant of blood pressure (1-3). The relation between the NOS substrate L-arginine and blood pressure has been widely studied in animal models and humans. Parenteral and oral administration of L-arginine has been shown to completely prevent the development of hypertension in salt-sensitive rats (4). In humans, infusion of L-arginine has been demonstrated to     result in a rapid reduction of blood pressure (5, 6), and a recent meta-analysis of randomized controlled trials showed that oral L-arginine supplementation 
significantly lowers both systolic and diastolic blood pressure (7).
L-Homoarginine differs from L-arginine by the presence of an additional CH2-group in the carbon chain, which makes it a homolog of L-arginine. Because of this structural similarity, it may act as a competing substrate or inhibitor of enzymes that use L-arginine as substrate. L-homoarginine has indeed been shown to act as substrate for NOS (8, 9). However, compared to L-arginine, the Km value of L-homoarginine is much higher, reflecting a lower 
catalytic efficiency of NOS using L-homoarginine as substrate (9). Therefore, production of NO may be reduced at a high L-homoarginine/L-arginine ratio. Compared to intravenous administration of L-arginine, an equimolar 
dose of L-homoarginine was less efficient in lowering blood pressure in salt-sensitive hypertensive rats (10), but no data on the on the effects of L-homoarginine administration or on the relation between endogenous levels of L-homoarginine and blood pressure in humans has been reported.In healthy volunteers, infusion of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) causes increased blood pressure (11, 12). However, reports on the relation between basal plasma concentrations of ADMA and blood pressure are inconsistent (13), and even an inverse correlation between ADMA and diastolic blood pressure has been reported in a large population-based study (14).Taken together, L-homoarginine and ADMA, being competitive NOS substrate and inhibitor, respectively, may modulate NO production from L-arginine. Additionally, these compounds may alter NO production by interfering with cellular uptake of L-arginine. This transmembrane transport is mediated by 
204
cationic amino acid transporters (CAT) of the y+ system (15-17). L-Arginine, L-homoarginine, and ADMA, but also other dibasic amino acids, such as symmetric dimethylarginine (SDMA), lysine, and ornithine, may either hamper or enhance each other’s cellular uptake via CAT, by competition and trans-stimulation, respectively (13, 16, 18). Current knowledge on the relationships of endogenous levels of L-arginine, L-homoarginine, and ADMA in plasma with blood pressure in the general 
population is fragmentary at best. To fill this gap, we measured concentrations of L-arginine, L-homoarginine, and ADMA in plasma of participants of the Hoorn Study, a population-based cohort study among elderly subjects, and investigated biochemical and clinical correlates of these compounds and their associations with blood pressure
Methods
SubjectsThe present study was conducted in the Hoorn Study (19) follow-up examination conducted in 2000 and the Hoorn Screening Study (20), which both are population-based studies in a white population. From the initial 822 participants, 76 subjects were excluded because of missing data on primary variables of interest, including two cases with extremely outlying values for L-arginine and ADMA, respectively. In total 746 subjects (369 men and 377 women) within the age range of 50 to 87 years remained. This population consisted of 267 subjects with normal glucose metabolism, 190 with impaired glucose metabolism, and 289 with type 2 diabetes mellitus, according to WHO-99 criteria (21). The study was approved by the local ethics committee and all participants gave their written informed consent.
Baseline examination and blood pressure measurementsAt the baseline medical examination, a blood sample was taken from all participants after overnight fasting. Weight and height were measured and body mass index (BMI) was calculated as the ratio of weight and height squared. Systolic (SBP) and diastolic (DBP) blood pressure were measured using a random-zero sphygmomanometer (Hawksley-Gelman, Lansing, Sussex, United Kingdom), while subjects were in a sitting position and after 
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they had rested for 5 minutes. Duplicate measurements were done, and 
mean values were used in analyses. Hypertension was defined as SBP ≥140 
mmHg or DBP ≥90 mmHg and/or use of antihypertensive medication (22). A standard 75-g oral glucose tolerance test was performed in all subjects, except those using glucose-lowering medication. Information about use of medication, smoking status, and history of CVD were determined by self-administered questionnaire.
Biochemical analysesPlasma concentrations of L-arginine, L-homoarginine, ADMA, and SDMA were determined using high-performance liquid chromatography with 
fluorescence detection as described previously (23), using modified chromatographic conditions (24). The intra-assay and inter-assay coefficients 
of variation (CV) for all analytes were <2.0% and <4.0%, respectively. A sandwich enzyme-linked immunosorbent assay (Mercodia, Uppsala, Sweden) was used to determine myeloperoxidase concentrations in plasma 
(25). Plasma C-reactive protein (CRP) concentrations were determined with a highly sensitive in-house sandwich enzyme-linked immunosorbent assay (26). Hemoglobin A1c (HbA1c) was analyzed by ion-exchange high-performance liquid chromatography on a modular monitoring system (Bio-Rad, Veenendaal, The Netherlands). Glucose, high-density lipoprotein (HDL) cholesterol and triglycerides were measured using standard enzymatic methods (Roche, Mannheim, Germany). Low-density lipoprotein (LDL) cholesterol concentration was determined with a direct method by the “N-geneous” assay (GenZyme, Cambridge, MA, USA). With this method, triglyceride concentrations up to 13.5 mmol/L do not interfere with measurement of LDL-cholesterol.
Renal function and cardiovascular disease
Estimated glomerular filtration rate (eGFR) was calculated according to 
the 4-variable Modification of Diet in Renal Disease (MDRD) formula as described by Levey et al. (27). Microalbuminuria was defined as a urinary 
albumin/creatinine ratio ≥2.0 mg/mmol. Prior cardiovascular disease was 
defined as abnormalities on a resting ECG (Minnesota codes 1.1-1.3, 4.1-
206
4.3, 5.1-5.3, or 7.1), having undergone coronary bypass surgery, angioplasty, peripheral arterial bypass or non-traumatic amputation, and/or an ankle-
brachial index of <0.9 in either leg.
StatisticsData are presented as mean with standard deviation (SD) or, for skewed variables, median and interquartile range. Skewed variables were log-transformed before statistical analysis. Student’s t-test was applied for comparison of variables between two groups.Biochemical and clinical correlates of L-arginine, L-homoarginine, and ADMA were assessed by linear regression, adjusted for age and sex. Independent correlates were determined by building multivariable linear regression models with L-arginine, L-homoarginine, and ADMA as dependent variables. 
Independent variables were chosen on the basis of significant univariate associations and/or biological plausibility. Age, sex, fasting glucose, and current smoking status were chosen as independent variables in all models. Additionally, BMI and microalbuminuria served as independent variables in the model for L-homoarginine. BMI, HDL-cholesterol and CRP were added as independent variables to the model for L-arginine, and myeloperoxidase and eGFR to the model for ADMA.
Because levels of L-homoarginine and ADMA differ between men and 
women, sex-specific tertiles were constructed to investigate whether blood 
pressure differs across tertiles of L-arginine, L-homoarginine, and ADMA. Associations of L-homoarginine, L-arginine, and ADMA with blood pressure expressed as continuous variable were studied by multivariable linear regression analyses with SBP and DBP as dependent variables. Regression 
coefficients were expressed as change in blood pressure (mmHg) per 1-SD increment of L-homoarginine, L-arginine or ADMA. Interaction terms were used to explore whether the relations of L-homoarginine and L-arginine with 
blood pressure differed according to sex, glucose tolerance status, use of anti-hypertensive medication, and presence of prior cardiovascular disease. Data were analyzed using SPSS software, version 19 (SPSS Inc., Chicago, IL). A 2-tailed P-value <0.05 was considered to indicate statistical significance, except for interaction analyses, where P <0.1 was used.
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Results
L-Homoarginine, L-arginine and ADMA in the study population Characteristics of the study population are presented in Table 1. Plasma concentrations of L-homoarginine had a slightly right-skewed distribution 
with an interindividual CV of 34.7% (Figure 1A). Plasma concentrations of L-arginine were almost normally distributed with a mean plasma 
concentration that was 60-fold higher and an interindividual CV (16.5%) that was 2-fold lower compared to L-homoarginine (Figure 1B). ADMA 
was normally distributed with a very low interindividual CV of 12.9% 
Table 1 – Characteristics of the study population
48.7%Prior cardiovascular disease
17.5
39.2
15.3
2.20
56.1
1.4
1.38
3.6
15.3
60.5
27.7
6.1
6.1
70.7
83
142
0.498
0.449
1.50
94.1
68.8
49.5
746
Data is presented as percentage, means (SD), or medians (interquartile range).
%Current smoking
(1.06-4.68)mg/LC-reactive protein
(47.4-67.0)g/LMyeloperoxidase
%Lipid lowering medication
%Antihypertensive medication
(1.0-1.9)mmol/LTriglycerides
(0.40)mmol/LHDL-cholesterol
(0.9)mmol/LLDL-cholesterol
%Microalbuminuria
(10.6)ml/min per 1.73 m2Estimated glomerular filtration rate
(4.2)kg/m2Body mass index
(0.8)%HbA1c
(5.5-7.0)mmol/LFasting glucose
%Hypertension
(11)mmHgDiastolic blood pressure
(20)mmHgSystolic blood pressure
(0.110)mol/LSDMA
(0.058)mol/LADMA
(0.52)mol/LHomoarginine
(15.6)mol/LArginine
(7.2)yearsAge
%Male sex
N
UnitVariable
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(Figure 1C). L-Arginine concentrations did not differ significantly between men and women (95.0 ± 15.6 versus 93.3 ± 15.4 µmol/L, respectively; P = 0.13). L-homoarginine concentrations were higher in men than in women (1.67 ± 0.53 versus 1.33 ± 0.46 µmol/L, respectively; P <0.001), whereas ADMA concentrations were lower in men than in women (0.438 ± 0.060 versus 0.459 ± 0.053 µmol/L, respectively; P <0.001). L-Arginine (P = 0.65), L-homoarginine (P = 0.27), and ADMA (P = 0.26) concentrations did not 
differ significantly between subjects with normal and impaired glucose metabolism, but compared to subjects with normal glucose metabolism subjects with type 2 diabetes had lower levels of L-arginine (91.7 ± 16.4 versus 95.3 ± 14.4 µmol/L; P = 0.006) and ADMA (0.441 ± 0.056 versus 0.451 ± 0.057 µmol/L; P = 0.027), and higher levels of L-homoarginine (1.60 ± 0.57 
B Median: 93.8 µmol/L
Mean:    94.1 µmol/L
SD:        15.6 µmol/L
CV:        16.5%
A Median: 1.45 µmol/L
Mean:    1.50 µmol/L
SD:        0.52 µmol/L
CV:        34.7%
C Median: 0.444 µmol/L
Mean:    0.449 µmol/L
SD:        0.058 µmol/L
CV:        12.9%
Figure 1 Distribution of the concentrations of L-homoarginine (panel A), L-arginine (panel B) and ADMA (panel C) in plasma. The biological variation is expressed as 
inter-individual coefficient of variation (CV).
209
9
Part III: Homoarginine and cardiovascular disease
J Hypertension (2013) - In press
versus 1.42 ± 0.50 µmol/L; P <0.001).
Correlates of L-homoarginine and L-arginineAs shown in Figure 2, L-arginine was positively correlated with both L-homoarginine and ADMA (r = 0.317 and r = 0.242, respectively; both 
P <0.001), whereas L-homoarginine and ADMA showed a weak inverse association (r = -0.088; P = 0.017).Biochemical and clinical correlates of L-homoarginine, L-arginine, and ADMA, assessed by age- and sex-adjusted linear regression analyses, are listed in Table 2. L-Homoarginine was positively associated with male sex, SBP, DBP, fasting glucose, HbA1c, and BMI, whereas it was negatively associated with age, microalbuminuria, and current smoking status. In 
A
B
C r = -0.088
P = 0.017
r = 0.317
P < 0.001
r = 0.243
P < 0.001
Figure 2 Scatterplots of the relations between plasma concentrations of L-homoarginine, L-arginine and ADMA. Strengths of the associations were assessed by Pearson correlation.
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contrast, L-arginine was negatively associated with fasting glucose, HbA1c, and BMI, but positively associated with current smoking status. Variables that 
were significantly associated with L-arginine but not with L-homoarginine were HDL-cholesterol, which was a positive correlate, and triglycerides, myeloperoxidase, and CRP, which were negative correlates. SDMA and 
glomerular filtration rate were uniquely associated with ADMA.To determine the independent correlates of L-homoarginine, L-arginine and ADMA, multivariable linear regression models were built. Age, sex, BMI, fasting glucose, current smoking status, and microalbuminuria were 
all significant independent determinants of L-homoarginine, together 
accounting for 18% of the variation in L-homoarginine concentrations. In the multivariable model for L-arginine, only current smoking status and 
CRP were significant independent variables, whereas age, sex, BMI, fasting 
glucose, and HDL-cholesterol did not significantly contribute to the model. 
The full model accounted for 8% of the variation in plasma concentrations of L-arginine. Age, sex, fasting glucose, myeloperoxidase, current smoking 
status, and glomerular filtration rate were all significant independent determinants of the plasma concentration of ADMA, together accounting for 
14% of its variation.
Associations of L-homoarginine and L-arginine with blood pressure
Both SBP and DBP increased significantly across sex-specific tertiles of 
L-homoarginine (Figure 3A and 3B, respectively), in line with the significant association between measures of blood pressure and L-homoarginine 
expressed as continuous variable (Table 2). In contrast, no significant trends 
were found for either SBP or DBP across increasing sex-specific tertiles of L-arginine (Figure 3C and 3D, respectively) and ADMA (Figure 3E and 3F, 
respectively), in accordance with the lack of significant associations between blood pressure and L-arginine and ADMA expressed as continuous variables (Table 2).The relations of L-homoarginine, L-arginine and ADMA with blood pressure were further explored by linear regression analysis. Regression models for SBP and DBP are shown in Tables 3 and 4, respectively. L-Homoarginine was positively associated with SBP in crude and age- and sex-adjusted 
212
regression models and this association was strengthened slightly after 
further adjustment for L-arginine and ADMA (Table 3, model 2: β [95% CI] of 3.90 [2.28 to 5.52] mmHg per 1-SD increase of L-homoarginine). Likewise, the age- and sex-adjusted positive association between L-homoarginine and DBP was strengthened upon adjustment for L-arginine and ADMA (Table 
4, model 2: β [95% CI] of 1.83 [0.95 to 2.72] mmHg per 1-SD increase of L-homoarginine). The strengths of these associations was not altered by further adjustment for potentially confounding or mediating factors, except 
A P trend < 0.0001 P trend = 0.002B
P trend = 0.45C P trend = 0.32D
E P trend = 0.23 F P trend = 0.58
Figure 3 
Systolic and diastolic blood pressure according to sex-specific tertiles of L homoarginine (panels A and B), L-arginine (panels C and D) and ADMA (panels E and F). Data is presented as mean blood pressure (SEM) and P for trend values were derived from age-adjusted linear regression analyses.
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for glucose and BMI, which both slightly attenuated the associations of L-homoarginine with SBP and DBP.The age- and sex-adjusted relations between L-arginine and blood pressure 
were not significant. After adjustment for L-homoarginine and ADMA, 
the relation between L-arginine and SBP remained non-significant, but a 
significant negative relation with DBP was observed (Table 4, model 2: β 
[95% CI] of -1.17 [-2.02 to -0.32] mmHg per 1-SD increase of L-arginine). The relation between L-arginine and DBP was attenuated after further adjustment for glucose and BMI, but not after adjustment for other potentially confounding or mediating factors.
ADMA was not significantly related to SBP and DBP, neither in age- and sex-adjusted linear regression models, nor upon further adjustment for L-arginine and L-homoarginine (Tables 3 and 4).Because the opposite relations of L-homoarginine and L-arginine with blood pressure became more pronounced after mutual adjustment, we further explored this antagonism by investigating the relation of the ratio of both amino acids with blood pressure. In age- and sex-adjusted regression models 
the L-arginine/L-homoarginine ratio was significantly inversely associated 
with both SBP and DBP (β [95% CI] of -3.87 [-5.39 to -2.35] and -1.69 [-2.52 to -0.86] mmHg per 1-SD increase of the L-arginine/L-homoarginine ratio, respectively).The relations of L-homoarginine, L-arginine and their ratio with SBP and 
DBP did not differ according to sex, glucose tolerance status, use of anti-hypertensive medication and presence of prior cardiovascular disease (P >0.1 for all interaction terms).
Plasma concentrations of SDMA were not significantly related to blood pressure, neither in age- and sex-adjusted linear regression models, nor upon further adjustment for L-arginine, L-homoarginine, and ADMA (data not shown).
Discussion
The main finding of this population-based study is that in elderly subjects plasma levels of L-homoarginine and L-arginine are independently associated 
with clinically relevant differences in blood pressure in an antagonistic fashion. The association between L-arginine and blood pressure has been subject of 
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numerous studies, but the positive association between endogenous levels of L-homoarginine and blood pressure is a novel observation.
Mechanisms for L-homoarginine synthesis and degradationL-homoarginine synthesis from L-lysine has been demonstrated in both rats and humans (28). Putative biochemical pathways for L-homoarginine synthesis and degradation are depicted in Figure 4. L-Homoarginine may be synthesized by two metabolic routes, catalyzed by enzymes of the urea cycle (29, 30) and L-arginine:glycine amidinotransferase (AGAT) (31-33), respectively. AGAT is a key enzyme in the synthesis of creatine (34), but we have recently shown that by substrate promiscuity it may also play a key role in synthesis of homoarginine in humans (33). It should be noted that next to production of L-homoarginine by these two metabolic routes, dietary intake may also contribute to endogenous levels of L-homoarginine. Some legumes have a very high content of non-protein amino acids, including L-homoarginine, and for example the grass pea (Lathyrus sativus ), which is used as feed for domestic animals as well as for human consumption, is a very rich source of L-homoarginine (35, 36).
Antagonism between L-homoarginine and L-argininePlasma concentrations of L-homoarginine and L-arginine were positively associated, but biochemical and clinical correlates were either uniquely related with L-homoarginine or L-arginine, or related to both amino acids in an opposite way. Fasting glucose, HbA1c and BMI were positively associated with L-homoarginine, but inversely with L-arginine, whereas current smoking was associated with lower levels of L-homoarginine and higher levels of L-arginine. The antagonism between both amino acids was 
also reflected by the fact that the L-arginine/L-homoarginine ratio was 
significantly related with blood pressure. Multivariable linear regression models, with concentrations of both amino acids as independent variables, demonstrated that this association was mainly driven by a strong direct association of L-homoarginine with both SBP and DBP, and to a lesser extent by an inverse association of L-arginine, which was much weaker and only 
significant with DBP.
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The positive association between L-homoarginine and blood pressure may be explained by several factors that in conjunction lead to diminished generation of NO. First, because L-arginine and L-homoarginine compete for cell entry via CAT, high L-homoarginine concentrations outside the cell will lead to reduced L-arginine uptake. Second, extracellular homoarginine 
may, by trans-stimulation of CAT, stimulate cellular efflux of L-arginine. Both mechanisms may lead to depletion of intracellular L-arginine and have been shown to lead to diminished NO production in endothelial cells (18). Third, intracellular competition between L-homoarginine and L-arginine for binding to NOS may further reduce NO production, because L-homoarginine 
is a less efficient NOS substrate than L-arginine (8, 9).
Clinical and epidemiological studies specifically investigating L-homoarginine are scarce. Valtonen et al. reported that in pregnant 
women serum concentrations of L-homoarginine were significantly higher during the second and third trimesters compared to concentrations in non-pregnant women (37), which is in line with a positive association between L-homoarginine and blood pressure, because pregnancy is often associated with hypertension. Serum L-homoarginine levels were found to be independently associated with cardiovascular and all-cause mortality 
Arginine
Ornithine
Lysine
AGATArginase ArginaseCitrulline
Urea
Urea
Homocitrulline
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arginine
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NO
Figure 4Biochemical pathways of L-homoarginine synthesis and degradation.L-Arginine is synthesized in the urea cycle (left). L-Homoarginine can be synthesized by the same set of enzymes, but with replacement of L-arginine, L-ornithine, and L-citrulline by L-homoarginine, L-lysine, and L-homocitrulline, respectively (right). A second pathway by which L-homoarginine can be synthesized, involves a transamidination reaction, with L arginine as donor and L-lysine as acceptor of an amidinogroup (center). This reaction is catalyzed by L-arginine:glycine amidinotransferase (AGAT), the rate-limiting enzyme in the synthesis of creatine. Pathways for L-homoarginine degradation include hydrolysis by arginase into L-lysine and urea, and conversion by nitric oxide synthase into L-homocitrulline and nitric oxide.
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in patients referred for coronary angiography and in hemodialysis patients 
(38-40). Interestingly, in these patient groups, low, rather than high, levels of L-homoarginine were associated with increased risk. Further studies are needed to further delineate the precise role of L-homoarginine in hypertension and cardiovascular disease. 
Study limitations and strengthsBecause NO is a powerful vasodilator, a causal relation between endogenous concentrations of the NOS substrates L-arginine and L-homoarginine and blood pressure is plausible. However, the cross-sectional design of the present 
study does not allow drawing definitive conclusions on causality. Stronger evidence for a causal relation might be obtained using an interventional study design, investigating whether changes in plasma concentrations of homoarginine and arginine upon supplementation with these amino acids are paralleled by changes in blood pressure.The study cohort consisted exclusively of elderly white subjects, and the relationships of L homoarginine and L-arginine with blood pressure may 
be different in younger individuals and other races. Although the original study population was recruited from the general population, a selection was made on the basis of glucose metabolism, i.e., individuals with impaired 
glucose metabolism and type 2 diabetes were overrepresented. No effect 
modification by glucose tolerance status was observed, but this design resulted in a fairly wide range of fasting glucose concentrations and BMI values, which may have exaggerated the attenuation of the strengths of the associations of L-homoarginine and L arginine with blood pressure upon adjustment for fasting glucose and BMI.A major limitation is that L-homoarginine, L-arginine and ADMA were measured in the circulation, whereas NOS is an intracellular enzyme. It is therefore possible that the circulatory levels of these NOS substrates and 
inhibitors do not appropriately reflect their levels in the vicinity of NOS. This would most likely result in attenuation of the strengths of their associations with blood pressure, i.e., the point estimates reported here probably 
underestimate the true effect size. Additionally, we cannot exclude the possibility that biochemical pathways other than NO production are involved 
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in the relations of L homoarginine and L-arginine with blood pressure.Levels of nitrate and nitrite (NOx) were not assessed in the present study. Measurement of NOx is based on the concept that nitrite and nitrate are inert oxidation products of NO, and the sum of their concentrations 
therefore adequately reflects NO production. However, during the past years it has become clear that these anions can be recycled in vivo to form NO (41). This reductive NOS-independent mechanism plays an important role in NO production under hypoxic conditions. Therefore, NOx are not only end products but also precursors of NO, making the relation between concentrations of NOx and NO production less straightforward than previously thought. A second reason for not including NOx data in the present study is that meaningful data from human subjects can only be derived with proper control of dietary nitrate intake, which requires a nitrate-free diet prior to blood sampling. In the present setting with free living subjects this was not feasible.For several reasons we have not included data on diet in the analyses. First, the strength of the present approach is that we related plasma levels of arginine, homoarginine and ADMA to systolic and diastolic blood pressure measured at the same time as blood sampling was performed. Data on diet from these free living subjects was obtained by questionnaire and thus 
reflects habitual or average intake of nutrients. Plasma concentrations of 
nutrients at a specific time are not only determined by average intake, but also by absorption, distribution, metabolism and excretion, that are all subject to biological variation. Second, assessment of nutrient intake by dietary recall or questionnaire is inherently imprecise. Third, although intake of arginine can be estimated in this way, this is not the case for homoarginine and ADMA. The main source of homoarginine in plasma is de novo synthesis and probably only a minor amount is of dietary origin. Likewise, ADMA mainly originates from endogenous synthesis, with only a minor dietary contribution.Major strengths of the present study are the very precise measurement of plasma levels of L-arginine, L-homoarginine, and methylated arginine species, the large number of subjects, and the availability of a wide array of clinical and biochemical variables to control for potential confounding. However, we cannot fully exclude the possibility of residual confounding by 
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variables that were not investigated in the present study.
PerspectivesA meta-analysis of clinical trials with antihypertensive drugs revealed 
a 22% reduction in coronary heart disease events and a 41% reduction in stroke for a blood pressure reduction of 10 mmHg systolic or 5 mmHg diastolic (41). These risk reductions are similar to estimates obtained by a meta-analysis of prospective observational studies (42), indicating that the 
benefit is explained by blood pressure reduction itself. In view of these data, the point estimates of the relationships between homoarginine and blood pressure observed in the present study are certainly of clinical relevance. Although both awareness and treatment of high blood pressure have shown increasing trends over the past decades, control rates for hypertension are still disappointingly low (22). Hence, there still is a clear need for novel drugs and therapies. The observation that homoarginine is involved in human blood pressure homeostasis is novel and warrants further research. The antagonistic relation of homoarginine and arginine with blood pressure 
suggests that lowering their ratio might be beneficial. It should be noted that both amino acids are derived from metabolic pathways as well as from food 
intake. Investigation of the metabolic pathways may lead to the identification of novel targets for pharmaceutical intervention, whereas studying the contribution of dietary intake may help improve current dietary approaches for the management of hypertension.
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Chapter 10
Promiscuous activity of arginine:glycine amidinotransferase is responsible for the synthesis of the novel cardiovascular risk factor homoarginine
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Abstract
Low plasma homoarginine has emerged as a risk marker for cardiovascular disease. We exploited cells of a patient with a rare inborn error of metabolism to explore potential pathways of homoarginine synthesis, using stable isotopes and mass spectrometry. Control lymphoblasts, as opposed to lymphoblasts from an arginine:glycine amidinotransferase (AGAT)-
deficient patient, were able to synthesize homoarginine from arginine and 
lysine. In contrast, in a patient with a deficiency of the urea cycle enzyme argininosuccinate synthase, plasma homoarginine was not decreased. We conclude that promiscuous activity of AGAT, a key enzyme in creatine synthesis, plays a pivotal role in homoarginine synthesis.
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IntroductionHomoarginine, a homolog of arginine, is often measured simultaneously with arginine and asymmetric dimethylarginine (ADMA), one of the methylated forms of arginine (1, 2). ADMA is an endogenous inhibitor of the production of nitric oxide from arginine by nitric oxide synthase (NOS) (3, 4) and elevated ADMA is associated with cardiovascular disease (5, 6). Homoarginine 
differs from arginine by the presence of an additional methylene group in the carbon chain. Because of this structural similarity, homoarginine may act as a competing substrate or inhibitor of enzymes that use arginine as substrate. Homoarginine has indeed been shown to act as substrate for NOS 
(7, 8), and may thus increase nitric oxide production. However, compared to arginine, the Km value of homoarginine is much higher, reflecting a lower 
catalytic efficiency of NOS using homoarginine as substrate (7, 8). In addition, homoarginine, by competing with arginine for cellular uptake, may limit the amount of intracellular arginine (9). Therefore, despite homoarginine being a substrate for NOS, production of nitric oxide may be reduced at a high homoarginine to arginine ratio. Taken together, homoarginine may 
affect the cardiovascular system by either enhancing or limiting nitric oxide production. In addition, homoarginine, being an inhibitor of liver and bone alkaline phosphatase (10), may also be relevant to bone metabolism. Low serum homoarginine has recently emerged as a potential new risk marker for stroke (11) and cardiovascular mortality (12-14), and in a study among female nursing home patients, low serum homoarginine was associated with high bone turnover (15). To increase our understanding of the role of homoarginine in cardiovascular and other diseases, it is important to unravel the metabolic pathways involved in homoarginine synthesis and degradation in humans.Evidence for in vivo synthesis of homoarginine from lysine was first reported in rats, where 14C-labeled homoarginine was measured in liver and kidney after injection of 14C-labeled lysine (16). In humans, an increase in urinary homoarginine after oral lysine administration has been demonstrated in adults (16) as well as children (17). The metabolic routes responsible for homoarginine synthesis from lysine in vivo have not yet been unraveled completely. Figure 1 shows a schematic representation of the two pathways 
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that have been suggested in literature most often. The first pathway uses arginine:glycine amidinotransferase (AGAT; EC 2.1.4.1.). The primary role of AGAT is the production of guanidino acetic acid (GAA) from arginine and 
glycine in the first step of the creatine-synthesis pathway (18). This makes 
AGAT an important enzyme in maintenance of energy metabolism in different tissues, including the myocardium (19). When AGAT uses lysine instead of glycine as amidino-acceptor, homoarginine is formed instead of GAA (20, 21). The second pathway for homoarginine synthesis that has been suggested in literature uses the urea-cycle enzymes (22, 23), in which instead of ornithine, 
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Figure 1Suggested metabolic routes for homoarginine formation and degradation. The main function of arginine:glycine amidinotransferase (AGAT) is the transfer of an amidino-group from arginine to glycine, resulting in formation of guanidino acetic acid, which is subsequently methylated by guanidinoacetate methyltransferase (GAMT) to form creatine. However, when AGAT use lysine instead of glycine as acceptor of the amidino-group, homoarginine is formed. Another possible pathway for homoarginine synthesis is by the enzymes of the urea cycle. When lysine instead of ornithine is used as substrate by ornithine transcarbamoylase (OTC), homocitrulline is formed, which can be converted into homoargininosuccinate by argininosuccinate synthase (ASS) and subsequently into homoarginine by argininosuccinate lyase (ASL). Because of its structural similarity to arginine, homoarginine can be used as substrate by arginase, forming lysine and urea, or by nitric oxide synthase (NOS) forming nitric oxide (NO) and homocitrulline.
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lysine is used by ornithine transcarbamoylase (OTC: EC 2.1.3.3.), resulting in formation of homocitrulline instead of citrulline. Next, homocitrulline is converted into homoargininosuccinate by argininosuccinate synthase (ASS; EC 6.3.4.5.), and subsequently into homoarginine by argininosuccinate lyase (ASL; EC 4.3.2.1.).In the present study we have exploited rare inborn errors of metabolism to gain more insight in the de novo synthesis of homoarginine in humans, using stable isotopes and mass spectrometry. To this end, the capacity 
for homoarginine synthesis in lymphoblasts from a patient affected with 
AGAT-deficiency was compared to control lymphoblasts. Furthermore, the 
concentration of homoarginine in plasma of an ASS-deficient patient was compared to levels in age-matched controls.
Materials and Methods
Chemicals and reagentsRPMI-medium, Earle’s balanced salt solution (EBSS), and Hank’s balanced salt solution (HBSS) were obtained from Invitrogen, (Carlsbad, CA, USA). 
Potassium hydroxide, 70% perchloric acid, and L-glutamine were purchased at Merck (Darmstadt, Germany) and D-glucose at VWR International (Poole, 
England). Fetal bovine serum, 10% (FBS) was obtained from Bodinco (Alkmaar, The Netherlands) and bovine serum albumin (BSA) from Sigma (St. Louis, MO, USA). 15N2-(guanidino)-arginine:HCl (98% 15N2), 13C2-15N-glycine 
(98% 13C2, 96-99% 15N), and 13C6-L-lysine:2 HCl (98% 13C6) were obtained from Eurisotop (Saint Aubin Cedex, France).
Patient samples
The previously described AGAT-deficient lymphoblasts with a homozygous pathogenic mutation in the AGAT-gene (24) were used. A control lymphoblastoid cell line was obtained from Centre d’ Etude du Polymorphisme Humain (Paris, France).
Plasma from a 4-day old male suffering from citrullinemia with a pathogenic mutation in the arginino -succinate synthase (ASS)-gene, was available for the determination of amino acid levels, including homoarginine.
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Lymphoblasts
Lymphoblasts were cultured in 50 mL RPMI-medium containing 10% FBS 
and 1% L-glutamine, until confluence was reached. After harvesting the cells by centrifuging 5 min at 571 x g and 20°C, the pellets were washed twice in 
25 mL EBSS + 0.1% D-glucose. Next, intracellular amino acids were depleted essentially as previously described (25). In brief, the washed cell pellets were 
incubated for one hour at 37°C in 35 mL EBSS supplemented with 0.1% D-
glucose and 0.25% BSA. After depletion, cells were harvested (5 min, 571 x 
g, 20°C), washed twice in 25 mL HBSS, and stored at -20°C.
Enzyme assays in lymphoblastsUpon analysis, lymphoblast pellets were thawed on ice. Each pellet was reconstituted in 1 mL 100 mmol/L Na2HPO4, pH 7.5 and cells were lysed using an ultrasonic probe (Bandalin Sonopuls mini 20 with MS 1.5 titanium 
microtip) for 3 x 10 s at ~0.250 kJ (= 90% of maximum power). After centrifugation (5 min, 8800 x g, 4°C), 50 µL supernatant was used for the determination of protein content.To determine whether AGAT is capable to synthesize homoarginine from arginine and lysine, a lymphoblast lysate sample containing 50 µg protein was incubated with 30 µL 100 mmol/L 15N2-(guanidino)-arginine and 30 µL 160 mmol/L 13C6-lysine. To reach a total volume of 200 µL, 100 mmol/L Na2HPO4, pH 7.5 was added. At t = 0 and after 18 hours incubation at 37°C, proteins were precipitated with 30 µL 4 mol/L perchloric acid, and the samples were neutralized with 20 µL 6 mol/L KOH. After centrifugation, the supernatant was used to measure the formation of 13C6-15N2-homoarginine (mass transition 253 to 89) with an LC-MS/MS method (1). In short, the internal standard D4-homoarginine was added to the samples and the basic amino acids were extracted using solid phase extraction. After derivatization, the resulting butyl ester derivatives were measured with LC-MS/MS.
To confirm that AGAT is functioning properly, a second assay was done in which a lymphoblast lysate sample containing 50 µg protein was incubated with 30 µL 100 mmol/L 15N2-(guanidino)-arginine and 30 µL 160 mmol/L 13C2-15N-glycine in a total volume of 200 µL. The formation of 13C2-15N3-
guanidino acetate was measured after 18 hours incubation at 37°C using GC-
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MS (26, 27). Additionally, lactate dehydrogenase (LDH; EC 1.1.1.27.) activity 
was determined to confirm viability of both the AGAT-deficient and the control cell line. Activity was determined using a spectrophotometric assay, which follows the accumulation of NADH in the presence of pyruvate (28).
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Figure 2 
Homoarginine formation in AGAT-deficient and control lymphoblasts. Chromatograms of 15N2-13C6-homoarginine in lymphoblasts of an AGAT-deficient (AGAT-/-) patient (upper panel) and a control (AGAT+/+) (lower panel). The closed line represents the amount of 15N2-13C6-
homoarginine present after an 18-hour incubation at 37°C in the presence of 15N2-(guanidino)-arginine and 13C6-lysine, and the dotted line represents the baseline measurement. 
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Measurement of homoarginine in plasma
In a 4-day old ASS-deficient male patient, plasma homoarginine was determined simultaneously with arginine, monomethylarginine (MMA) and both asymmetric and symmetric dimethylarginine (ADMA and SDMA, respectively) using our recently validated HPLC method with tandem mass spectrometry detection (1). The concentrations of these amino acids were compared to concentrations measured in plasma of 10 age-matched children without inborn or acquired disorders of amino acid metabolism. 
Results
Homoarginine formation in lymphoblasts
Both the lysates of AGAT-deficient and the control cell lines showed normal LDH-activity, indicating proper quality of the lysates. During the 18-hour 
incubation at 37°C in the presence of 15N2-(guanidino)-arginine and 13C6-lysine, control lymphoblasts produced 0.475 pmol 15N2-13C6-homoarginine/
min/mg protein (Figure 2). Lysates from the AGAT-deficient lymphoblasts, however, did not show any detectable 15N2-13C6-homoarginine formation. 
To confirm that the control lymphoblasts expressed functional AGAT, the production of 15N3-13C2-GAA from 15N2-(guanidino)-arginine and 15N-13C2-glycine was also measured. The lysates of the control lymphoblasts showed an activity of 27.6 pmol 15N3-13C2-GAA/min/mg protein, which is in line with 
the previously reported reference range of 21 – 70 pmol 15N3-13C2-GAA/min/mg protein (27). In the AGAT-deficient lymphoblasts 15N3-13C2-GAA formation 
was not detectable, confirming the absence of any residual AGAT-activity. Possible homoarginine formation from lysine catalyzed by the urea-cycle enzymes would lead to the formation of 13C6-homoarginine instead of 15N2-13C6-homoarginine, since 15N2-(guanidino)-arginine is not involved. In lysates 
of both the AGAT-deficient as well as the control lymphoblasts formation of 13C6-homoarginine was not detectable. 
Homoarginine in plasma of an ASS-deficient patient
As expected, the plasma arginine concentration in the ASS-deficient patient was very low, i.e., 10.8 µmol/L, approximately 6-fold lower than the mean concentration (62.0 ± 20.0 µmol/L) in the healthy age-matched control 
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subjects. In contrast, the homoarginine concentration in the plasma of the 
ASS-deficient patient was approximately 8-fold higher than in the age-matched controls (5.1 µmol/L versus 0.61 ± 0.40 µmol/L, respectively). 
Concentrations of the methylated arginines in the plasma of the ASS-deficient patient were similar to the concentrations measured in the control subjects (0.65 µmol/L versus 0.81 ± 0.16 µmol/L for ADMA, 0.85 µmol/L versus 0.78 ± 0.36 µmol/L for SDMA, and 0.078 µmol/L versus 0.109 ± 0.025 µmol/L for MMA).
Discussion
The main finding of this study is that de novo synthesis of homoarginine 
was not detectable in AGAT-deficient lymphoblasts, whereas in a control lymphoblast cell line detectable amounts of homoarginine were newly 
synthesized from arginine and lysine. A second key finding is that in plasma 
from an ASS-deficient patient the concentration of homoarginine was 8-fold higher than in control subjects, as opposed to the decreased level that would be expected if the urea-cycle enzymes were mainly responsible for homoarginine synthesis. In creatine synthesis, the intermediate GAA is formed by AGAT-catalyzed transfer of an amidino-group between arginine and glycine. Substrate promiscuity of AGAT leads to transfer of the amidino-group from arginine to lysine, leading to conversion of the latter into homoarginine. Overall, our data show that this promiscuous activity of AGAT, rather than urea cycle enzymes, is likely responsible for de novo synthesis of homoarginine in humans.Already in 1964 Ryan and Wells showed that labeled homoarginine was synthesized from labeled lysine in rats (16), and that in humans oral administration of lysine resulted in the urinary excretion of homoarginine and homocitrulline. Although this proved that homoarginine originates from lysine, the possible routes involved remained unclear. After it was shown that arginase is able to accept homoarginine as a substrate (29), the idea of an alternate urea-cycle was put forth (23). Also the involvement of a transamidination reaction similar to that of AGAT was suggested by Ryan et al (21). In support of this notion, homoarginine producing plants contain a gene for an arginine:lysine amidinotransferase (20). Amidinotranferases 
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are well conserved within plants, but similarity decreases when compared 
to mammals. The specific amino acid binding domains, however, remain conserved (20).Compared to the formation of GAA by AGAT in control lymphoblasts, the rate of homoarginine synthesis was about 60-fold lower at similar substrate concentrations. This is in line with homoarginine synthesis by transfer of an amidino-group from arginine to lysine being a secondary activity of AGAT, next to its main role in the synthesis of GAA from arginine and glycine. It should be noted that enzyme promiscuity is widespread, probably because 
the catalysis of multiple reactions offers evolutionary advantages (30). There are several parallels between homoarginine and GAA in support of a common origin of both metabolites. First, mean levels of both homoarginine and GAA are higher in men compared to women (13, 31). Second, both compounds are mainly formed in the kidney where AGAT is located (16, 18), and are 
significantly decreased in plasma of patients with end-stage renal disease 
(32).
The elevated homoarginine levels we measured in the ASS-deficient patient, were also reported in several other urea-cycle disorders (17, 33). Kato suggested that this elevation is the result of decreased degradation of lysine, increasing its availability as substrate for AGAT-catalyzed homoarginine synthesis (34). Another possibility is downregulation of arginase as a compensatory reaction to the very low levels of arginine associated with ASS-
deficiency. Assuming unaltered AGAT-catalyzed synthesis of homoarginine, a reduction of homoarginine degradation by arginase may then lead to elevated plasma levels. It should be noted that although our data unequivocally implicate AGAT in homoarginine synthesis, a role of urea-cycle enzymes cannot be fully excluded. 
To be able to give a more definitive answer on the involvement of the urea-cycle enzymes in homoarginine synthesis, measurement of homoarginine synthesis in cell lines lacking one or more urea-cycle enzymes may be useful. Additionally, it cannot be fully excluded that uptake from the diet contributes to normal endogenous homoarginine levels, since the grass pea, lentil and similar legumes, which are used for human consumption, contain a high amount of non-protein amino acids, including homoarginine (35-37). 
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More research is needed to evaluate to what extent dietary homoarginine contributes to plasma levels of homoarginine in humans.
As to whether high or low homoarginine levels are more beneficial with respect to cardiovascular disease, remains to be established. Low homoarginine levels have been associated with cardiovascular risk and mortality (12-14), possibly reflecting the local failing creatine metabolism in the myocardium (19), whereas high homoarginine levels may interfere with nitric oxide production, potentially leading to elevated blood pressure (9). 
Research in the field of creatine metabolism has produced an extensive body of knowledge on the regulation of AGAT activity (18), which may also provide valuable clues to potential pharmaceutical or dietary strategies to alter homoarginine synthesis by targeting AGAT. Supplementation with creatine, 
for example, effectively reduces synthesis of GAA by feedback repression of AGAT and may therefore also reduce synthesis of homoarginine. In contrast to this expectation, in healthy volunteers receiving creatine supplementation 
that effectively reduced GAA levels, circulating homoarginine levels were 
increased by 35% (38). This likely reflects involvement of secondary 
pathways, and shows that more research into this field is required.In conclusion, our data show that promiscuous activity of AGAT, a key enzyme in the synthesis of creatine, plays a pivotal role in the synthesis of the novel cardiovascular risk factor homoarginine.
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SummaryProduction of the endogenous vasodilator nitric oxide (NO) from arginine by NO synthase (NOS) is inhibited by asymmetric dimethylarginine (ADMA). Because diminished NO synthesis leads to endothelial dysfunction, vasoconstriction, elevated blood pressure, and thrombus formation, high ADMA levels may enhance cardiovascular disease (CVD) risk.Both ADMA and its inactive isomer symmetric dimethylarginine (SDMA) are formed during the posttranslational methylation of arginine residues in proteins by protein-arginine methyltransferases (PRMT), in which monomethylargine (MMA) is formed as intermediate. Upon proteolysis, free amino acids, including the methylated arginines, are released into the cytosol. Cellular ADMA and MMA are cleared from the cell either through enzymatic hydrolysis by dimethylarginine dimethylaminohydrolase (DDAH) or through export to the plasma via cationic amino acid transporters (CAT), which are also responsible for transmembrane transport of other cationic amino acids, such as SDMA, arginine, and homoarginine.Although synthesis and degradation of ADMA as well as ADMA-mediated inhibition of NO synthesis occur intracellularly, most clinical studies on CVD report on plasma ADMA levels, based on the underlying assumption that 
the concentration of ADMA in plasma reflects intracellular ADMA. However, reports on the relation between plasma and intracellular ADMA levels in vascular and other tissues and organs are scarce. Therefore, the main focus of this thesis was to study intracellular ADMA, and its relation to plasma levels. In addition, the role of homoarginine as a novel risk marker for CVD was explored. This naturally occurring homolog of arginine may inhibit NO production and has been associated with CVD. 
Intracellular ADMA: metabolism and relation to plasma levelsFor the accurate and precise determination of arginine, ADMA, SDMA, MMA, and homoarginine in plasma and intracellularly in tissues and cultured cells, a new method, based on stable isotope dilution liquid chromatography with detection by tandem mass spectrometry, was developed and validated (Chapter 2). Lower limits of quantification were 0.4 nmol/L for ADMA and SDMA and 0.8 nmol/L for MMA, arginine and homoarginine. Intra-assay 
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precision (CV%) was <3.5%, and inter-assay precision <9.6% for all analytes. 
The method proved to be suitable for quantification in small tissue samples and cultured cells, and was successfully applied on samples from a tracer 
study, which revealed the remarkably fast (<60 min) appearance in plasma of stable isotope-labeled ADMA, SDMA, and MMA during infusion of D3-methyl-1-13C-methionine in healthy volunteers.
The contribution of proteolysis to the generation of free cellular ADMA, and its fast appearance in plasma was explored in the humane erythrocyte of critically ill subjects and healthy controls (Chapter 3). We showed that the erythrocyte is an important player in both storage and generation of ADMA. 
Upon erythrocyte lysis, proteolytic activity led to a rapid release of >25% 
of protein-incorporated ADMA, whereas less than 0.04% of the amino acids present in hemoglobin were released, showing that ADMA was released from proteins other than hemoglobin. Furthermore, fast bidirectional transport of free ADMA across the plasma membrane of intact erythrocytes led to a rapid equilibrium between intra- and extracellular ADMA. In line with up-
regulation of CAT during critical illness, a significant association between intracellular and plasma ADMA concentrations was observed in critically ill patients, but not in healthy controls. Additionally, despite a rapid increase of free ADMA during incubation of erythrocyte lysates, the total amount of ADMA remained constant, indicating the absence of active DDAH in the erythrocyte. Generation of large amounts of free ADMA upon erythrocyte lysis may contribute to the high ADMA levels in plasma observed in patients with sickle cell disease and HELLP syndrome, and possibly also in other hemolysis-associated diseases.
In a rabbit model of prolonged critical illness, we confirmed that DDAH activity is important in the regulation of circulatory ADMA (Chapter 4). DDAH activities in muscle, kidney, and liver were inversely associated with plasma 
ADMA, and together explained almost 50% of the variation in plasma ADMA concentrations. DDAH activity in heart was not predictive for plasma ADMA, 
but showed a significant negative association with the ADMA content of heart tissue. This suggests that cardiac DDAH is more important for regulation of 
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ADMA at the local level than of circulatory ADMA, whereas DDAH in muscle, kidney, and liver are more important for regulation of circulatory ADMA than of ADMA at the local level.
Since it is ethically impossible to obtain specimens of cardiovascular tissue from healthy volunteers, we explored the relations between intracellular and plasma concentrations of the methylated arginines and homoarginine, using peripheral blood mononuclear cells (PBMC), which can be easily obtained from whole blood (Chapter 5). Only for homoarginine a weak positive association was observed between concentrations in plasma and in PBMC. Concentrations of arginine, MMA, ADMA, and SDMA in plasma showed 
non-significant inverse associations with their respective intracellular concentrations in PBMC, showing that, at least in healthy individuals, plasma 
levels of these amino acids poorly reflect their intracellular levels in PBMC.
The rationale and design of a proof-of-concept trial evaluating the effect of uninterrupted perioperative (par)enteral nutrition supplementation on 
amino acid profile, cardiomyocytes structure, and cardiac perfusion and metabolism of patients undergoing coronary artery bypass grafting (CABG) was described in Chapter 6A. This study offered the unique opportunity to measure the methylated arginines and homoarginine in heart tissue, aortic tissue, plasma, and PBMC from patients undergoing CABG (Chapter 6B). In these patients, ADMA concentrations in plasma were positively related to intracellular ADMA in both PBMC and heart tissue. However, intracellular 
ADMA in PBMC was not significantly related to ADMA in heart tissue, suggesting that plasma levels of ADMA, in contrast to ADMA in PBMC, 
reflect cardiac ADMA. In addition, we observed that DDAH activities in heart and PBMC were positively associated with their respective local ADMA concentrations. Upregulation of DDAH may be a compensatory response to elevated intracellular ADMA levels in coronary artery disease.
Homoarginine and cardiovascular diseaseHomoarginine, a homolog of arginine, may interfere with enzymes that use arginine a substrate, such as NOS. This may lead to reduced production of 
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NO and subsequent increased blood pressure. Low serum homoarginine, however, has recently been postulated as potential new risk marker for CVD. Because knowledge on the possible physiological role of homoarginine in the cardiovascular environment is limited, we reviewed current literature on homoarginine (Chapter 7) with emphasis on metabolic routes for homoarginine synthesis and utilization, bio-analytical aspects, and potential mechanisms underlying its association with CVD.
Analysis of circulatory amino acids, including ADMA and homoarginine, is 
performed in various fields of research. However, the impact of coagulation or use of anticoagulants is often disregarded. Therefore, concentrations of homoarginine, ADMA and other amino acids measured in serum, EDTA-plasma and heparin-plasma, were compared (Chapter 8). Anticoagulation 
with either EDTA or heparin led to small differences in concentration 
(highest for tryptophan: 5.3%), which are clinically most likely irrelevant. Concentrations of amino acids, measured in serum were higher than in 
heparin-plasma, especially for taurine (42.3%), arginine (36.4%), and 
glutamic acid (16.2%). This may be caused by poorly controllable ex vivo release from blood cells during clotting. This study showed that heparin-plasma and EDTA-plasma are most suitable for amino acid analysis, but should not be used interchangeably in a single study. 
Homoarginine is a competitive substrate for NOS, but being a less efficient substrate than arginine, high homoarginine levels may lead to reduced NO formation, resulting in endothelial dysfunction and increased vascular resistance. Data on the relationship between blood pressure and plasma levels of arginine, homoarginine, and ADMA are scarce. Therefore, we investigated these relationships in the Hoorn Study, a population-based cohort of elderly subjects (Chapter 9). The main findings of this study were that plasma levels of homoarginine and arginine are independently 
associated with clinically relevant differences in blood pressure in an antagonistic fashion, and that ADMA is not related to blood pressure.To elucidate the underlying (patho)physiological mechanisms of homoarginine in CVD, it is important to understand which biochemical 
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routes are involved in homoarginine synthesis. Previous studies have shown that lysine is the main precursor of homoarginine in both animals and humans, in which both enzymes of the urea cycle and arginine:glycine amidinotransferase (AGAT) have been implicated. To assess the relative importance of both pathways in humans, we exploited rare inborn errors of metabolism (Chapter 10). To this end, the concentration of homoarginine in 
plasma of an argininosuccinate synthase-deficient patient was compared to those in age-matched controls. Furthermore, homoarginine formation was 
measured in lymphoblasts from an AGAT-deficient patient and a control cell line. The data showed that, at least in humans, promiscuous activity of AGAT, a key enzyme in the synthesis of creatine, plays a pivotal role in the synthesis of the novel cardiovascular risk factor homoarginine.
ConclusionThe main focus of this thesis was to study the metabolism of intracellular ADMA, and its relation to plasma levels. Most clinical studies report on plasma ADMA levels, based on the underlying assumption that the 
concentration of ADMA in plasma reflects intracellular ADMA levels. In this thesis we questioned the validity of this assumption. Intracellular ADMA 
concentrations in both PBMC and erythrocytes were not significantly associated with plasma ADMA levels in healthy volunteers. In contrast, ADMA 
concentrations in erythrocytes from critically ill patients were significantly associated with plasma ADMA levels, and in patients undergoing CABG, a 
significant association was observed between intracellular ADMA in PBMC and plasma ADMA. 
Differences between the relations in healthy subjects and critically ill 
patients or patients undergoing CABG, may reflect differences in CAT-mediated clearance rates, DDAH activity, PRMT activity, or protein turnover in health and disease. For instance, CAT in erythrocytes, platelets and PBMC is upregulated in patients with chronic renal failure or heart failure. Upregulated CAT may result in faster egress of ADMA from the cell, leading to a closer association between intracellular and extracellular levels. This is in line with our study on the role of the erythrocyte in generation and storage of ADMA, which showed that proteolysis of ADMA-containing proteins, and 
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fast bidirectional transport of ADMA across the plasma membrane, may contribute to the elevation of plasma levels. In an animal model of critical illness, we showed that DDAH activities in muscle, kidney, and liver were inversely and independently associated with plasma ADMA, together explaining half of the variation in plasma ADMA concentrations. DDAH activity in heart was not predictive for plasma ADMA. 
However, for DDAH activity in heart we observed a significant negative association with the ADMA content in heart, suggesting that cardiac DDAH is more important for the regulation of ADMA at the local level, than for circulatory ADMA levels. Surprisingly, in heart tissue of patients undergoing 
CABG, DDAH activity showed significant positive correlations with its ADMA content, whereas inverse relations would be expected. The apparent reversal of the association between DDAH activity and ADMA content could be a result of the upregulation of DDAH as a reaction to the high ADMA concentrations 
in the heart, confirming the importance of DDAH in the regulation of ADMA in cardiac tissue during disease.The combined results from the separate ADMA studies described in this thesis indicate that the question whether the level of ADMA in plasma 
adequately reflects intracellular ADMA at the tissue level, cannot be answered unequivocally. The relation between intra- and extracellular ADMA seems strongly dependent on physiological conditions. In general, the relationship between plasma ADMA and intracellular ADMA is weak under normal physiological conditions and much stronger in some pathopysiological states.
In addition to ADMA, homoarginine, a structural homolog of arginine and a competitative substrate or even inhibitor of NOS, was studied in relation to CVD. A literature review showed that both high and low homoarginine concentrations appear to be associated with increased CVD risk. To understand this apparent contradiction, it is necessary to understand the metabolism of homoarginine. For its synthesis from lysine, two major pathways have been suggested, catalyzed either by enzymes of the urea cycle or by AGAT, a key enzyme in creatine synthesis. By exploiting inborn errors of metabolism, 
we were able to confirm that promiscuous activity of AGAT, rather than the 
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urea cycle enzymes, plays a pivotal role in the synthesis of homoarginine 
from lysine. The relation between low homoarginine and CVD may reflect impairment of myocardial creatine synthesis, caused by low AGAT activity, which secondarily results in reduced homoarginine synthesis.In the Hoorn Study, a population-based cohort of elderly subjects, we showed that plasma levels of homoarginine were positively associated with systolic and diastolic blood pressure, whereas arginine was inversely associated with diastolic blood pressure only. These antagonistic relationships support the notion that homoarginine is a competitive substrate for NOS. Because 
homoarginine is a less efficient substrate than arginine, high homoarginine levels may lead to reduced NO formation, resulting in endothelial dysfunction and increased vascular resistance and blood pressure. 
Overall, it seems that different mechanisms underlie the relations of CVD with high and low homoarginine levels. High homoarginine may, by impairing NO production, be causally involved, whereas low homoarginine may be an 
innocent bystander reflecting deficient creatine metabolism.
Future perspectives
We have shown that in healthy subjects plasma ADMA does not reflect its intracellular concentrations in erythrocytes and PBMC. In contrast, in 
patients with coronary artery disease or multiple organ failure significant correlations appeared between plasma ADMA concentrations and intracellular concentrations in heart, erythrocytes and/or PBMC. Increased proteolysis and upregulation of CAT during disease may underlie the tighter association between intra- and extracellular ADMA. However, to what extent each of these mechanisms contribute to the elevation of ADMA in plasma, and to what extent DDAH upregulation is able to compensate remains to be investigated.
Homoarginine seems to be an interesting new risk marker for CVD, but further mechanistic and epidemiological studies are required to determine whether homoarginine is causally involved in atherogenesis. If low homoarginine is only an innocent bystander in the failing creatine synthesis 
pathway in the heart, lowering of homoarginine may be beneficial in patients 
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Part IV: Summary and conclusion
11
with hypertension. However, more research is needed before homoarginine can be tested as a potential drug target in the future. Additionally, the consumption of certain homoarginine containing legumes, such as grass pea and lentil, may contribute to the endogeous homoarginine pool. However, to what extent homoarginine from diet contributes to plasma levels, as well as 
the effect of homoarginine intake from these legumes on CVD, is currently unknown and needs further investigation.
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Intracellulair asymmetrisch dimethylarginine 
(ADMA) en homoarginine: 
metabolisme en relatie met plasmaspiegels
SamenvattingProductie van de endogene vaatverwijder stikstofoxide (NO) uit arginine door stikstofoxide synthase (NOS) wordt geremd door asymmetrisch dimethylarginine (ADMA). Omdat verminderde NO vorming leidt tot endotheeldisfunctie, vaatvernauwing, verhoogde bloeddruk, en trombose, kunnen hoge ADMA niveaus het risico op hart- en vaatziekten (HVZ) verhogen.Zowel ADMA als zijn inactieve isomeer symmetrisch dimethylarginine (SDMA) worden gevormd tijdens de posttranslationele methylering van arginine residuen in eiwitten door proteïne-arginine methyltransferases (PRMT), waarbij monomethylargine (MMA) als tussenproduct wordt gevormd. Tijdens proteolyse komen aminozuren, inclusief de gemethyleerde arginines, vrij in het cytosol. De vrijgekomen ADMA en MMA worden vervolgens uit de cel verwijderd via enzymatische hydrolyse door dimethylarginine dimethylaminohydrolase (DDAH), of door hun transport naar het plasma via kationische aminozuur transporters (CAT), die ook verantwoordelijk zijn voor transmembraantransport van andere kationische aminozuren zoals SDMA, arginine, en homoarginine.
Hoewel vorming en afbraak van ADMA evenals de remming van NOS door ADMA intracellulaire processen zijn, rapporteren de meeste klinische studies naar HVZ de ADMA spiegels in plasma gebaseerd op de onderliggende veronderstelling dat de intracellulaire ADMA concentratie wordt weerspiegeld in plasma. Informatie over de relatie tussen ADMA in plasma en intracellulaire ADMA niveaus in vaatweefsel, andere weefsels en organen is echter schaars. Daarom ligt de focus van dit proefschrift op het bestuderen van intracellulair ADMA in relatie tot plasmaspiegels. Verder is de rol van homoarginine als nieuwe risicofactor voor HVZ onderzocht. Deze natuurlijk voorkomende homoloog van arginine kan mogelijk NO productie door NOS remmen en is geassocieerd met HVZ.
255
&
Appendices
256
Intracellulair ADMA: metabolisme en de relatie tot plasmaspiegelsOm arginine, ADMA, SDMA, MMA en homoarginine nauwkeurig en precies te kunnen bepalen in plasma en intracellulair in weefsels en gekweekte cellen, is er een nieuwe analytische methode ontwikkeld en gevalideerd, 
gebruikmakend van stabiele isotopen, vloeistofchromatografie en detectie met tandem massaspectrometrie (Hoofdstuk 2). De kwantificeringslimieten waren 0,4 nmol/L voor ADMA en SDMA en 0,8 nmol/L voor MMA, arginine en 
homoarginine. Binnen een analytische run bedroeg de precisie (CV%) voor 
alle analyten <3,5% en tussen verschillende analytische runs was de precisie 
<9.6%. De methode is geschikt voor analyse in kleine weefselmonsters en gekweekte cellen, en is met succes toegepast op monsters van een tracer onderzoek met stabiele isotopen, waarbij tijdens infusie van D3-methyl-1-13C-methionine in gezonde vrijwilligers, de stabiele isotoop gelabelde 
vormen van ADMA, SDMA en MMA opmerkelijk snel (<60 min) verschenen in plasma.
De bijdrage van proteolyse aan de vorming van vrij cellulair ADMA, en het snelle verschijnen daarvan in plasma werd onderzocht in erytrocyten van ernstig zieke patiënten en gezonde controles (Hoofdstuk 3). Hierbij toonden we aan dat de erytrocyt een belangrijke speler is in zowel opslag als vorming van ADMA. Na lysis van de erytrocyt, kwam door snelle proteolytische 
activiteit meer dan 25% van het ADMA in eiwitten vrij. Daarentegen 
kwam minder dan 0,04% van de aminozuren in hemoglobine vrij. Hieruit 
blijkt dat ADMA afkomstig is uit andere eiwitten dan hemoglobine. Verder 
leidde efficiënt transport van vrij ADMA over de plasmamembraan van intacte erytrocyten snel tot de instelling van een evenwicht tussen intra- 
en extracellulair ADMA. Een significante associatie tussen intracellulaire en plasma concentraties van ADMA werd waargenomen bij kritiek zieke patiënten, maar niet bij gezonde controles. Dit is in overeenstemming met opregulatie van CAT tijdens kritieke ziekte. Verder zagen we dat ondanks een snelle toename van vrij ADMA tijdens incubatie van erytrocyt lysaten, de totale hoeveelheid ADMA constant bleef, wat duidt op de afwezigheid van actief DDAH in erytrocyten. Vorming van grote hoeveelheden vrij ADMA na lysis van erytrocyten kan bijdragen aan de hoge ADMA niveaus in plasma van 
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patiënten met sikkelcelanemie, HELLP-syndroom, en mogelijk ook in andere ziekten die met hemolyse gepaard gaan.
In een diermodel voor langdurig kritieke ziekte, hebben we kunnen bevestigen dat DDAH activiteit belangrijk is voor de regulatie van ADMA in de bloedsomloop (Hoofdstuk 4). DDAH activiteiten in spier, nier en lever toonden een invers verband met ADMA in plasma. Samen verklaarden deze 
DDAH activiteiten bijna 50% van de variatie in plasma ADMA concentraties. DDAH activiteit in het hart was daarentegen niet voorspellend voor plasma 
ADMA, maar er was wel een significant negatieve associatie met ADMA in hartweefsel. Dit suggereert dat DDAH in het hart belangrijker is voor de regulering van ADMA op lokaal niveau dan voor de regulatie van ADMA in de bloedsomloop, terwijl DDAH in de spieren, nieren en lever meer van belang is voor de regulering van ADMA in de bloedsomloop dan voor ADMA op lokaal niveau.
Het is niet ethisch verantwoord om biopten van cardiovasculair weefsel af te nemen bij gezonde vrijwilligers. Daarom hebben we de relatie tussen intracellulaire en plasmaconcentraties van de gemethyleerde arginines en homoarginine eerst onderzocht in perifeer bloed mononucleaire cellen (PBMC), welke gemakkelijk kunnen worden verkregen uit volbloed 
(Hoofdstuk 5). Hierbij werd alleen voor homoarginine een zwak positief verband waargenomen tussen concentraties in plasma en in PBMC. Concentraties van arginine, MMA, ADMA en SDMA in plasma waren niet 
significant invers geassocieerd met hun intracellulaire concentraties in PBMC. Hieruit blijkt dat bij gezonde personen, plasmaspiegels van deze aminozuren geen goede afspiegeling zijn van de intracellulaire niveaus in PBMC.
In Hoofdstuk 6A is de opzet van een proof-of-concept studie beschreven, 
welke het effect van ononderbroken peri-operatieve (par)enterale voeding 
op het aminozuurprofiel, de cardiomyocyten structuur, en cardiale perfusie en op het metabolisme evalueert bij patiënten die een bypassoperatie van de kransslagader ondergaan. Deze studie bood de unieke kans om 
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de gemethyleerde arginines en homoarginine te meten in hartweefsel, aorta, plasma en PBMC van patiënten die een bypass operatie ondergaan 
(Hoofdstuk 6B). Bij deze patiënten werd een positieve relatie gevonden tussen ADMA concentraties in het plasma en intracellulaire concentraties in zowel PBMC als in hartweefsel. Intracellulaire ADMA concentraties in 
PBMC waren echter niet significant gerelateerd aan ADMA concentraties in het hartweefsel, wat suggereert dat ADMA niveaus in plasma een betere weergave geven van ADMA in hartweefsel dan ADMA niveaus in PBMC. Verder werd geconstateerd dat DDAH activiteit in het hart en in PBMC positief geassocieerd waren met hun respectieve lokale ADMA concentraties. Dit zou een gevolg kunnen zijn van de opregulatie van DDAH in een compenserende reactie op de verhoogde intracellulaire ADMA niveaus bij atherosclerose van de kransslagaders.
Homoarginine in hart-en vaatziektenHomoarginine is een homoloog van arginine en zou kunnen interfereren met enzymen die arginine als substraat gebruiken, zoals NOS. Hoge homoarginine concentraties kunnen daarom leiden tot verminderde productie van NO, met hoge bloeddruk als gevolg. Daarentegen is een lage homoarginine concentratie in serum onlangs geïntroduceerd als potentiële nieuwe risicofactor voor HVZ. Omdat er weinig kennis is op het gebied van de mogelijke fysiologische rol van homoarginine in de cardiovasculaire omgeving, hebben we bestaande literatuur over homoarginine geëvalueerd (Hoofdstuk 7), waarbij de nadruk 
lag op metabole routes voor de synthese en afbraak van homoarginine, op bioanalytische aspecten, en op potentiële mechanismen die ten grondslag kunnen liggen aan de relatie tussen homoarginine en HVZ.
In verschillende onderzoeksvelden worden analyses van aminozuren, inclusief de analyses van ADMA en homoarginine, uitgevoerd. De invloed van stolling en het gebruik van antistollingsmiddelen worden hierbij vaak buiten beschouwing gelaten. Daarom hebben we concentraties van homoarginine, ADMA en andere aminozuren gemeten en vergeleken in serum, EDTA-plasma en heparine-plasma (Hoofdstuk 8). Antistolling met hetzij EDTA of heparine 
leidde tot kleine verschillen in concentratie (hoogste voor tryptofaan: 5,3%), 
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die klinisch hoogst waarschijnlijk irrelevant zijn. Aminozuur concentraties gemeten in serum waren hoger dan in heparine-plasma, met name voor 
taurine (42,3%), arginine (36,4%) en glutaminezuur (16,2%). Deze verschillen worden mogelijk veroorzaakt door slecht controleerbare ex vivo afgifte van aminozuren door de bloedcellen gedurende de stolling. Deze studie toonde aan dat heparine-plasma en EDTA-plasma het meest geschikt zijn voor aminozuuranalyse, maar dat beide soorten plasma niet door elkaar gebruikt dienen te worden binnen een enkele studie.
Homoarginine is een competitief substraat voor NOS, maar het is een 
minder efficiënt substraat dan arginine. Hoge homoarginine concentraties kunnen daarom leiden tot verminderde vorming van NO, met als gevolg endotheeldisfunctie en verhoogde vaatweerstand. Gegevens over de relatie tussen bloeddruk en plasmaspiegels van arginine, homoarginine en ADMA zijn schaars. Daarom hebben we deze relaties onderzocht in de Hoorn Studie, een studiecohort van ouderen (Hoofdstuk 9). De belangrijkste bevinding van dit onderzoek was dat de plasmaspiegels van homoarginine en arginine 
onafhankelijk van elkaar op een antagonistische manier zijn geassocieerd met klinisch relevante verschillen in bloeddruk. ADMA was daarentegen niet gerelateerd aan de bloeddruk in deze studie.
Om onderliggende (patho)fysiologische mechanismen van homoarginine in HVZ op te helderen is het belangrijk te begrijpen welke biochemische routes betrokken zijn bij homoarginine synthese. Eerdere studies hebben aangetoond dat in zowel mensen als dieren lysine de voorloper is van homoarginine. In de literatuur worden zowel de enzymen van de ureumcyclus als arginine:glycine amidinotransferase (AGAT) genoemd als mogelijk verantwoordelijk voor homoarginine vorming. Om het relatieve belang van beide routes in de mens te bestuderen, hebben we gebruik gemaakt van zeldzame aangeboren stofwisselingsziekten (Hoofdstuk 10). De homoarginine concentratie in 
het plasma van een argininosuccinaat synthase-deficiënte patiënt werd vergeleken met de concentraties in controles van dezelfde leefdtijd. Verder werd homoarginine vorming gemeten in lymfoblasten van een AGAT-
deficiënte patiënt en in een controle cellijn. De resultaten toonden aan dat, in ieder geval bij mensen, promiscue activiteit van AGAT, een essentieel enzym 
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in de synthese van creatine, een centrale rol speelt in de vorming van de nieuwe cardiovasculaire risicofactor homoarginine.
ConclusiesHet belangrijkste doel van dit proefschrift was om het metabolisme van intracellulair ADMA in relatie tot plasmaspiegels te bestuderen. In veel klinische studies wordt uitsluited ADMA in plasma gemeten, wat berust op de veronderstelling dat de concentratie van ADMA in plasma een juiste weerspiegeling geeft van intracellulair ADMA. In dit proefschrift hebben we onze vraagtekens gezet bij de juistheid van deze veronderstelling. Intracellulaire ADMA concentraties in zowel PBMC als in erytrocyten 
waren bij gezonde vrijwilligers niet significant geassocieerd met ADMA concentraties in plasma. ADMA concentraties in erytrocyten van ernstig 
zieke patiënten daarentegen waren wel significant geassocieerd met ADMA spiegels in plasma. Verder werd er bij patiënten die een bypass operatie 
ondergingen, een significante associatie waargenomen tussen intracellulair ADMA in PBMC en ADMA in plasma.De verschillen tussen de relaties bij gezonde vrijwilligers en ernstig zieke patiënten of patiënten die een bypass operatie ondergaan, kunnen een weerspiegeling zijn van verschillen in CAT expressie, DDAH activiteit, 
PRMT activiteit, of eiwit afbraak tijdens gezondheid of ziekte. Zo wordt CAT in erytrocyten, bloedplaatjes en PBMC opgereguleerd in patiënten met chronisch nier- of hartfalen. Opgereguleerd CAT kan leiden tot een sneller transport van ADMA uit de cel, waardoor een nauwere associatie tussen intracellulaire en extracellulaire niveaus ontstaat. Dit is in overeenstemming met onze studie over de rol van de erytrocyten in de vorming en opslag 
van ADMA, waarin we aantoonden dat eiwitafbraak van eiwitten die ADMA bevatten samen met snel transport van ADMA over de plasmamembraan kan bijdragen aan de verhoging van ADMA spiegels in plasma.In een diermodel van kritieke ziekte hebben we aangetoond dat DDAH 
activiteiten in spier, nier en lever omgekeerd en onafhankelijk geassocieerd waren met plasma ADMA en samen de helft van de variatie in plasma ADMA concentraties verklaren. DDAH activiteit in hart was niet voorspellend voor 
plasma ADMA. Echter, voor DDAH activiteit in het hart werd een significante 
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negatieve associatie gevonden met de ADMA concentratie in het hart, wat suggereert dat DDAH in het hart belangrijker is voor de regulatie van ADMA op lokaal niveau, dan voor ADMA niveaus in plasma. In hartweefsel van patiënten die een bypass operatie ondergaan, vonden we verrassend genoeg 
dat de DDAH activiteit significant en positief gecorreleerd was met de lokale ADMA concentratie, terwijl een inverse relatie zou worden verwacht. Deze omkering van de associatie tussen DDAH activiteit en ADMA concentratie kan een gevolg zijn van de opregulatie van DDAH als reactie op de hoge ADMA concentraties in het hart, wat het belang van DDAH in de regulatie van ADMA niveaus in hartweefsel tijdens ziekte bevestigt.De gecombineerde resultaten van de afzonderlijke studies naar ADMA, zoals beschreven in dit proefschrift, laten zien dat de vraag of de ADMA spiegel in 
plasma een juiste reflectie van intracellulair ADMA op weefselniveau geeft niet eenduidig beantwoord kan worden. De relatie tussen intra- en 
extracellulair ADMA lijkt sterk afhankelijk van de fysiologische condities. Grofweg kan men stellen dat er onder normale fysiologische omstandigheden een zwakke relatie is tussen plasma ADMA en intracellulair ADMA, terwijl deze relatie veel sterker is in diverse pathofysiologische omstandigheden.Naast ADMA is ook homoarginine, een structurele homoloog van arginine en competitief substraat of potentiële remmer van NOS, onderzocht in relatie tot HVZ. Uit een literatuuronderzoek bleek dat zowel hoge als lage homoarginine concentraties zijn geassocieerd met een verhoogd risico op HVZ. Om deze schijnbare tegenstrijdigheid te kunnen verklaren, is het noodzakelijk om het metabolisme van homoarginine verder te ontrafelen. Voor de synthese van homoarginine uit lysine zijn er twee mogelijke routes beschreven. In de ene route wordt gebruik gemaakt van de enzymen van de ureumcyclus en in de andere van AGAT, een essentieel enzym in creatine synthese. Met behulp van zeldzame aangeboren stofwisselingsziekten, konden we bevestigen dat promiscue activiteit van AGAT, en niet de ureumcyclus enzymen, een centrale rol spelen bij de vorming van homoarginine uit lysine. De relatie tussen een lage homoarginine concentratie en HVZ is mogelijk een afspiegeling van het falen van creatine vorming in het hart veroorzaakt door lage AGAT activiteit, wat secundair resulteert in een verminderde homoarginine vorming.In de Hoorn Studie, een studiecohort van ouderen, toonden we aan dat 
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de plasmaspiegels van homoarginine positief geassocieerd waren met de systole en diastole bloeddruk, terwijl arginine invers geassocieerd was met alleen diastole bloeddruk. Deze antagonistische verhouding ondersteunt het idee dat homoarginine een competitief substraat is voor NOS. Omdat 
homoarginine een minder efficiënt substraat voor NOS is dan arginine, kunnen hoge homoarginine niveaus leiden tot verminderde vorming van NO, met als gevolg endotheeldisfunctie, verhoogde vasculaire weerstand en hoge bloeddruk.Over het geheel genomen lijkt het erop dat verschillende mechanismen ten grondslag liggen aan de relaties tussen HVZ met hoge en lage homoarginine niveaus. Een hoge homoarginine concentratie kan door het remmen van NO productie causaal betrokken zijn, terwijl laag homoarginine, als gevolg van een verlaagd creatine metabolisme, mogelijk slechts een onschuldige toeschouwer is.
ToekomstperspectievenBij gezonde vrijwilligers hebben we laten zien dat plasma ADMA geen accurate weerspiegeling geeft van de intracellulaire concentraties in erytrocyten en PBMC. Bij patiënten met atherosclerose van de kransslagader of meervoudig 
orgaanfalen daarentegen, vonden we wel een significante correlatie tussen plasma ADMA concentraties en intracellulaire concentraties in het hart, erytrocyten en/of PBMC. Verhoogde proteolytische activiteit en opregulatie van CAT tijdens ziekte kunnen ten grondslag liggen aan deze sterkere associatie tussen intra- en extracellulair ADMA. Echter, in welke mate deze mechanismen bijdragen aan de verhoging van ADMA in plasma, en in hoeverre DDAH opregulatie hiervoor kan compenseren moet nog worden onderzocht.
Homoarginine is een interessante nieuwe risicofactor voor HVZ, maar verdere mechanistische en epidemiologische studies zijn nodig om te bepalen of homoarginine causaal is betrokken bij het ontstaan van atherosclerose. Als lage homoarginine slechts een onschuldige toeschouwer is bij het falen van creatine vorming via AGAT in het hart, zou het verlagen van homoarginine bij 
patiënten met hypertensie mogelijk gunstige effecten kunnen hebben. Er is 
echter meer onderzoek nodig voordat homoarginine getest kan worden als een potentieel doelwit voor geneesmiddelen in de toekomst. Bovendien kan het nuttigen van bepaalde peulvruchten die homoarginine bevatten, zoals graserwten en linzen, bijdragen aan het endogene homoarginine niveau. In hoeverre homoarginine uit het dieet werkelijk bijdraagt aan plasmaniveaus, 
en wat het effect is van homoarginine inname uit deze peulvruchten op HVZ, is nog onbekend en verdient verder onderzoek.
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Dankwoord
Eindigend met de quote waarmee ik dit proefschrift ook begon: 
I’ll face it ‘cause it’s the heart of everything De laatste loodjes wegen het zwaarst, nu alleen de verdediging nog. Maar niet zonder mijn dank uit te spreken aan iedereen die mij de afgelopen jaren heeft gesteund en bijgestaan tijdens de totstandkoming van dit proefschrift.
Open up your eyes, save yourself from fading away now, don’t let it go Open je ogen en aanschouw, hier vereeuwigd op papier ligt mijn proefschrift in je handen. Natuurlijk heb je het van voor tot achter gelezen om het nu, na het lezen van het dankwoord met een goed gevoel dicht te kunnen slaan. Toch stiekem achterin begonnen? Ga dan snel naar de Nederlandse samenvatting, je hoeft niet langs start.
Open up your eyes, see what you’ve become, don’t sacrifice Terug kijkend op de afgelopen jaren zie ik hoeveel ik heb geleerd en ben gegroeid. Trots dat al het werk hier is gebundeld en dat ik geen enkel hoofdstuk heb laten schieten. Ik hoop dat dit laatste niet heeft geleid tot het verwonden of sneuvelen van Chihuahua’s die niets vermoedend de postbode nakeften tijdens het op de deurmat neervallen van dit ietwat dikker dan geanticipeerde proefschrift.
It’s truly the heart of everything Waar het in deze laatste pagina’s werkelijk om draait, mijn intense dankbaarheid, want zonder alle support was dit proefschrift er niet geweest. 
Het feit dat je dit boek in handen hebt, geeft aan dat je op de één of andere manier, op het werk of privé, betrokken bent geweest bij de vier jaar leidend tot mijn promotie. Mijn dank daarvoor. Toch wil ik een aantal mensen in het bijzonder bedanken voor hun bijdrage aan deze onvergetelijke periode.
Allereerst, mijn promotor Henk Blom en copromotoren Tom Teerlink en 
Peter Scheffer, zonder wie dit hele avontuur nooit had plaats gevonden. 
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Henk, twee jaar na de start van mijn promotie traject was het groot feest in “ The Basket “, want je benoeming tot hoogleraar en daarmee het feit dat je mijn promotor zou worden moest gevierd worden. Later zouden op deze locatie nog verschillende onvergetelijke borrels volgen. Als mijn promotor benaderde je ieder vraagstuk met een lach en veel positivisme. Dankzij jouw vertrouwen in mij mag ik de komende jaren mijn wetenschappelijke carrière voortzetten in Washington. Enorm bedankt!
Tom, vaak kwam het geruststellende motto “komt wel goed” voorbij. Soms van jouw kant en dan weer van mijn kant. Onze vooruitziende blik bleek de waarheid, want zie hier het is goed gekomen. Je hebt iedere letter gecontroleerd en geen dubbele spatie is je ontgaan. Op een positieve manier met opbouwende kritiek werken tot perfectie. Ik heb veel van je geleerd en 
onze samenwerking was een fijne ervaring. Ook in Hamburg en Chicago was het erg gezellig. Voortaan als ik langs de Starbucks loop zal ik even om me heen kijken of je niet in de buurt bent om “The Simple 7” even door te nemen. Met het oog op mijn verblijf in Washington zal ik dus regelmatig terug denken aan deze mooie periode. Bedankt!
Peter, bedankt voor alle kritische vragen en input die dit proefschrift mede hebben gevormd. Met name de validatie van onze nieuwe mass-spec methode voor ADMA is mede dankzij jou tot een goed einde gebracht. Vanaf nu zullen jullie het zonder mij moeten doen tijdens de lunch, maar laat dat de pret niet drukken.
In dit rijtje mag Karel Jakobs ook niet ontbreken. Karel, toen ik nog maar net binnen kwam lopen bij het metabool lab, had jij de touwtjes nog in handen. Bedankt voor de mogelijkheid hier mijn promotie te kunnen doen. Met veel plezier zal ik ook terugdenken aan de gezellige etentjes in de Hoef en het predicaat prettig gestoord dat het me de volgende dag opleverde wanneer ik 
na afloop weer op de fiets naar Haarlem was gereden.
Ook wil ik de leden van de leescommissie, bestaande uit prof. dr. Yvo M. Smulders, prof. dr. Jacqueline M. Dekker, prof. dr. Hans W.M. Niessen, dr. 
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Geerten P. van Nieuw Amerongen en dr. Henk Lingeman, bedanken voor het gronding doorlezen en beoordelen van mijn proefschrift.
Diverse samenwerkingsverbanden hebben geleid tot mooie artikelen en uiteindelijk dit proefschrift. Hiervoor gaat mijn dank uit naar alle coauteurs, analisten en stagiaires die hieraan een steentje hebben bijgedragen. Tevens mijn dank aan de medewerkers van afdeling 2-2 van het Kennemer Gasthuis in Haarlem voor hun inzet in het verkrijgen van HUVECs.In het bijzonder wil ik nog de samenwerking met Marlieke Visser en het AMC noemen, samen stonden we op de OK om uniek materiaal te verzamelen. Zonder jouw initiatief waren hoofdstuk 6a en 6b er niet geweest. Ik ben erg benieuwd naar de complete verzameling artikelen over de voedingsinterventie studie in jouw proefschrift. Succes!
Ook binnen het lab (MLV? VML? MLK?... gewoon ML!) mag ik een aantal mensen niet vergeten. Sigrid de Jong en Rob Barto, die vanaf dag 1 voor mij klaar stonden. Sigrid je bent een absolute expert in ADMA en aminozuur piekjes integreren en je CV’s zijn niet te evenaren. In bijna alle hoofdstukken heb je een grote rol gespeeld. Rob, je hebt me erg op weg geholpen op de API 3000, en bij elke storing was je er om me uit de brand te helpen. Leonard, jij was de eerste die binnen het lab over homoarginine begon. Inmiddels is ons gezamenlijke stuk geaccepteerd en het onderzoek naar homoarginine in volle gang. Bedankt voor vier mooie jaren.Maar ook op Jan, Bert, Rick, Rob Kok, Desirée, Silvy, Gajja, Mathilde, Warsha, Ana, Birthe (vanaf nu alleen taarten bakken?), Eric, Bram, Mirjam, Eduard, Simone, Ulbe, Farisa, Abdelatif, Peter Bier, Herman, Willeke, Ben, Marjolein, Anneke en Karin kon ik steeds weer vertrouwen. Bedankt voor alle gezelligheid!Verder wil ik iedereen binnen de Klinische Chemie, die mij heeft geholpen bij het verzamelen van samples als prikassistent of als gezonde vrijwilliger enorm bedanken.
De afgelopen jaren heb ik de eer gehad twee stagiaires te mogen begeleiden. Eerst Sifra Balk, je hebt veel voorwerk gedaan, en ik denk dat we beide veel 
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geleerd hebben tijdens jouw stage. Later Eliane Swieringa, opgeven zit niet in jouw vocabulaire. Wat heb jij veel werk verzet, en dat werd beloond met een mooie publicatie. Allebei heel veel succes tijdens je verdere carrière.
Joe, Monica, Hong, Martijn, Leonard, Daan, Ofir, Ellen, Hari, Ruben, Marisa, Appoline, Melinda, Sandra, Marie, Arjen en Hinde, as fellow PhD-students and/or room mates you were there for a laugh, a serious talk, to help out when my computer disagreed, or to give some friendly opinions. Thank you all for the  fun and good memories. 
A life without the party squad? wow, that would be a life missing a lot of great memories. Joe, Eric and Monica, thanks so much and I will never forget.
Lieve paranimfjes, Jan en Frederike, bedankt dat jullie mij willen bijstaan tijdens de grote dag, laat me alsjeblieft niet struikelen over die paar treetjes. 
Anneke, Frederike en Brigitta, wie had ooit gedacht dat we 12½ jaar na onze eerste ontmoeting, ja zo lang is het alweer, nog steeds zo’n hechte club zouden zijn. Ook al kost het soms wat moeite alle agenda’s naast elkaar te leggen en een datum te prikken. Ik hoop dat er nog vele vervolgen komen op onze reis naar Schotland (zonder jullie was de omslag van mijn boekje nooit zo mooi geworden), of onze weekendjes Leuven, Gent en Groningen. Bedankt voor jullie vriendschap!
Ook wil ik Peter Cammermans en de hele Casca(do)-club bedanken, want ... “was ik moe of wat verdrietig, voelde ik mij niet optimaal, ging het niet zoals ik mij had voorgesteld allemaal, ook al lachte het leven niet, ik ging gewoon (met jullie) een liedje zingen, en dan wist ik dat het goed kwam allemaal”.
Je familie kan je niet kiezen, gelukkig heb ik er één die altijd voor me klaar staat. Mijn broer(“tje”)s, Erik-jan en Jos, en natuurlijk ook jullie meisjes, Silvia en Saskia. Ik heb genoten van onze jaarlijkse weekendjes met mama en de kleine meiden, maar ook dat we samen onze frustraties weg konden zweten 
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op de sportschool. Bedankt voor alle interesse en support, en Sil fijn dat je met de lay-out wilde helpen. 
Oma, vol trots vertelt u altijd over mij aan een ieder die het wil horen. Bedankt!
Lieve Ilse en Sara, bedankt voor jullie onvoorwaardelijke liefde en alle lieve 
knuffels, die ervoor zorgden dat het glas altijd half vol was en de inhoud soms zelfs over het randje klotste. Jullie zijn twee toppertjes en ik ben trots jullie tante te mogen zijn.
Papa, we zien elkaar veel te weinig, maar ik weet dat je trots op me bent, en daar gaat het om.
Tenslotte mama, zonder jouw support was dit alles niet mogelijk geweest. Met jou heb ik alle blije maar ook alle minder blije momenten kunnen delen. Samen zingen, sporten of een stevige wandeling, en intussen mijn hart kunnen luchten. Dag en nacht stond je voor me klaar. Bedankt mama, ik hou van je.
Curriculum vitaeMariska Davids was born on March 27th 1982 in Haarlem, The Netherlands. In 2000 she completed her secondary education at R.K. Lyceum voor Gymnasium, Atheneum en HAVO, Sancta Maria in Haarlem receiving a VWO degree. After this she started her Bachelor Life Science and Technology at 
both the University of Leiden and Technical University of Delft. She finished her Bachelor in 2006 with an internship at the department of human clinical genetics of the Leiden University Medical Center in Leiden, focussing on the 
selection of monoclonal antibody fragments for α-synuclein in Alzheimer’s Disease. During this period in 2002 and 2003 she was a member of the executive committee of students association LIFE of the study Life Science 
and Technology, where she was responsible for student affairs and education, and she took part in several organizing committees (e.g. Freshmen, Excursion, and Lustrum committee). In 2005 the Master phase of the study Life Science 
and Technology was started focusing on the profile Functional Genomics. Her minor company oriented internship was done at Viazym B.V, located at the reactor institute in Delft, where she studied the immobilization of Candida 
Antarctica lipase (CALA) on different carriers, and she completed the course 
radiation hygiene level 5B. The final Master internship was performed at the hospital pharmacy of the Slotervaart Hospital in Amsterdam, where a method was optimized and validated for the intracellular determination of 12 antiretroviral drugs in patients with HIV-1 using HPLC coupled to tandem mass spectrometry. From 2008 until 2012 she worked as a Ph.D. student at the Metabolic Laboratory of the department of Clinical Chemistry of the VU University Medical Center in Amsterdam, to complete the research presented in this thesis.
270
List of publications     1.  ter Heine R, Davids M, Rosing H, van Gorp EC, Mulder JW, van der Heide YT, Beijnen 
JH, Huitema AD. Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci 877: 575-580, 2009. 2.  Visser M, Paulus WJ, Vermeulen MA, Richir MC, Davids M, Wisselink W, de Mol BA, van Leeuwen PA. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail 12: 1274-1281, 2010. 3.  Visser M, Davids M, Verberne HJ, Kok WE, Niessen HW, van Venrooij LM, Cocchieri R, Wisselink W, de Mol BA, van Leeuwen PA. Rationale and design of a proof-of-concept 
trial investigating the effect of uninterrupted perioperative (par)enteral nutrition on 
amino acid profile, cardiomyocytes structure, and cardiac perfusion and metabolism of patients undergoing coronary artery bypass grafting. J Cardiothorac Surg 6:36: 2011. 4.  Davids M, Richir MC, Visser M, Ellger B, van den BG, van Leeuwen PA, Teerlink T. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness. Metabolism 61: 482-490, 2012. 5.  Davids M, Teerlink T. Asymmetric dimethylarginine (ADMA) and cardiovascular disease. Ned Tijdschr Klin Chem Labgeneesk 37: 10-14, 2012. 6.  Davids M, van Hell AJ, Visser M, Nijveldt RJ, van Leeuwen PA, Teerlink T. Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. 
Am J Physiol Heart Circ Physiol 302: H1762-H1770, 2012. 7.  Davids M, Swieringa E, Palm F, Smith DEC, Smulders YM, Scheffer PG, Blom HJ, Teerlink T. Simultaneous determination of asymmetric and symmetric dimethylarginine, Lmonomethylarginine, L-arginine, and L-homoarginine in biological samples using stable isotope dilution liquid chromatography tandem mass spectrometry. J Chromatogr 
B 900: 38-47, 2012. 8.  Davids M, Ndika JD, Salomons GS, Blom HJ, Teerlink T. Promiscuous activity of arginine:glycine amidinotransferase is responsible for the synthesis of the novel cardiovascular risk factor homoarginine. FEBS Lett 586: 3653-3657, 2012. 9.  Deracinois B, Pottiez G, Chafey P, Teerlink T, Camoin L, Davids M, Broussard C, Couraud PO, Dehouck MP, Cecchelli R, Karamanos Y, Flahaut C. Glial-cell-mediated re-induction 
of the blood-brain barrier phenotype in brain capillary endothelial cells: a differential gel electrophoresis study. Proteomics, 2013 [In press]. 10. Van der Zwan LP, Davids M, Scheffer PG, Dekker JM, Stehouwer CDA, Teerlink T. L-Homoarginine and L-arginine are antagonistically related to bloodpressure in an elderly population - The Hoorn Study. J Hypertension, 2013 [In press]. 11. Davids M, Peters JHC, de Jong S, Teerlink T. Measurement of nitric ocide-related amino 
acids in serum and plasma: effects of blood clotting and type of anticoagulant. Clin Cim 
Acta, 2013 [In press].
271
&
Appendices
272
List of abbreviations
4D-study: Die Deutsche Diabetes Dialyse study18F-FDG PET: 18F-fluorodeoxy-glucose positron emission tomographyADMA:  Asymmetric dimethylarginineAGAT:  Arginine:Glycine amidinotransferaseAla:  AlanineALAT (Ch. 6A):  Alanine aminotransferaseALAT (Ch. 7): Arginine:Lysine amidinotransferaseArg:  ArginineASL:  Argininosuccinate lyaseASS:  Argininosuccinate synthaseAsx:  Aspartic acid + asparagineATP:  Adenosine triphosphateBIS:  Bioelectrical impedance spectrometryBMI:  Body mass indexBSA:  Bovine serum albuminCABG:   Coronary artery bypass graftingCAT:  Cationic amino acid transporterCK:   Creatine kinaseCML:  CarboxymethyllysineCRP:  C-reactive protein
CSF:  Cerebrospinal fluid
CV:  Coefficient of variationCVD:  Cardiovascular diseaseCXP:  Collision cell exit potentialDBP:  Diastolic blood pressureDDAH:  Dimethylarginine dimethylaminohydrolaseDP:  Declustering potentialEBSS:  Earle’s balanced salt solutionECG:   Electrocardiogram
eGFR:  Estimated glomerular filtration rateEP:  Entrance potentialESI:  Electrospray ionizationEURO-score:  European system for cardiac operation risk evaluation scoreEVG:  Elastica van GiesonFFM:   Fat free massGAA:  GuanidinoacetateGAMT:  Guanidinoacetate methyltransferaseGC-MS:  Gas chromatography mass spectrometryGlx:   Glutamic acid + glutamine
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Gly:   GlycineHarg:   HomoarginineHbA1c:  Hemoglobin A1cHBSS:  Hank’s balanced salt solutionHDL:  High-density lipoproteinHE:   Hematoxylin and eosinHELLP-syndrome: Hemolysis, elevated liver enzymes, and low platelets                                                  syndromeHHH-syndrome:  Hyperornithinemia, hyperammonemia, and                                    homocitrullinuria syndromeHis:  HistidineHPLC:  High-performance liquid chromatography
HPLC-flu: High-performance liquid chromatography-fluorescenceHUVEC:  Human umbilical vein endothelial cellsICU:  Intensive care unitIle:  IsoleucineIMT:  Intima-media thicknessLC-MS/MS: Liquid chromatography tandem mass spectrometryLDH:  Lactate dehydrogenaseLDL:  Low-density lipoproteinLeu:  LeucineLOD:  Lower limit of detection
LOQ:  Lower limit of quantificationLURIC-study: Ludwigshaven risk and cardiovascular health studyLys:  Lysine
MDRD:  Modification of diet in renal diseaseMMA:  MonomethylarginineMPO:   MyeloperoxidaseMPS:  Myocardial perfusion scintigraphyNO:  Nitric oxideNOS:  Nitric oxide synthaseOTC:  Ornithine transcarbamoylase
PAS/D:   Periodic acid Schiff digestedPBMC:  Peripheral blood mononuclear cellsPCA:  Perchloric acidPhe:  PhenylalaninePIC:   Protease inhibitor cocktailPRMT:  Protein-arginine methyltransferase
QC:  Quality controlS/N:  Signal-to-noise ratioSBP:  Systolic blood pressureSD:  Standard deviation
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SDMA:  Symmetric dimethylarginine
SDS:  Summed difference scoreSEM:  Standard error of the meanSer:  SerineSOFA-score:  Sequential organ failure assessment scoreSPE:  Solid phase extractionSPECT:   Single-photon emission computed tomographySRS:  Summed rest scoreSSS:  Summed stress scoreThr:  Threonine
TLCK:   Nα-tosyl-L-lysine-chloromethylketoneTyr:   TyrosineVal:  Valine
275
&
Appendices

